# Patent

## Title
Substituted 2-azabicycles and their use as orexin receptor modulators

## Abstract

The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the National Stage of International Application No. PCT/US2014/024293, filed Mar. 12, 2014, which claims the benefit of U.S. Provisional Application No. 61/780,378, filed Mar. 13, 2013, which is incorporated herein by reference in its entirety.


TECHNICAL FIELD
The present invention is directed to substituted 2-azabicyclic compounds, pharmaceutical compositions comprising them, methods of making them, and methods of using them for the modulation of the orexin receptor for the treatment of disease states, disorders, and conditions mediated by orexin receptor activity.
BACKGROUND
Orexin/hypocretin signaling is mediated by two receptors and two peptide agonists. The peptides (orexin-A and orexin-B) are cleavage products of the same gene, pre-pro orexin. In the central nervous system, neurons producing pre-pro orexin are found solely in the perifornical nucleus, the dorsal hypothalamus, and the lateral hypothalamus (Peyron et al., 1998, J. Neurosci. 18: 9996-10015). Orexigenic cells in these regions project to many areas of the brain, extending rostrally to the olfactory bulbs and caudally to the spinal cord (Van den Pol, 1999, J. Neurosci. 19: 3171-3182).
The orexins bind to two high affinity receptors, referred to as orexin-1 and orexin-2 receptors. Orexin-1 and orexin-2 receptors are G-protein-coupled, seven transmembrane receptors that share over 64% amino acid sequence identity with one another. Both receptors are generally excitatory, the common cellular response to orexin-induced receptor activation being increases in intracellular calcium. Homology between the species orthologs is high and there are no known pharmacological differences. Orexin-A and -B are usually considered equal ligands for orexin-2 receptor but orexin-B is thought to be 5- to 100-fold weaker ligand than orexin-A at the orexin-1 receptor (Sakurai et al., 1998, Cell 92: 573-585; Ammoun et al., 2003, J. Pharmacol. Exp. Ther. 305: 507-514).
Many regions of the brain have fairly selective expression of the orexin-1 or orexin-2 receptors (Marcus et al., 2001, J. Comp Neurology 435, 6-25; Trivedi et al., 1998, FEBS Letters, 438, 71-75). Orexin-1 receptors are selective for the limbic system (bed nucleus of the stria terminalis and amygdala), cingulate cortex and noradrenergic neurons in the locus coeruleus. Conversely, the orexin-2 receptor is almost the exclusive orexin receptor in the histaminergic neurons in the tuberomammilary nucleus which play a critical role in wake promotion; in paraventricular neurons and the parabrachial nucleus. In other brain regions like the dorsal raphe, the ventral tegmental area or the prefontal cortex both receptors are coexpressed.
The broad CNS distribution of cells producing orexin, as well as cells expressing the orexin receptors, suggests involvement of orexin in a number of physiological functions, including feeding and metabolism, regulation of wakefulness and sleep, sympathetic activation and stress response (de Lecea, 2012, Progress in Brain Research, 198, 15-24; Kukkonen, 2013, Am J. Physiol. Cell Physiol., 304, C2-C32). Orexin also plays a key role regulating motivation and reward associated with food intake and with drugs of abuse (Mahler et al., 2012, Progress in Brain Research, 198, 79-121).
Several lines of evidence indicate that the orexin system is an important modulator of arousal. Rodents administered orexin intracerebroventricularly spend more time awake (Piper et al., 2000, J. Neurosci. 12: 726-730. Orexin-mediated effects on arousal have been linked to orexin neuronal projections to histaminergic neurons in the tuberomammillary nucleus (Yamanaka et al., 2002, Biochem. Biophys. Res. Comm. 290: 1237-1245). Rodents whose pre-pro orexin gene has been knocked out, or whose orexigenic neurons have been killed, display altered sleep/wake cycles similar to narcolepsy (Chemelli et al., 1999, Cell 98: 437-451; Hara et al., 2001, Neuron 30: 345-354). Dog models of narcolepsy have been shown to have mutant or non-functional orexin-2 receptors (Lin et al., 1999, Cell 98: 365-376). Orexin signaling as a target for sleep-promoting therapies was further validated clinically by findings of attenuated orexin levels and loss of orexinergic neurons in human narcoleptic patients (Mignot et al., 2001, Am. J. Hum. Genet. 68: 686-699; Minot & Thorsby, 2001, New England J. Med. 344: 692) or, in rare cases, to mutations in the orexin-2 gene (Peyron et al., 2000, Nature Med. 6: 991-997). Disorders of the sleep-wake cycle are therefore likely targets for orexin-2 receptor modulator activity. Examples of sleep-wake disorders that may be treated by agonists or other modulators that up-regulate orexin-2 receptor-mediated processes include narcolepsy, jet lag (sleepiness) and sleep disorders secondary to neurological disorders such as depression. Examples of disorders that may be treated by antagonists or other modulators that down-regulate orexin-2 receptor-mediated processes include insomnia, restless leg syndrome, jet lag (wakefulness) and sleep disorders secondary to neurological disorders such as mania, schizophrenia, pain syndromes and the like.
Evidence has accumulated to demonstrate a clear involvement of orexin signaling in reward pathways associated with drug dependence (Mahler et al., 2012, Progress in Brain Research, 198, 79-121). Orexinergic neurons send projections to the ventral tegmental area and other brain regions involved in reward processing. Orexin ligands mediate reward behavior, and antagonizing these effects with a selective orexin-1 receptor antagonist in various preclinical model of addiction has suggested that these actions are mediated through orexin-1 receptor. Specifically, a selective orexin-1 antagonist attenuates morphine conditioned place preference and reinstatement (Harris et al., 2005, Nature, 437, 556-5599; Narita et al., 2006, J Neurosci., 26, 398-405; Harris et al., 2007, Behav Brain Res, 183, 43-51), stress-induced cocaine reinstatement, cocaine-induced behavioral and synaptic plasticity (Borgland et al., 2006, Neuron, 49, 589-601), and intake and cue and stress-induced reinstatement of ethanol (Lawrence et al., 2006, Br J Pharmacol, 148, 752-759), in addition to attenuating precipitated morphine withdrawal (Sharf et al., 2008, Biol Psychiatry, 64, 175-183) and nicotine self-administration (Hollander et al., 2008, Proc Natl Acad Sci USA., 105, 19480-19485). Another recent study has also suggested a role for OX2R (Shoblock et al., 2011, Psychopharmacology, 215, 191-203).
Orexin's role in more complex emotional behavior is also emerging (Johnson et al., 2012, Progress in Brain Research, 198, 133-161). Changes in orexin levels in patients with panic and posttraumatic stress disorders have been noted as have changes in the prevalence of anxiety behaviors in narcoleptic patients (Johnson et al., 2010, Nature Medicine, 16, 111-115; Fortuyn et al., 2010, General Hospital Psychiatry, 32, 49-56; Strawn et al., 2010, Psychoneuroendocrinology, 35, 1001-1007). Lactate infusion or acute hypercapnia, which causes panic in humans, and are used as an animal model of panic, activates orexin neurons in the perifornical hypothalamus. This activation correlates with anxiety in the social interaction test or open field test. Blocking orexin signaling with either siRNA or selective orexin-1 receptor antagonists attenuates panic-like responses to lactate (Johnson et al., 2010, Nature Medicine, 16, 111-115; Johnson et al., 2012, Neuropsychopharmacology, 37, 1911, 1922).
Cerebral spinal fluid (CSF) levels of orexin are lower in depressed or suicidal patients, and the level of orexin inversely correlates with illness severity (Brundin et al., 2007, European Neuropsychopharmacology, 17, 573-579; Salomon et al., 2003, Biol Psychiatry, 54, 96-104). A positive correlation between orexin-1 receptor mRNA in the amygdala and depressive behavior in the forced swim test in mice has been reported (Arendt, 2013, Behavioral Neuroscience, 127, 86-94).
The orexin system also interacts with brain dopamine systems. Intracerebroventricular injections of orexin in mice increase locomotor activity, grooming and stereotypy; these behavioral effects are reversed by administration of D2 dopamine receptor antagonists (Nakamura et al., 2000, Brain Res. 873: 181-187). Therefore, orexin receptor modulators may be useful to treat various neurological disorders; e.g., agonists or up-regulators to treat catatonia, antagonists or down-regulators to treat Parkinson's disease, Tourette's syndrome, anxiety, delerium and dementias.
Orexins and their receptors have been found in both the myenteric and submucosal plexus of the enteric nervous system, where orexins have been shown to increase motility in vitro (Kirchgessner & Liu, 1999, Neuron 24: 941-951) and to stimulate gastric acid secretion in vitro (Takahashi et al., 1999, Biochem. Biophys. Res. Comm. 254: 623-627). Orexin effects on the gut may be driven by a projection via the vagus nerve (van den Pol, 1999, supra), as vagotomy or atropine prevent the effect of an intracerebroventricular injection of orexin on gastric acid secretion (Takahashi et al., 1999, supra). Orexin receptor antagonists or other down-regulators of orexin receptor-mediated systems are therefore potential treatments for ulcers, irritable bowel syndrome, diarrhea and gastroesophageal reflux.
Body weight may also be affected by orexin-mediated regulation of appetite and metabolism. Some effects of orexin on metabolism and appetite may be mediated in the gut, where, as mentioned, orexins alter gastric motility and gastric acid secretion. Orexin antagonists therefore are likely to be useful in treatment of overweight or obesity and conditions related to overweight or obesity, such as insulin resistance/type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins and osteoarthritis. Conversely, orexin agonists are likely to be useful in treatment of underweight and related conditions such as hypotension, bradycardia, ammenorrhea and related infertility, and eating disorders such as anorexia and bulimia.
Intracerebroventricularly administered orexins have been shown to increase mean arterial pressure and heart rate in freely moving (awake) animals (Samson et al., 1999, Brain Res. 831: 248-253; Shirasaka et al., 1999, Am. J. Physiol. 277: R1780-R1785) and in urethane-anesthetized animals (Chen et al., 2000, Am. J. Physiol. 278: R692-R697), with similar results. Orexin receptor agonists may therefore be candidates for treatment of hypotension, bradycardia and heart failure related thereto, while orexin receptor antagonists may be useful for treatment of hypertension, tachycardia and other arrhythmias, angina pectoris and acute heart failure.
From the foregoing discussion, it can be seen that the identification of orexin receptor modulators, will be of great advantage in the development of therapeutic agents for the treatment of a wide variety of disorders that are mediated through these receptor systems.
SUMMARY
The present invention is directed to compounds of Formula I:




wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl; R2 is H, alkyl, alkoxy, or halo; Z is NH, N—CH3, N—CH2CH3, N—CH2-cyclopropyl, N—C(═O)CH3, N—CH2CH2OCH3 or O; R3 is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5-membered or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two groups selected from halo, alkoxy, hydroxymethyl and alkyl; and n is 1 or 2. Enantiomers and diastereomers of the compounds of Formula I are also described, as well as the pharmaceutically acceptable salts.

Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising therapeutically effective amounts of compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.



BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 depicts an Oak Ridge Thermal Ellipsoid Plot Program (ORTEP), shown at 40% probability level, of one embodiment of the invention, Example 13.
FIG. 2 depicts an ORTEP, shown at 40% probability level, of one embodiment of the invention, Example 14.



DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples.
The term “alkyl” refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. In some embodiments, an alkyl group is a C1-C6 alkyl group. In some embodiments, an alkyl group is a C1-C4 alkyl group. Examples of alkyl groups include methyl (Me) ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. Alkyl groups of the invention can be substituted with, for example, halogen atoms. One exemplary substitutent is fluoro. Preferred substituted alkyl groups of the invention include trihalogenated alkyl groups such as trifluoromethyl groups.
Alkyl groups of the invention can also refer to “cycloalkyl” moieties. Cycloalkyl refers to monocyclic, non-aromatic hydrocarbon groups having from 3 to 7 carbon atoms. Examples of cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopropyl, 2-methylcyclopentyl, and the like.
The term “alkoxy” includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. In some embodiments, an alkoxy group is a C1-C6 alkoxy group. In some embodiments, an alkoxy group is a C1-C4 alkoxy group. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on.
The term “aryl ring” represents” a mono- or bi-cyclic aromatic, hydrocarbon ring structure. Aryl rings can have 6 or 10 carbon atoms in the ring.
The term “halogen” represents chlorine, fluorine, bromine, or iodine. The term “halo” represents chloro, fluoro, bromo, or iodo.
The term “heteroaryl ring” represents a mono- or bicyclic aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur. Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms.
The term “isoxazolyl” represents the following moiety:
The term “isoxazolyl” represents the following moiety:




The isoxazolyl moiety can be attached through any one of the 3-, 4-, or 5-position carbon atoms. Isoxazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

The term “oxazolyl” represents the following moiety:




The oxazolyl moiety can be attached through any one of the carbon atoms.

The term “oxadiazolyl” represents a 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, or 1,3,4-oxadiazole moiety:




The oxadiazolyl moieties can be attached through any one of the carbon or nitrogen atoms. Within the scope of the invention, “oxadiazolyl” groups can be substituted with an alkyl or halo group, preferably a methyl group.
The term “pyridyl” represents the following moiety:




The pyridyl moiety can be attached through any one of the 2-, 3-, 4-, 5-, or 6-position carbon atoms.

The term “pyrimidinyl” represents the following moiety:




The pyrimidinyl moiety can be attached through any one of the 2-, 4-, 5-, or 6-position carbon atoms. Within the scope of the invention, “pyrimidinyl” groups of the invention can be substituted with halogen, for example fluoro, or alkyl, for example methyl.

The term “pyrazinyl” represents the following moiety:




The pyrazinyl moiety can be attached through any one of the 2-, 3-, 5-, or 6-position carbon atoms.

The term “pyridazinyl” represents the following moiety:




The pyridazinyl moiety can be attached through any one of the 3-, 4-, 5-, or 6-position carbon atoms.

The term “pyrazolyl” represents the following moiety:




The pyrazolyl moiety can be attached through any one of the 1-, 2-, 3-, 4-, or 5-position carbon atoms. Pyrazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.
The term “triazolyl” represents a 1,2,3-triazole or a 1,2,4-triazole moiety:




The triazolyl moieties can be attached through any one of their atoms.

The term “imidazolyl” represents the following moiety:




The imidazolyl moiety can be attached through any one of the 2-, 4-, or 5-position carbon atoms, or via the N-1 nitrogen atom. Imidazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

The term “thiazolyl” represents the following moiety:




The thiazolyl moiety can be attached through any one of the carbon atoms. Thiazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

The term “naphthyridinyl” represents the following moiety:




The naphthyridinyl moiety can be attached through any one of the carbon atoms. Naphthyridinyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups, or halo groups.

The term “imidazothiazolyl” represents the following moiety:




The imidazothiazolyl moiety can be attached through any one of the carbon atoms. imidazothiazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

“Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
“Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
“Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered. A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
“Subject” includes humans. The terms “human,” “patient,” and “subject” are used interchangeably herein.
“Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.
In treatment methods according to the invention, a therapeutically effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. A “therapeutically effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
“Compounds of the present invention,” and equivalent expressions, are meant to embrace compounds of the Formula (I) as described herein, which expression includes the pharmaceutically acceptable salts, and the solvates, e.g., hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.
As used herein, the term “isotopic variant” refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound. For example, an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more non-radioactive or radioactive isotopes, such as for example, deuterium (2H or D), carbon-13 (13C), nitrogen-15 (15N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be 2H/D, any carbon may be 13C, or any nitrogen may be 15N, and that the presence and placement of such atoms may be determined within the skill of the art. Likewise, the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies. Radiolabeled compounds of the invention can be used in diagnostic methods such as Single-photon emission computed tomography (SPECT). The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for their ease of incorporation and ready means of detection. Further, compounds may be prepared that are substituted with positron emitting isotopes, such as 11C, 18F, 15O and 13N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
All isotopic variants of the compounds of the invention, radioactive or not, are intended to be encompassed within the scope of the invention. In one aspect, provided herein are deuterated analogs of compounds of Formula I as described in the Examples section. In one embodiment, deuterated analogs of compounds of Formula I comprise deuterium atoms attached to one or more positions on the 2-azabicyclic ring, such as bridgehead carbons, or non-bridgehead carbons of the 2-azabicyclic ring, and preferably comprise one or more deuterium atoms attached to non-bridgehead carbons of the 2-azabicyclic ring. Also contemplated within the scope of embodiments described herein are compounds in which a single proton in compounds of Formula I is replaced with a deuterium, or 2 protons in compounds of Formula I are replaced with deuterium, or more than 2 protons in compounds of Formula I are replaced with deuterium. Deuteration of a compound of Formula I may also be effected on one or more substituents (such as e.g., ring A, R1, R2, or R5) present on the 2-azabicyclic ring.
It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.”
Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers.” When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (−)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture.”
“Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the acid- and nitro-forms of phenyl nitromethane, that are likewise formed by treatment with acid or base.
Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
Compounds of the invention may also exist as “rotamers,” that is, conformational isomers that occur when the rotation leading to different conformations is hindered, resulting a rotational energy barrier to be overcome to convert from one conformational isomer to another.
The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof.
Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
The present invention is directed to compounds of Formula I:




wherein

    
    
        X is N or CR1 
        Y is N or CR2 
        R1 is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;
        R2 is H, alkyl, alkoxy, or halo;
        Z is NH, N—CH3, N—CH2CH3, N—CH2-cyclopropyl, N—C(═O)CH3, N—CH2CH2OCH3 or O;
        R3 is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;
        R4 is H or alkyl;
        
            or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;
        
        
        R5 is phenyl, pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two groups selected from halo, alkoxy, hydroxymethyl and alkyl; and
        n is 1 or 2.
    
    


In one aspect, the invention is directed to compounds of Formula I:




wherein

    
    
        X is N or CR1 
        Y is N or CR2 
        R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrazolyl;
        R2 is H, alkyl, alkoxy, or halo;
        Z is NH, or O;
        R3 is H, alkyl, alkoxy, halo, or triazolyl;
        R4 is H or alkyl;
        
            or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;
        
        
        R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and
        n is 1 or 2.
    
    


Enantiomers and diastereomers of the compounds of Formula I are also within the scope of the invention. Also within the scope of the invention are the pharmaceutically acceptable salts of the compounds of Formula I, as well as the pharmaceutically acceptable salts of the enantiomers and diastereomers of the compounds of Formula I. Also within the scope of the invention are isotopic variations of compounds of Formula I, such as, e.g., deuterated compounds of Formula I.
In preferred embodiments, Z is NH. In other embodiments, Z is O. In yet other embodiments, Z is NH, N—CH3, N—CH2CH3, N—CH2-cyclopropyl, N—C(═O)CH3, or N—CH2CH2OCH3.
In preferred embodiments, X is CR1 and Y is CR2.
In other embodiments, X is CR1 and Y is N.
In yet other embodiments, X is N and Y is CR2.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is H. In other embodiments, R1 is alkoxy, for example, C1-6alkoxy such as methoxy or ethoxy.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is halo, preferably F, Cl, or Br.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is triazolyl, optionally substituted with up to two substituents selected from halo and alkyl, with 1,2,3-triazolyl being preferred. In preferred embodiments, the 1,2,3-triazolyl is attached through the 2-position nitrogen atom. In other embodiments, the 1,2,3-triazolyl is attached through the 1-position nitrogen atom.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is pyrimidinyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is oxazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is isoxazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is oxadiazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The oxadiazolyl group can optionally be substituted with alkyl, for example methyl. In exemplary embodiments, the substituted oxadiazolyl moiety is 1,2,4-oxadiazolyl substituted with methyl.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is pyridyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The pyridyl group can optionally be substituted with alkyl, for example methyl or halo.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is imidazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The imidazolyl group can optionally be substituted with alkyl, for example methyl or halo.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is phenyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The phenyl group can optionally be substituted with alkyl, for example methyl or halo.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is pyrazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The pyrazolyl group can optionally be substituted with one or two C1-6alkyl, for example methyl.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is thiazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.
In those embodiments wherein X is CR1, for example, where X is CR1 and Y is CR2 or X is CR1 and Y is N, R1 is pyridazinyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.
In preferred embodiments wherein Y is CR2, for example, X is CR1 and Y is CR2 or X is N and Y is CR2, R2 is H. In other embodiments, R2 is alkyl, for example C1-6alkyl such as methyl.
In those embodiments wherein Y is CR2, for example, X is CR1 and Y is CR2 or X is N and Y is CR2, R2 is alkoxy, for example, C1-6alkoxy such as methoxy or ethoxy.
In those embodiments wherein Y is CR2, for example, X is CR1 and Y is CR2 or X is N and Y is CR2, R2 is halo, preferably one of F, Cl, or Br.
In preferred embodiments, R3 is H. In other embodiments, R3 is alkyl, for example, C1-6alkyl such as methyl.
In yet other embodiments, R3 is alkoxy, for example, C1-6alkoxy such as methoxy or ethoxy.
In still other embodiments, R3 is halo, preferably F, Cl, or Br.
In other embodiments, R3 is triazolyl, with 1,2,3-triazolyl being preferred. In preferred embodiments, the 1,2,3-triazolyl is attached through the 2-position nitrogen atom. In other embodiments, the 1,2,3-triazolyl is attached through the 1-position nitrogen atom.
In preferred embodiments, R4 is H. In other embodiments, R3 is alkyl, for example C1-6alkyl such as methyl.
In alternative embodiments, R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring.
In other embodiments, R3 and R4, together with the atoms to which they are attached, form a 5-membered heteroaryl ring. Preferably, the 5-membered heteroaryl ring includes one nitrogen atom.
In other embodiments, R3 and R4, together with the atoms to which they are attached, form a 6-membered heteroaryl ring. Preferably, the 6-membered heteroaryl ring includes one nitrogen atom.
In some embodiments of the invention, R5 is a phenyl ring optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, cyano, alkoxy, and halo, or from the group consisting of alkyl and halo. In some embodiments of the invention, R5 is a heteroaryl ring. In some of such embodiments, R5 is a heteroaryl optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, cyano, alkoxy, and halo, or from the group consisting of alkyl and halo. In preferred embodiments, R5 is pyridyl, which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trihaloalkyl such as trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R5 is pyridyl substituted at any available position with trifluoromethyl.
In preferred embodiments, R5 is pyrazinyl, which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trihaloalkyl such as trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R5 is pyrazinyl substituted at any available position with trifluoromethyl.
In preferred embodiments, R5 is pyrimidinyl, which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trihaloalkyl such as trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R5 is pyrimidinyl substituted at any available position with trifluoromethyl.
In other embodiments, R5 is benzoxazolyl which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R5 is benzoxazolyl, pyridazinyl, or naphthyridinyl substituted at any available position with trifluoromethyl.
In other embodiments, R5 is pyridazinyl which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R5 is benzoxazolyl, pyridazinyl, or naphthyridinyl substituted at any available position with trifluoromethyl.
In other embodiments, R5 is naphthyridinyl which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R5 is benzoxazolyl, pyridazinyl, or naphthyridinyl substituted at any available position with trifluoromethyl.
In preferred embodiments, n is 1. In other embodiments, n is 2.
In some embodiments of Formula I, R1 is H and R3 is as defined above for Formula I, preferably R3 is triazolyl, oxazolyl, pyridyl or pyrimidinyl. In other embodiments of Formula I, R3 is H and R1 is as defined above for Formula I, preferably R1 is triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl or pyrimidinyl.
In some embodiments of Formula I, the group




is a pyridyl group, preferably X is N, R3 is a ring selected from triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl or pyridyl or pyrimidinyl; R4 is H or alkyl, preferably methyl; Z is NH or O, preferably O; preferably NH, R5 is a heteroaryl, preferably pyridyl or pyrazinyl. In some of such embodiments, R3 is a ring at the ortho position relative to the carbonyl group in Formula I, and R4 is at the ortho, meta or para position on the relative to the carbonyl group in Formula I, preferably R4 is at the meta position adjacent to R3. In some other such embodiments, R3 is a ring at the ortho position relative to the carbonyl group in Formula I, and R4 is at the ortho, meta or para position relative to the carbonyl group in Formula I, preferably R4 is at the meta position not adjacent to R3. R3 and R5 are optionally substituted as described above.

In some embodiments of Formula I, the group




is a pyridyl group, preferably Y is N, R1 is a ring selected from triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl or pyridyl or pyrimidinyl; R4 is H or alkyl, preferably methyl; Z is NH or O, preferably O; preferably NH, R5 is a heteroaryl, preferably pyridyl or pyrazinyl. In some of such embodiments, R1 is a ring at the ortho position relative to the carbonyl group in Formula I, and R4 is at the ortho, meta or para position on the relative to the carbonyl group in Formula I, preferably R4 is at the meta position adjacent to R1. In some other such embodiments, R1 is a ring at the ortho position relative to the carbonyl group in Formula I, and R4 is at the ortho, meta or para position relative to the carbonyl group in Formula I, preferably R4 is at the meta position not adjacent to R1. R1 and R5 are optionally substituted as described above.

In some embodiments of Formula I, the group




is a phenyl group, R3 is a ring selected from triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl or pyridyl or pyrimidinyl at the ortho position; R4 is H or alkyl, preferably methyl; Z is NH or O, preferably O; preferably NH, R5 is a heteroaryl, preferably pyridyl or pyrazinyl. In some of such embodiments, R3 is a ring at the ortho position relative to the carbonyl group in Formula I, and R4 is at the ortho, meta or para position on the relative to the carbonyl group in Formula I, preferably R4 is at the meta position adjacent to R3. In some other such embodiments, R3 is a ring at the ortho position relative to the carbonyl group in Formula I, and R4 is at the ortho, meta or para position relative to the carbonyl group in Formula I, preferably R4 is at the meta position not adjacent to R3. R3 and R5 are optionally substituted as described above.

Also provided herein is a compound of Formula IA:




wherein

    
    
        ring A is a heteroaryl ring selected from furanyl, thiazolyl, imidazothiazolyl, and pyrazinyl;
        R1 is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;
        R2 is H, alkyl, alkoxy, or halo;
        Z is NH, N—CH3, N—CH2CH3, N—CH2-cyclopropyl, N—C(═O)CH3, N—CH2CH2OCH3 or O;
        R3 is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;
        R4 is H or alkyl;
        
            or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;
        
        
        R5 is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two substituents selected from halo, alkoxy, hydroxymethyl and alkyl; and
        n is 1 or 2.
    
    


Enantiomers and diastereomers of the compounds of Formula IA are also within the scope of the invention. Also within the scope of the invention are the pharmaceutically acceptable salts of the compounds of Formula IA, as well as the pharmaceutically acceptable salts of the enantiomers and diastereomers of the compounds of Formula IA. Also within the scope of the invention are isotopic variations of compounds of Formula IA, such as, e.g., deuterated compounds of Formula IA.
In some embodiments, ring A is a furanyl ring. In some embodiments, ring A is a thiazolyl ring. In some embodiments, ring A is a imidazothiazolyl ring. In other embodiments, ring A is a pyrazinyl ring.
All of the embodiments described for Formula I above, with respect to the variables R1, R2, Z, R3, R4, R5 and n, also apply for Formula IA, and are expressly contemplated herein.
The invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by orexin receptor activity. These methods are accomplished by administering to the subject a compound of the invention. In some embodiments, the compounds described herein are selective for orexin-1 receptor activity. In some embodiments, the compounds described herein are selective for orexin-1 receptor activity over orexin-2 receptor activity.
Diseases, disorders, and conditions mediated by orexin receptor activity include disorders of the sleep-wake cycle, insomnia, restless legs syndrome, jet-lag, disturbed sleep, sleep disorders secondary to neurological disorders, mania, depression, manic depression, schizophrenia, pain syndromes, fibromyalgia, neuropathic pain, catatonia, Parkinson's disease, Tourette's syndrome, anxiety, delirium, dementia, overweight, obesity, or conditions related to overweight or obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, osteoarthritis, hypertension, tachycardia, arrhythmias, angina pectoris, acute heart failure, ulcers, irritable bowel syndrome, diarrhea gastroesophageal reflux, mood disorders, post-traumatic stress disorder, panic disorders, attention deficit disorders, cognitive deficiencies, or substance abuse.
Compounds of the invention are particularly suited for the treatment of mood disorders, post-traumatic stress disorder, panic disorders, attention deficit disorders, cognitive deficiencies, or substance abuse.
In one aspect, compounds of the invention are particularly suited for the treatment of mood disorders. Non-limiting examples of mood disorders include anxiety-related mood disorders, depression, panic-related mood disorders, stress related mood disorders and the like. In another aspect, compounds of the invention are suitable for the treatment of post-traumatic stress disorder, panic disorders, attention deficit disorders, cognitive deficiencies, or substance abuse (e.g., morphine abuse, cocaine abuse, alcohol abuse and the like). It will be understood that certain disorders such as, for example, depression and/or schizophrenia and/or substance abuse and/or cognitive impairments also have elements of anxiety and/or panic and/or stress associated with them and the treatment of such conditions and/or combinations of conditions are also contemplated within the scope of embodiments presented herein. In some embodiments, advantageously, compounds of the invention treat a mood disorder (e.g., anxiety) with reduced concomitant sedation and/or with reduced effect on sleep (e.g. attenuated arousal effects). In one embodiment, compounds of the invention are particularly suited for the treatment of anxious depression. In another embodiment, compounds of the invention are particularly suited for the treatment of panic, schizophrenia, and substance abuse.
Sleep disorders include, but are not limited to, sleep-wake transition disorders, insomnia, restless legs syndrome, jet-lag, disturbed sleep, and sleep disorders secondary to neurological disorders (e g, manias, depressions, manic depression, schizophrenia, and pain syndromes (e.g., fibromyalgia, neuropathic).
Metabolic disorders include, but are not limited to, overweight or obesity and conditions related to overweight or obesity, such as insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins and osteoarthritis.
Neurological disorders include, but are not limited to, Parkinson's disease, Alzheimer's disease, Tourette's Syndrome, catatonia, anxiety, delirium and dementias.
In treatment methods according to the invention, a therapeutically effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. A “therapeutically effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
In addition, the compounds of the invention may be used in combination with additional active ingredients in the treatment of the above conditions. The additional active ingredients may be coadministered separately with a compound of the invention or included with such an agent in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by orexin activity, such as another orexin modulator or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.
The compounds of the invention are used, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of at least one compound in accordance with the invention; and (b) a pharmaceutically acceptable excipient.
Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.
For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily. For example, a total daily dosage of about 5 mg to 5 g daily may be accomplished by dosing once, twice, three, or four times per day.
Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
The active agents of this invention may also be administered by non-oral routes. For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses may range from about 1 to 1000 .mu.g/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
For topical administration, the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.
Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0° C. and the reflux temperature of the solvent. Reactions may be heated employing conventional heating or microwave heating. Reactions may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.
The synthesis of exemplary intermediates having the structure




is described in Schemes 1-6 below and in the Examples section below (Intermediates A-1 to A-59).





Intermediate compounds of formula (IIIa) and (IIIb) can be prepared as outlined in Scheme 1 from commercially available or synthetically accessible compounds of formula (A) where R3A, R4A are —H, halo, —C1-4alkyl, —C1-4alkoxy or R3A and R4A together with the atoms to which they are attached form a 6-membered aryl or 6 membered heteroaryl ring and X and Y are as defined in formula (I) as above. Compounds of formula (IIa) and (IIb), are obtained by reacting a compound of formula (A), with commercially available 1,2,3-triazole, in the presence K2CO3 in DMF or dioxane, at temperatures ranging from about 60° C. to about 100° C. Compounds of formula (IIIa) and (IIIb) are obtained by reacting compounds of formula (II) in the presence of a base such as NaOH in a solvent such as EtOH at temperatures ranging from about 80° C. to about 100° C. One skilled in the art will recognize that 1,2,3-triazole can exist in two tautomeric forms defined as 2H-[1,2,3]triazole and 1H-[1,2,3]triazole thus accounting for the formation of (IIIa) and (IIIb).




Intermediate compounds of formula (III) can be prepared as outlined in Scheme 2 from commercially available or synthetically accessible compounds of formula (IVa-c). Compounds of formula (Va) and (Vb) are obtained by reacting compounds of formula (IVa), (IVb) and (IVc) where Hal is —Br, or —I; W is CO2H, CO2Alkyl, or CN and R3A and R4A are —H, halo, —C1-4alkyl, —C1-4 alkoxy or R3A and R4A together with the atoms to which they are attached form a 6-membered aryl or 6 membered heteroaryl ring, and X and Y are as defined in Formula I above, with commercially available 1,2,3-triazole, in the presence of, for example, copper(I)iodide, Cs2CO3 and trans-N,N′-dimethyl-1,2-cyclohexanediamine in, for example, DMF or dioxane, at temperatures ranging from about 60° C. to about 120° C. Compounds of formula (IVc) can be converted to the corresponding esters (Vb) by treatment with, for example, alkyl iodide in the presence of a base such as K2CO3 in a solvent such as DMF. Compounds of formula (III) are obtained by reacting a compound of formula (Va) and (Vb) in the presence of a base such as NaOH in a solvent such as EtOH at temperatures ranging from about 80° C. to about 100° C. One skilled in the art will recognize that 1,2,3-triazole can exist in two tautomeric forms defined as 2H-[1,2,3]triazole and 1H-[1,2,3]triazole thus compounds of formula (Va), (Vb), and (III) can also exist as the N1 linked variant (structure not shown). It will be understood that the heterocycle in (Va) and (Vb) is not limited to triazole and may be any other suitable heterocycle.




Intermediate compounds of formula (IX) can be prepared as outlined in Scheme 3 from commercially available or synthetically accessible compounds of formula (VI) where R3A, R4A are —H, halo, —C1-4alkyl, —C1-4alkoxy or R3A and R4A together with the atoms to which they are attached form a 6-membered aryl or 6 membered heteroaryl ring, and X and Y are as defined in formula (I) as above, G is SnBu3, or 4,4,5,5 tetramethyl-1,dioxaboralane, and HAL is Cl, or Br, preferably Br. Compounds of formula (VIII) are obtained by reacting a compound of formula (VI) with commercially available (VII) in the presence of a catalyst such as 1,1′-Bis(di-tert-butylphosphino)ferrocene palladium dichloride and a base such as Na2CO3 in a solvent such as 2-MeTHF or THF at temperatures ranging from about 60° C. to about 90° C. Compounds of formula (IX) are obtained by reacting a compound of formula (VIII) in the presence of a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80° C. to about 100° C. or acids such as H2SO4 in solvents such as H2O at temperatures ranging from about 80° C. to about 100° C. It will be understood that the heterocycle in (VII) is not limited to pyrimidine and may be any other suitable heterocycle.




Intermediate compound of formula (XIV) can be prepared as outlined in Scheme 4 from commercially available compound (X). Compound (XI) is obtained by reacting compound (X) with commercially available acrolein in a solvent such as 1,4 dioxane at temperatures of about 200° C. in, for example, a microwave reactor. Compound (XII) can be prepared from compound (XI) by treatment with an acid such as HBr in a solvent such as toluene at a temperature of about 90° C. Compound (XIII) can be obtained by treatment of compound (XII) with, for example, commercially available iodoethane and a base such as K2CO3 in a solvent such as DMF at temperatures ranging from about 45° C. to about 65° C. Compound (XIV) is obtained by treating compound (XIII) with a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80° C. to about 100° C.




Intermediate compounds of formula (XVI) are prepared as outlined in Scheme 5 from commercially available or synthetically accessible compounds of formula (XIV) where R2B is —H, —C1-4alkyl, or —C1-4alkoxy, or R2B is —H, halo, —C1-4alkyl, or —C1-4alkoxy, and HAL is halo, preferably Cl, or Br. Compounds of formula (XV) are obtained by reacting a compound of formula (XIV) with commercially available (VII) in the presence of a catalyst such as Pd(dppf)Cl2 and a base such as Na2CO3 in a solvent such as 2-MeTHF at temperatures ranging from about 75° C. to about 150° C. Compounds of formula (XVI) are obtained by reacting a compound of formula (XV) in the presence of a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80° C. to about 100° C. It will be understood that the heterocycle in (VII) is not limited to pyrimidine and may be any other suitable heterocycle.




Intermediate compounds of formula (XXI) can be prepared as outlined in Scheme 6 from commercially available or synthetically accessible compounds of formula (XVII) where Hal is Br or I; and where R3A and R4A are —H, halo, —C1-4alkyl, —C1-4alkoxy, or R3A and R4A together with the atoms to which they are attached form a 6-membered aryl or 6 membered heteroaryl ring. Compounds of formula (XVIIIa) can be converted to the corresponding ester (XVIIIb) by treatment with, for example, thionyl chloride in a solvent such as MeOH. Compounds of the formula (XX) are obtained by reacting compounds of formula (XVIIIb) with commercially available compounds of the formula XIX where L is a heterocycle such as pyrazole, pyridyl, or oxazole or any other heterocycle described herein; G is SnBu3 or 4,4,5,5 tetramethyl-1,dioxaboralane and R1A and R2A are —H, —C1-4alkyl, or —C1-4alkoxy, or R1A and R2A are —H, halo, —C1-4alkyl, or —C1-4alkoxy; in the presence of a catalyst such as Pd(Ph3P)4 and a base such as Na2CO3 in a mixture of solvents such as DME and H2O at temperatures ranging from about 100° C. to about 150° C. Compounds of formula (XXI) are obtained by reacting a compound of formula (XX) in the presence of a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80° C. to about 100° C.




According to Scheme 7, compound (XXV), where n is 1 or 2, is obtained by reaction of (XXII), (XXIII) where PG of H2N-PG is H, benzyl (Bn), methyl benzyl, and the like, and (XXIV) in an aqueous medium where H+ is HCl, AcOH and the like as described in C. Chiu et al. Synthetic Communications 1996, 26, 577-584 and S. Larsen et al. J. Am. Chem. Soc. 1985, 107, 1768-1769. In a particularly preferred embodiment, a compound of formula (XXV), where n is 1, is obtained by reacting, for example, commercially available cyclopentadiene, (+)-α-methyl-benzylamine and formaldehyde in an aqueous medium with AcOH. Enantio-enriched compounds of formula (XXVa) and (XXVb) are obtained by chiral resolution of (XXV) using a chiral acid, such as commercially available L or D-dibenzoyl tartaric acid and the like, followed by formation of the free base using a base such as aqueous NaOH and the like, as described in C. Chiu et al. Synthetic Communications 1996, 26, 577-584. In a preferred embodiment, a compound of formula (XXV) is treated with, for example, D-dibenzoyl tartaric acid followed by a base such as aqueous NaOH to afford an enantio-enriched compound of formula (XXVa). Compound (XXVII) is obtained from (XXVa) through a hydroboration/oxidation sequence of the olefin to install the hydroxyl group; followed by, for example, an optional one-pot palladium-mediated hydrogenolysis and PG “swap” (i.e. methyl benzyl to Boc); and subsequent oxidation of the hydroxyl group using an oxidant such as IBX, SO3-pyridine, Swern conditions [(COCl)2, DMSO, Et3N], and the like, in a solvent such as EtOAc, DMSO, DCM, and the like, at temperatures ranging from about −78° C. to room temperature (about 23° C.). In a preferred embodiment, a compound of formula (XXVa) where PG is methyl benzyl, is treated with, for example, BH3 followed by H2O2 and NaOH to install the hydroxyl group, and, for example, a one-pot palladium mediated hydrogenolysis using hydrogen gas (1 atm), Pd/C, and Boc2O, in EtOH at room temperature (23° C.) exchanges the methyl benzyl for a Boc group. The Boc-protected intermediate is oxidized with, for example, IBX in refluxing such as, for example, EtOAc to afford a compound of formula (XXVII). Compound (XXVb) could also be subjected to the same set of transformations as compound (XXVa) to obtain the corresponding opposite enantiomer (structure not shown).
A compound of formula (XXVIII) where Z is OH, is obtained from reduction ([R]) of the ketone in a compound of formula (XXVII), with a reducing agent such as L-Selectride, NaBH4 and the like, in a solvent such as THF, MeOH and the like at temperatures ranging from about −78° C. to room temperature (about 23° C.). Alternatively, the racemic form of a compound of formula (XXVIII) can be obtained from reduction of commercially available (R/S)-tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate as described in R. Nencka et al. Tetrahedron 2012, 68, 1286-1298.
An alternative route to a compound of formula (XXVII) can be prepared from commercially available (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one (XXVI). A compound of formula (XXV) is obtained from treatment of compound (XXVI) with a reducing agent such as LiAlH4 and the like, followed by protection of the free amine with a suitable protecting group. A compound of formula (XXVII) is obtained from a compound of formula (XXV) by a hydroboration/oxidation sequence of the olefin to install the hydroxyl group; followed by oxidation of the hydroxyl group using an oxidant such as IBX, SO3-pyridine, Swern conditions [(COCl)2, DMSO, Et3N], and the like, in a solvent such as EtOAc, DMSO, DCM, and the like at temperatures ranging from about −78° C. to room temperature (about 23° C.); and, optionally, a one-pot palladium mediated hydrogenolysis and PG “swap” (i.e. Bn to Boc). In a preferred embodiment, a compound of formula (XXV) where PG is Bn is subjected to the conditions described in F. Carroll et al. J. of Med. Chem. 1992, 35, 2184-2191, followed by PG swap (Bn to Boc) to obtain a compound of formula (XXVII) where PG is Boc.
A compound of formula (XXVIII) where Z is NH2, is obtained by reacting a compound of formula (XXVII) with an amine NH2-Q, where Q is OH or Bn, followed by reduction of the corresponding oxime or imine with a suitable reducing agent such as NaBH4 (with or without a metal salt additive such as NiCl2 and the like), Raney Ni (H2 atm), Zn(BH4)2, and the like in a solvent such as MeOH and the like. In a particular embodiment, the oxime intermediate from reaction of a compound of formula (XXVII) with an amine NH2-Q, where Q is OH, is obtained by reacting a compound of formula (XXVII) with commercially available hydroxylamine hydrochloride and triethylamine in EtOH at temperatures ranging from room temperature (about 23° C.) to reflux. The oxime intermediate is reduced with NaBH4 in combination with NiCl2 in MeOH to give a compound of formula (XXVIII) where Z is NH2. Alternatively, the imine intermediate from reaction of a compound of formula (XXVII) with an amine NH2-Q, where Q is Bn, is obtained by reacting a compound of formula (XXVII) with commercially available benzylamine. In-situ reduction of the imine intermediate with a reducing agent such as sodium triacetoxyborohydride and the like, followed by debenzylation under, for example, palladium mediated hydrogenolysis affords a compound of formula (XXVIII) where Z is NH2.
Referring to Scheme 7, the synthesis of compounds wherein n is 2 is described in the Examples section, for instance in Intermediates C-1-C-11, and in Examples 248-283.




According to Scheme 8, a compound of formula (XXIX), where Z is O or NH, is obtained from a compound of formula (XXVIII), by a SNAr reaction or metal mediated cross-coupling reaction with a compound R5—U; where R5—U is a suitable commercially available or synthetically accessible halogen-substituted heteroaryl compound, where R5 is defined in formula (I) as above and W is F, Cl, Br, I, or OTf. A compound of formula (XXIX) where Z is O, is obtained from a compound of formula (XXVIII), where Z is OH, by SNAr coupling with a compound R5—W as described above, in the presence of a base, such as NaH, K2CO3 and the like, in a solvent such as DMF at temperatures ranging from room temperature (about 23° C.) to about 90° C. In a preferred embodiment the base is NaH and the solvent is DMF. A compound of formula (XXIX), where Z is NH, is obtained from a compound of formula (XXVIII), where Z is NH2, by metal mediated cross-coupling with a compound R5—W as described above, in the presence of a palladium catalyst, a phosphine ligand such as BINAP and the like, a base such as NaOtBu and the like, in a solvent such as toluene, DME, and DMF, at temperatures ranging from room temperature (about 23° C.) to about 100° C. In a preferred embodiment the palladium catalyst is Pd(OAc)2, the ligand is BINAP, the base is NaOtBu, and the solvent is toluene. Alternatively, a compound of formula (XXIX) where Z is NH, is obtained from a compound of formula (XXVIII), where Z is NH2, by SNAr coupling with a compound R5—W as described above, in the presence of a base, such as NaH, K2CO3 in a solvent such as DMF at temperatures ranging from room temperature (about 23° C.) to about 90° C. In a preferred embodiment the base is K2CO3 and the solvent is DMF. Removal of PG (where PG is Boc, Bn, methyl benzyl, and the like) in compounds of formula (XXIX) is accomplished using methods known to one skilled in the art to give compounds of formula (XXX). In a preferred embodiment, where PG is Boc in a compound of formula (XXIX) and Z is O or NH, is treated with, for example, HCl in dioxane to afford a compound of formula (XXX).
A compound of formula (XXXI) is obtained from a compound of formula (XXX), by reaction of a compound of formula (XXX) with a compound of formula (XXXII), under amide bond formation conditions. Compounds of formula (XXXII), where X, Y, R3, and R4 are as defined in formula (I), are commercially available, as described, or synthetically accessible appropriately substituted aryl or heteroaryl carboxylic acids or acid salts. A compound of formula (XXX), either as a free base or as an acid salt, is reacted with a compound of formula (XXXII) in the presence of a dehydrating agent such as HOBt/EDAC, CDI, HATU, HOAT, T3P; a suitably selected base such as DIPEA, TEA; in an organic solvent or mixture thereof, such as toluene, MeCN, EtOAc, DMF, THF, DCM to afford a compound of formula (XXXI). In a particularly preferred embodiment a compound of formula (XXXI) is obtained using, for example, the dehydrating agent HATU, the base DIPEA, and the solvent DMF; or the dehydrating agent T3P, the base Et3N, and the solvent mixture of DCM/DMF. Alternatively, one skilled in the art can transform a compound of formula (XXXII) to the corresponding acid chloride or an activated ester before amide formation with a compound of formula (XXX).
Referring to Scheme 8, the synthesis of compounds wherein n is 2 is described in the Examples section, for instance in Intermediates C-1-C-11, and in Examples 248-283.
In one group of embodiments, provided herein is a compound of Formula I of Examples 1-84 with structures and names as set forth in the Examples section. In another group of embodiments, provided herein is a compound of Formula I of Examples 1-4, 7-92, 94-204, 206, 208-660 with structures and names as set forth in the Examples section below. In yet another embodiment, provided herein is a compound of Formula I of Examples 85-92, 94-204, 206, 208-660 with structures and names as set forth in the Examples section below. In one group of embodiments, provided herein is a compound of Formula IA selected from Examples 5, 6, 93, 205, and 207 having the structures and names as set forth in the Examples section below. In one group of embodiments, provided herein is a compound of Formula I or Formula IA having structures and names as set forth in Table 2 below.
EXAMPLES
Abbreviations














Term
Acronym









Acetic Acid
HOAc



Acetonitrile
ACN



Apparent
app



Aqueous
aq



Atmosphere
atm



2-(1H-9-Azobenzotriazole-1-yl)-1,1,3,3-
HATU



tetramethylaminium hexafluorophosphate



Benzyl
Bn



2,2′-bis(diphenylphosphino)-1,1′-binaphthalene
BINAP



[1,1′-Bis(di-tert-
PdCl2(dtbpf)



butylphosphino)ferrocene]dichloropalladium(II)



Broad
br



tert-Butylcarbamoyl
Boc/Boc



Dichloromethane
DCM



Diisopropylethylamine
DIPEA



1,2-Dimethoxyethane
DME



N,N-Dimethylformamide
DMF



Dimethylsulfoxide
DMSO



Doublet
d



Electrospray ionization
ESI



Enantiomeric excess
ee



Ethanol
EtOH



Ethyl Acetate
EtOAc, or EA



Grams
g



Hertz
Hz



High-pressure liquid chromatography
HPLC



Hours
h



Liquid chromatography and mass spectrometry
LCMS



Mass spectrometry
MS



Mass to charge ratio
m/z



Methanol
MeOH



Microliter
μL



Milligrams
mg



Milliliter
mL



Millimoles
mmol



Minute
min



Molar
M



Multiplet
m



Normal
N



Nuclear magnetic resonance
NMR



Palladium on carbon
Pd/C



Palladium hydroxide on carbon
Pd(OH)2/C



Parts per million
ppm



Phenyl
Ph



Propylphosphonic anhydride
T3P



Retention time
Rt



Room temperature
rt



Quartet
q



Singlet
S



Supercritical Fluid Chromatography
SFC



Temperature
T



Thin layer chromatography
TLC



Times
X



Triethylamine
TEA



Trifluoroacetic acid
TFA



Triplet
t










Chemistry:

In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.
Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were “dried,” they were generally dried over a drying agent such as Na2SO4 or MgSO4. Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM Discover instrument.
Where compounds were “purified via silica gel chromatography” normal-phase flash column chromatography was performed on silica gel (SiO2) using prepackaged cartridges, eluting with the indicated solvents.
Where compounds were purified by “Shimadzu Method X” the method employed was either:
Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 μm, 30×100 mm, T=45° C.), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6 min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.
or
Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Shimadzu LC-8A Series HPLC with an XBridge C18 OBD column (5 μm, 50×100 mm), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.
Where compounds were purified by “Agilent Prep Method X” the method employed was either:
Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Agilent 1100 Series HPLC with an XBridge C18 OBD column (5 μm, 30×100 mm), mobile phase of 5% ACN in 20 mM NH4OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 40 mL/min.
or
Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Agilent 1100 Series HPLC with an XBridge C18 OBD column (5 μm, 50×100 mm), mobile phase of 5% ACN in 20 mM NH4OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 80 mL/min.
Where compounds were purified by “Gilson Prep Method X” the method employed was: Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Gilson HPLC with an XBridge C18 column (5 μm, 100×50 mm), mobile phase of 5-99% ACN in 20 mM NH4OH over 10 min and then hold at 99 ACN for 2 min, at a flow rate of 80 mL/min.
Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
Where acids are employed for amide bond coupling the free acid or acid salt may be used interchangeably.
Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. The format of the 1H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration). Definitions for multiplicity are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad. For compounds that are present as a mixture of rotamers the ratio is represented so that the total is 1, e.g. 0.80:0.20. Alternatively, 1H NMR data may be reported for only the major rotamer as indicated, or the data may be reported for one or more rotamers such that the total is less than 1. It will be understood that for compounds comprising an exchangeable proton, said proton may or may not be visible on an NMR spectrum depending on the choice of solvent used for running the NMR spectrum and the concentration of the compound in the solution.
Chemical names were generated using ChemDraw Ultra 12.0 (CambridgeSoft Corp., Cambridge, Mass.) or ACD/Name Version 10.01 (Advanced Chemistry).
Compounds designated (R/S) are racemic compounds where the relative stereochemistry is as drawn.
Examples 63-65, 68-72, 75, 78-79, 81-82, 84, 164-165, 303-419, 421-660 are suitable for preparation using methods analogous to the methods described in the synthetic schemes and in the Examples section.
Intermediates













Intermediate
Name
Structure
Reference







A-1 
2-(2H-1,2,3-triazol- 2-yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 2


 


A-2 
3-fluoro-2- (pyrimidin-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 50


 


A-3 
6-methyl-2-(2H- 1,2,3-triazol-2- yl)nicotinic acid




Prepared according to WO 2011/050198 Intermediate 70


 


A-4 
6-methyl-2-(1H- 1,2,3-triazol-1- yl)nicotinic acid




Prepared according to WO 2011/050198 Intermediate 71


 


A-5 
4-methoxy-2-(2H- 1,2,3-triazol-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 54


 


A-6 
2-fluoro-6- (pyrimidin-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 14


 


A-7 
5-fluoro-2- (pyrimidin-2- yl)benzoic acid.




Prepared according to WO 2011/050198 Intermediate 13


 


A-8 
3-ethoxy-6- methylpicolinic acid




WO 2010/063663 Description 39


 


A-9 
2-(4H-1,2,4-triazol- 4-yl)benzoic acid




Commercially available, CAS 167626-65-5


 


A-10
5-fluoro-2-(2H- 1,2,3-triazol-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 1


 


A-11
2-fluoro-6-(2H- 1,2,3-triazol-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 12


 


A-12
4-fluoro-2-(2H- 1,2,3-triazol-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 4


 


A-13
2-methoxy-6-(2H- 1,2,3-triazol-2- yl)benzoic acid




Prepared analogous to Intermediate A-X using 2-bromo-6- (2H-1,2,3-triazol-2- yl)benzoic acid


 


A-14
5-(4-fluorophenyl)- 2-methylthiazole-4- carboxylic acid




Commercially available, CAS 433283-22-8


 


A-15
4-methoxy-2- (pyrimidin-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 88


 


A-16
3-fluoro-2-(2H- 1,2,3-triazol-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 5


 


A-17
6- methylimidazo[2,1- b]thiazole-5- carboxylic acid




Commercially available, CAS 77628-51-4


 


A-18
3-fluoro-2- methoxybenzoic acid




Commercially available, CAS 106428-05-1









Synthesis of 3-fluoro-2-(pyrimidin-2-yl)benzonitrile (Intermediate in the synthesis of intermediate A-2)




To a solution of 3-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (4.98 g, 19.1 mmol) and 2-bromopyrimidine (3.85 g, 23 mmol) in THF (96 mL) was added Na2CO3 (6 g, 57.4 mmol) followed by water (43 mL). The reaction mixture was degassed with N2 for 10 minutes. PdCl2(dtbpf) (374 mg, 0.57 mmol) was added and the reaction mixture was stirred at 80° C. for 5 h. The solution was cooled to room temperature and a mixture of EtOAc and water was added. The aqueous was extracted twice with EtOAc and the combined organic layers were dried over MgSO4, filtered and evaporated. The title compound was precipitated by dissolving the residue in a minimum amount of EtOAc and then adding hexanes. The solid was filtered, washed with hexanes and dried to afford the title compound (2.46 g, 64%). MS (ESI) mass calcd. for C11H6FN3, 199.1. m/z found 200.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.02-8.91 (m, 2H), 7.65 (dt, J=7.7, 1.0 Hz, 1H), 7.60-7.52 (m, 1H), 7.51-7.43 (m, 1H), 7.41 (t, J=4.9 Hz, 1H).
Intermediate A-19: 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid




Step A: 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinonitrile. To 3-bromo-5-methylpicolinic acid (1.5 g, 7.6 mmol) in DMF (19 mL) was added K2CO3 (1.2 g, 8.4 mmol) and 2H-1,2,3-triazole (440 μL, 7.6 mmol). The mixture was heated to 100° C. for 16 h, cooled to room temperature and extracted with EtOAc (2×). The combined organics were dried (Na2SO4) and concentrated. Purification via silica gel chromatography (5-60% EtOAc in hexanes) gave the title compound (490 mg, 35%)1H NMR (500 MHz, Chloroform-d) 8.58-8.53 (m, 1H), 8.29-8.24 (m, 1H), 7.98 (s, 2H), 2.54 (s, 3H) and 5-methyl-3-(1H-1,2,3-triazol-1-yl)picolinonitrile (387 mg, 27%).
Step B: (sodium 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinate). To a solution of the title compound of Step A (489 mg, 2.6 mmol) in EtOH (7 mL) was added 4 N NaOH (660 μL, 2.6 mmol). The mixture was heated at 100° C. for 24 h. The reaction mixture was concentrated in vacuo to a white solid which was used without further purification in subsequent steps. MS (ESI) mass calcd. for C9H8N4O2, 204.1. m/z found 205.0 [M+H]+.
Intermediate A-20: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid




Step A: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinonitrile. To 3-bromo-6-methylpicolinonitrile (2.2 g, 11 mmol) in DMF (28 mL) was added K2CO3 (1.7 g, 12 mmol) and 2H-1,2,3-triazole (650 μL, 11 mmol). The mixture was heated to 100° C. for 36 h, cooled to rt and extracted with EtOAc. The combined organics were dried (Na2SO4) and concentrated. Purification via silica gel chromatography (10-100% EtOAc in hexanes) gave the title compound (1 g, 48%).
Step B: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid. To a solution of the title compound of Step A (730 mg, 4 mmol) in EtOH (10 mL) was added 4 N NaOH (1 mL, 4 mmol). The mixture was heated at 100° C. for 24 h. The reaction mixture was concentrated in vacuo to a white solid which was used without further purification in subsequent steps. MS (ESI) mass calcd. for C9H8N4O2, 204.1. m/z found 205.1 [M+H]+.
Intermediate A-21: 3-ethoxyisoquinoline-4-carboxylic acid




Step A: ethyl 3-hydroxyisoquinoline-4-carboxylate. To a suspension of ethyl 3-aminoisoquinoline-4-carboxylate (583 mg, 2.70 mmol) in 6.8 mL of H2SO4 5N cooled to 0° C. was added sodium nitrite (223 mg, 3.24 mmol, dissolved in 1 mL of water). The reaction mixture was stirred at 0° C. for 2.5 h and then NaOH(aq) 1N was added until pH=7. The aqueous phase was extracted twice with DCM and the combined organic phases were dried over MgSO4, filtered and evaporated to give the title compound of Step A which was used without further purification in the next step (583 mg, 99%). MS (ESI) mass calcd. for C12H11NO3, 217.1. m/z found 218.1 [M+H]+.
Step B: ethyl 3-ethoxyisoquinoline-4-carboxylate. To the title compound of Step A (583 mg, 2.68 mmol) in THF (13 mL) was added triphenylphosphine (1.06 g, 4.03 mmol), ethanol (0.24 mL, 4.03 mmol) and DIAD (0.79 mL, 4.03 mmol). The reaction mixture was stirred at room temperature for 16 h and then the solvent was evaporated. The crude was purified via silica gel chromatography (0-30% EtOAc in hexanes) to afford the title compound of Step B (498 mg, 76%). MS (ESI) mass calcd. for C14H15NO3, 245.1. m/z found 246.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 8.97 (s, 1H), 7.91-7.82 (m, 2H), 7.65-7.60 (m, 1H), 7.42-7.36 (m, 1H), 4.59-4.48 (m, 4H), 1.48-1.39 (m, 6H).
Step C: 3-ethoxyisoquinoline-4-carboxylic acid. The title compound of Step B (492 mg, 2 mmol) dissolved in MeOH (15 mL) was added NaOH(aq) 2M (2.5 mL). The reaction mixture was stirred at 60° C. for 16 h and then NaOH(aq) 4M (2 mL) was added and the mixture was stirred at 70° C. for 4 h. MeOH was evaporated and the aqueous phase was cooled to 0° C. and acidified with the addition of HCl(aq) 6N. The solid was filtered, washed with cold water and dried to afford the title compound (285 mg, 65%). MS (ESI) mass calcd. for C12H11NO3, 217.1. m/z found 218.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 13.36 (s, 1H), 9.15 (s, 1H), 8.13-8.06 (m, 1H), 7.82-7.70 (m, 2H), 7.54-7.47 (m, 1H), 4.50 (q, J=7.0 Hz, 2H), 1.35 (t, J=7.0 Hz, 3H).













Intermediate
Name
Structure
Reference







A-22
3-methyl- 2-(2H- 1,2,3- triazol-2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 82


 


A-23
4-fluoro- 2- (pyrimidin- 2- yl)benzoic acid




Prepared according to WO 2011/050198 Intermediate 87









Intermediate A-24: 2-methoxy-6-(pyrimidin-2-yl)benzoic acid




Step A: Methyl 2-methoxy-6-(pyrimidin-2-yl)benzoate. In a microwave vial was dissolved methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS 1146214-77-8) (500 mg, 1.71 mmol) and 2-bromopyrimidine (344 mg, 2.05 mmol) in THF (8.5 mL). Na2CO3 (544 mg, 5.14 mmol) was then added followed by water (4 mL) and the reaction mixture was degassed with N2 for 10 minutes. PdCl2(dtbpf) (CAS 95408-45-0) (45 mg, 0.069 mmol) was then added and the reaction mixture was heated at 80° C. for 4 h. The mixture was cooled to room temperature and water and EtOAc added. The reaction mixture was extracted with EtOAc (3×). The combined organic layers were dried over Na2SO4, filtered and concentrated. The crude was purified via silica gel chromatography (0-70% EtOAc in hexanes) to afford the title compound (265 mg, 63%). MS (ESI) mass calcd. for C13H12N2O3, 244.1. m/z found 245.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.78 (d, J=4.9 Hz, 2H), 7.99 (dd, J=7.9, 0.9 Hz, 1H), 7.49 (t, J=8.1 Hz, 1H), 7.19 (t, J=4.8 Hz, 1H), 7.09 (dd, J=8.3, 0.9 Hz, 1H), 3.90 (s, 3H), 3.89 (s, 3H).
Step B: 2-methoxy-6-(pyrimidin-2-yl)benzoic acid. To a solution of the title compound of Step A (265 mg, 1.09 mmol) in THF (4 mL) was added 2 M NaOH (2 mL). The mixture was heated at 50° C. for 72 h. The reaction mixture was cooled to room temperature and concentrated in vacuo to remove THF. Then, 1 M HCl(aq) was added and the aqueous was extracted with 10:1 DCM/2,2,2-trifluoroethanol (3×). The combined organic layers were dried over Na2SO4, filtered and concentrated to give intermediate A-24, which was used without further purification in subsequent steps. MS (ESI) mass calcd. for C12H10N2O3, 230.1. m/z found 231.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 12.63 (s, 1H), 8.86 (d, J=4.9 Hz, 2H), 7.77 (dd, J=7.9, 1.0 Hz, 1H), 7.51 (t, J=8.1 Hz, 1H), 7.45 (t, J=4.9 Hz, 1H), 7.25 (dd, J=8.4, 1.0 Hz, 1H), 3.83 (s, 3H).
Intermediate A-25: 7-ethoxyquinoline-8-carboxylic acid




Step A: 7-methoxyquinoline-8-carboxylic acid. In separate batches (1 g) a mixture of 2-amino-6-methoxybenzoic acid (11 g, 66 mmol) and acrolein (4.8 mL, 72 mmol) in 1,4-dioxane (66 mL) was heated in a microwave reactor for 20 min at 200° C. After combining the reactions, the mixture was concentrated and purified via silica gel chromatography (0-10% MeOH in DCM) to give the title compound (2.8 g, 20%). MS (ESI) mass calcd. for C11H19NO3, 203.1. m/z found 204.0 [M+H]+.
Step B: 7-hydroxyquinoline-8-carboxylic acid. The title compound of Step A (2.9 g, 14.1 mmol) in HBr (14 mL) was heated at 90° C. for 1 h. The mixture was then concentrated washed with PhCH3 and used without further purification in subsequent steps.
Step C: ethyl 7-ethoxyquinoline-8-carboxylate. To the title compound of Step B (800 mg, 3.9 mmol) and K2CO3 (1.4 g, 10.4 mmol) in DMF (15 mL) was added iodoethane (560 mL, 6.9 mmol). After stirring overnight at room temperature, the reaction was concentrated and purified via silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound. MS (ESI) mass calcd. for C14H15NO3, 245.1. m/z found 246.0 [M+H]+.
Step D: 7-ethoxyquinoline-8-carboxylic acid. To the title compound of Step C (1.3 g, 5.4 mmol) in THF (22 mL) and H2O (11 mL) was added LiOH hydrate (675 mg, 16.5 mmol) and MeOH. The mixture was heated at 67° C. for 12 h. Additional LiOH hydrate (675 mg, 16.5 mmol) was added and the heating was continued at 70° C. for 1 day. Additional LiOH hydrate (1.4 g, 33 mmol) was added and the heating was continued at 75° C. for 1 day. The reaction was allowed to cool to room temperature, acidified to pH=3 with 1 N HCl(aq) and concentrated. Purification via prep HPLC gave the title compound (1 g, 84%). MS (ESI) mass calcd. for C12H11NO3, 217.1. m/z found 218.0 [M+H]+.
Intermediate A-27: 3-methyl-2-(oxazol-2-yl)benzoic acid




Step A: ethyl 3-methyl-2-(oxazol-2-yl)benzoate. In a microwave vial was dissolved ethyl 2-iodo-3-methylbenzoate (627 mg, 2.16 mmol) and 2-(tributylstannyl)oxazole (0.54 mL, 0.07 mmol) in DME (2.59 mL). The solution was degassed with N2 for 5 minutes then CuI (21 mg, 0.11 mmol) and Pd(PPh3)4 (125 mg, 0.11 mmol) were added. The reaction was purged with N2 and heated at 150° C. for 1 h. The reaction was cooled to room temperature, filtered through a pad of Celite and purified via silica gel chromatography (0-40% EtOAc in hexanes) to give the title compound of step A (333 mg, 67%). MS (ESI) mass calcd. for C13H13NO3, 231.1. m/z found 232.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 7.89-7.82 (m, 1H), 7.79 (d, J=0.8 Hz, 1H), 7.48-7.43 (m, 2H), 7.30 (d, J=0.9 Hz, 1H), 4.17 (q, J=7.1 Hz, 2H), 2.27 (s, 3H), 1.18 (t, J=7.1 Hz, 3H).
Step B: 3-methyl-2-(oxazol-2-yl)benzoic acid. To the title compound of step A (166 mg, 0.72 mmol) was added MeOH (7.2 mL) and 1M NaOH(aq) (7.2 mL). MeOH was evaporated and then 1 M HCl(aq) was added. To the solution was added DCM and the aqueous was extracted with DCM (3×). The combined organic layers were dried over MgSO4, filtered and evaporated to give the title compound (145 mg). MS (ESI) mass calcd. for C11H9NO3, 203.1. m/z found 204.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.79-7.68 (m, 1H), 7.65-7.49 (m, 2H), 7.35 (s, 1H), 4.34 (s, 1H), 2.20 (s, 3H).













Intermediate
Name
Structure
Reference







A-28
3-(2H- 1,2,3- triazol- 2-yl) picolinic acid




Prepared according to WO 2011/050198 Intermediate 72


 


A-29
1H-indole- 7- carboxylic acid




Commercially available, CAS 1670-83-3









Intermediate A-30: 2-methoxy-6-(1H-pyrazol-5-yl)benzoic acid




Step A: Ethyl 2-methoxy-6-(1H-pyrazol-5-yl)benzoate. In a microwave vial was dissolved ethyl 2-bromo-6-methoxybenzoate (500 mg, 1.54 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (330 mg, 1.70 mmol) in DME (10 mL) and water (2 mL). Na2CO3 (259 mg, 3.09 mmol) was then added followed by Pd(PPh3)4 (89 mg, 0.077 mmol) and the reaction mixture was degassed with N2 for 10 minutes. The reaction mixture was then heated at 100° C. for 1 h in the microwave. The mixture was cooled to room temperature, filtered through Celite and washed with EtOAc and DCM. The crude solution was concentrated in vacuo and directly purified via silica gel chromatography (10-80% EtOAc in hexanes) to afford the title compound (125 mg, 33%). MS (ESI) mass calcd. for C13H14N2O3, 246.3. m/z found 247.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 7.63 (d, J=2.2 Hz, 1H), 7.44-7.37 (m, 1H), 7.24 (d, J=8.1 Hz, 1H), 6.94 (dd, J=8.3, 0.9 Hz, 1H), 6.53 (d, J=2.3 Hz, 1H), 4.29 (q, J=7.2 Hz, 2H), 3.88 (s, 3H), 1.25-1.16 (m, 3H).
Step B: 2-methoxy-6-(1H-pyrazol-5-yl)benzoic acid. Prepared analogous to intermediate A-24 step B to give title compound. MS (ESI) mass calcd. for C11H10N2O3, 218.1. m/z found 219.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 12.85 (br. s, 1H), 7.71 (d, J=2.2 Hz, 1H), 7.39 (t, J=8.0 Hz, 1H), 7.35-7.28 (m, 1H), 7.04 (dd, J=8.3, 1.0 Hz, 1H), 6.51 (d, J=2.3 Hz, 1H), 3.80 (s, 3H).
Intermediate A-31: 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoic acid




Step A: Methyl 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoate. Prepared analogous to intermediate A-30 step A to give title compound. MS (ESI) mass calcd. for C13H14N2O2, 230.1. m/z found 231.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.04 (dd, J=7.8, 1.5 Hz, 1H), 7.61 (td, J=7.5, 1.5 Hz, 1H), 7.53 (td, J=7.7, 1.4 Hz, 1H), 7.35 (s, 1H), 7.28 (dd, J=7.6, 1.4 Hz, 1H), 3.71 (s, 3H), 3.58 (s, 3H), 1.84 (s, 3H).
Step B: 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoic acid. To a solution of the title compound of Step A (680 mg, 2.95 mmol) in MeOH (15 mL) was added 4 M LiOH (4 mL). The mixture was heated at 50° C. overnight. MeOH was removed and HCl added until pH=2. White solids precipitated from the reaction mixture and the precipitate was filtered, washed with EtOAc and collected to give intermediate A-31, which was used without further purification in subsequent steps. MS (ESI) mass calcd. for C12H12N2O2, 216.1. m/z found 217.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.87 (s, 1H), 7.95 (dd, J=7.8, 1.5 Hz, 1H), 7.67 (td, J=7.5, 1.5 Hz, 1H), 7.59 (td, J=7.6, 1.4 Hz, 1H), 7.33 (dd, J=7.6, 1.4 Hz, 1H), 7.25 (s, 1H), 3.48 (s, 3H), 1.77 (s, 3H).













Intermediate
Name
Structure
Reference







A-33
2-bromo-3- fluorobenzoic acid




Commercially available, CAS 132715-69-6









Intermediate A-33: 3-fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid




To 3-fluoro-2-iodobenzoic acid (4.5 g, 16.9 mmol) dissolved in dioxane (33.8 mL) and H2O (0.09 mL) was added Cs2CO3 (11.02 g, 33.8 mmol), CuI (161 mg, 0.85 mmol), 2H-1,2,3-triazole (1.96 mL, 33.8 mmol), and trans-N,N-dimethyl-1,2-cyclohexanediamine (0.53 mL, 3.38 mmol). The mixture was then heated to 100° C. overnight, cooled to room temperature, diluted with H2O, and extracted with EtOAc. The aqueous layer was then acidified and extracted with EtOAc. The combined organics were dried and concentrated. From this concentrate a solid precipitated to provide intermediate A-33 (285 mg, 8%). MS (ESI) mass calcd for C9H6FN3O2, 207.0. m/z found 208.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 6.81-6.77 (m, 1H), 6.46-6.40 (m, 2H), 6.30-6.23 (m, 1H), 6.18-6.12 (m, 1H).
Intermediate A-34: 2-(5-fluoropyrimidin-2-yl)benzoic acid




Step A: 5-fluoro-2-iodopyrimidine. To a solution of 2-chloro-5-fluoropyrimidine (4 mL, 32 mmol) in propionitrile (33 mL) was added chlorotrimethylsilane (12 mL, 97 mmol) and sodium iodide (15 g, 97 mmol), and the reaction mixture was heated to 150° C. for 1 h. Upon completion of the reaction, the reaction mixture was cooled to room temperature and the solvent removed. The residue was taken up in EtOAc and a solution of saturated NaHCO3. The organic layer was dried over MgSO4, filtered and evaporated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (2.82 g, 39%).
Step B: 2-(5-fluoropyrimidin-2-yl)benzonitrile. In a microwave vial was dissolved 2-cyanophenylboronic acid (500 mg, 3.40 mmol) in THF (15 mL), and the reaction mixture was degassed with N2. Then, the title compound of step A (915 mg, 4.08 mmol), Na2CO3 (1.08 g, 10.2 mmol), water (5 mL), and PdCl2(dtbpf) (CAS 95408-45-0) (89 mg, 0.14 mmol) were added, and the reaction mixture was stirred at room temperature for 1 h and then heated via microwave heating to 75° C. for 2 h. The mixture was cooled to room temperature and water and EtOAc added. The reaction mixture was extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated. The crude was purified via silica gel chromatography (0-30% EtOAc in hexanes) to afford the title compound (280 mg, 41%). MS (ESI) mass calcd. for C11H6FN3, 199.1. m/z found 200.0 [M+H]+.
Step C: 2-(5-fluoropyrimidin-2-yl)benzoic acid. A solution of the title compound of step B (1.24 g, 6.22 mmol) in H2SO4 (6 mL) and water (6 mL) was stirred at 80° C. for 1 h. Then, the reaction mixture was cooled to 0° C. and the aqueous phase extracted with DCM (2×). A solution of 20 M NaOH (11 mL) was added to the aqueous layer until pH  ̃3-4. The aqueous layer was extracted again with EtOAc and DCM. The combined organic layers were dried over MgSO4, filtered and concentrated to afford the title compound (672 mg, 50%). MS (ESI) mass calcd. for C11H7FN2O2, 218.1. m/z found 219.1 [M+H]+.
Intermediate A-35: 3-fluoro-2-(5-fluoropyrimidin-2-yl)benzoic acid




Prepared analogous to Intermediate A-34, substituting 2-cyanophenylboronic acid with (2-cyano-6-fluorophenyl)boronic acid (CAS 656235-44-8). MS (ESI) mass calcd. for C11H6F2N2O2, 236.0. m/z found 237.1 [M+H]+.

Intermediate A-36: 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoic acid




Step A: Methyl 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoate. A solution of methyl 3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS 887234-98-2) (3 g, 11 mmol) in THF (30 mL) was degassed with N2. Then, 2-chloro-5-fluoropyrimidine (1.6 mL, 13.04 mmol), Na2CO3 (3.45 g, 32.6 mmol), water (10 mL), and Pd(dppf)Cl2 (354 mg, 0.434 mmol) were added, and the reaction mixture was stirred at 100° C. overnight. The mixture was cooled to room temperature and water and EtOAc added. The reaction mixture was extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated. The crude was purified via silica gel chromatography (0-40% EtOAc in hexanes) to afford the title compound (1.07 g, 40%).
Step B: 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoic acid. To a solution of the title compound of Step A (1.46 g, 5.93 mmol) in MeOH (20 mL) was added 1 M NaOH (12 mL), and the reaction mixture was stirred at room temperature overnight. The solvent was removed and the crude was diluted with water until pH=10. The aqueous layer was extracted with EtOAc. The aqueous layer was further acidified with 12 M HCl(aq) until pH=2 and extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated to afford the title compound (1.19 g, 83%). MS (ESI) mass calcd. for C12H9FN2O2, 232.1. m/z found 233.1 [M+H]+.













Intermediate
Name
Structure
Reference







A-37
2-(pyrimidin-2- yl)benzoic acid




Comercially available, CAS 400892-62-8


 


A-38
5-methyl-2-(2H- 1,2,3-triazol-2- yl)nicotinic acid




Prepared analogous to WO 2011/050200 Intermediate 47, Example 160


 


A-39
2-(2H-1,2,3-triazol- 2-yl)nicotinic acid




Comercially available, CAS 1369497-44-8


 


A-40
6-methyl-3-(2H- 1,2,3-triazol-2- yl)picolinic acid




2012/089606 Intermediate D40.


 


A-41
6-methyl-3- (pyrimidin-2- yl)picolinic acid




WO 2010/122151 Intermediate D28


 


A-42
3-(pyrimidin-2- yl)picolinic acid




WO 2010/122151 Intermediate D105


 


A-43
3-phenylpyrazine- 2-carboxylic acid




Comercially available, CAS 2881- 85-8


 


A-44
1H-indazole-7- carboxylic acid




Comercially available, CAS 677304-69-7


 


A-45
3-phenylfuran-2- carboxylic acid




Comercially available, CAS169772-63-8









Intermediate A-46: 5-methyl-2-(pyrimidin-2-yl)nicotinic acid




Step A: Methyl 5-methyl-2-(pyrimidin-2-yl)nicotinate. To a sealed tube containing methyl 2-chloro-5-methylnicotinate (CAS 65169-43-9) (745 mg, 4.01 mmol), CuI (38 mg, 0.2 mmol), LiCl (169 mg, 4.01 mmol), and Pd(PPh3)4 (231 mg, 0.2 mmol) in toluene (15 mL) was added 2-(tributylstannyl)pyrimidine (1.5 mL, 4.4 mmol), and the reaction mixture was heated at 120° C. overnight. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were dried over MgSO4, filtered and evaporated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (494 mg, 52%). MS (ESI) mass calcd. for C12H11N3O2, 229.1. m/z found 229.99.
Step B: 5-methyl-2-(pyrimidin-2-yl)nicotinic acid. To a solution of the title compound of step A (466 mg, 2.03 mmol) in MeOH (10 mL) was added 10 M NaOH (1 mL), and the reaction mixture was stirred at room temperature for 2 h. The solvent was removed and the crude was diluted with water and acidified with 6 M HCl(aq) until pH=3. The aqueous layer was saturated with solid NaCl and extracted with 20% iPrOH in CHCl3 (3×). The combined organic layers were dried over MgSO4, filtered and concentrated to afford the title compound (432 mg, 99%). MS (ESI) mass calcd. for C11H9N3O2, 215.1. m/z found 216.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 8.90 (br. s, 2H), 8.64 (br. s, 1H), 8.17 (s, 1H), 7.55 (br. s, 1H), 2.51 (s, 3H).
Intermediate A-47: Lithium 5-methyl-3-(pyrimidin-2-yl)picolinate




Step A: Methyl 5-methyl-3-(pyrimidin-2-yl)picolinate. Prepared analogous to intermediate A-46, step A substituting methyl 2-chloro-5-methylnicotinate with methyl 3-bromo-5-methylpicolinate. MS (ESI) mass calcd. for C12H11N3O2, 229.1. m/z found 230.0 [M+H]+.
Step B: Lithium 5-methyl-3-(pyrimidin-2-yl)picolinate. To a solution of the title compound of step A (592 mg, 2.58 mmol) in THF (5 mL) was added 4 M LiOH (0.8 mL) and water (1.5 mL), and the reaction mixture was stirred at room temperature for 2.5 h. The solvent was removed and the crude reaction mixture placed under vacuum overnight to give the title compound (591 mg), which was used in the next step without further purification. MS (ESI) mass calcd. for C11H9N3O2, 215.1. m/z found 216.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 8.83 (d, J=4.9 Hz, 2H), 8.39 (br. s, 1H), 8.23-8.18 (m, 1H), 7.38 (t, J=4.9 Hz, 1H), 2.44 (s, 3H).
Intermediate A-48: 3-fluoro-2-(oxazol-2-yl)benzoic acid




Step A: 2-bromo-N-(2,2-dimethoxyethyl)-6-fluorobenzamide To a solution of 2-bromo-6-fluorobenzoic acid (2 g, 9.1 mmol) in DMF (27 mL) was added HBTU (5.20 g, 13.7 mmol) and DIPEA (4.7 mL, 27 mmol), and the reaction mixture was stirred for 10 min. Then, 2,2-dimethoxyethylamine (1.3 mL, 11.9 mmol) was added and the reaction mixture stirred at room temperature for 12 h. The reaction mixture was diluted with EtOAc and washed with saturated aqueous NaHCO3. The combined organic layers were dried over MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound (2.3 g, 82%).
Step B: 2-(2-bromo-6-fluorophenyl)oxazole. To P2O5 (6.4 g, 22.6 mmol) was added methanesulfonic acid (52 mL, 801 mmol), and the reaction mixture was stirred at room temperature for 1 h. Then, the title compound of step A (2.3 g, 7.54 mmol) was added to the reaction mixture, and the mixture heated to 140° C. for 2 h. DCM was added and the mixture was slowly poured into a saturated solution of aqueous NaHCO3 on ice. The mixture was extracted with DCM. The combined organic layers were dried over MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-10% EtOAc in hexanes) gave the title compound (1.5 g, 82%). MS (ESI) mass calcd. for C9H5BrFNO, 240.95. m/z found 242.0 [M+H]+.
Step C: Methyl 3-fluoro-2-(oxazol-2-yl)benzoate. A solution of the title compound of step B (2.18 g, 8.99 mmol), Pd(OAc)2 (40 mg, 0.18 mmol), 1,1′-bis(diphenylphosphino)ferrocene (199 mg, 0.36 mmol), and Et3N (3.7 mL, 27 mmol) in 1:1 MeOH/1,4-dioxane (36 mL) was degassed with N2 for 15 min. Then, the mixture was stirred at 95° C. under an atmosphere of carbon monoxide overnight. The reaction mixture was diluted with EtOAc and washed with a solution of NaHCO3. The organic layer was separated, dried over MgSO4, filtered, and concentrated. Purification via silica gel chromatography (0-12% EtOAc in hexanes) gave the title compound (1.7 g, 83%). MS (ESI) mass calcd. for C11H8FNO3, 221.1. m/z found 222.0 [M+H]+.
Step D: 3-fluoro-2-(oxazol-2-yl)benzoic acid. To a solution of the title compound of step C (1.65 g, 7.46 mmol) in MeOH (22 mL) was added 2 M NaOH (7.5 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was acidified with 1 M HCl(aq) and the solvents evaporated in vacuo. The mixture was diluted with water and extracted with DCM. The combined organic were dried over MgSO4, filtered and concentrated to afford the title compound (905 mg, 58%). MS (ESI) mass calcd. for C10H6FNO3, 207.0. m/z found 208.0 [M+H]+. MP=182° C.
Intermediate A-49: 5-fluoro-2-(oxazol-2-yl)benzoic acid




Step A: Methyl 5-fluoro-2-(oxazol-2-yl)benzoate. To a solution of methyl 2-bromo-5-fluorobenzoate (1.1 g, 4.8 mmol) and 2-(tri-n-butylstannyl)oxazole (1.3 mL, 6.2 mmol) in toluene (14 mL) was added Pd(PPh3)4 (550 mg, 0.476 mmol), and the reaction mixture was heated via microwave heating to 150° C. for 30 min. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes, followed by a second column 0-10% EtOAc in hexanes) gave the title compound (553 mg, 52%). MS (ESI) mass calcd. for C11H6FNO3, 221.1. m/z found 222.1 [M+H]+.
Step B: 5-fluoro-2-(oxazol-2-yl)benzoic acid. Prepared analogous to intermediate 48, step D, to give the title compound (858 mg, 99%). MS (ESI) mass calcd. for C10H6FNO3, 207.0. m/z found 208.1 [M+H]+.
Intermediate A-50: 2-fluoro-6-(oxazol-2-yl)benzoic acid




Prepared analogous to intermediate 48, substituting 2-bromo-6-fluorobenzoic acid with 2-bromo-3-fluorobenzoic acid. MS (ESI) mass calcd. for C10H6FNO3, 207.0. m/z found 208.0 [M+H]+.
Intermediate A-51: 4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid




Step A: 5-(2-bromo-5-fluorophenyl)-3-methyl-1,2,4-oxadiazole. To a solution of bromo-5-fluorobenzoyl chloride (2.17 g, 9.13 mmol) in THF (18 mL) was added DIPEA (1.7 mL, 10 mmol). Then, acetamide oxime (676 mg, 9.13 mmol) was added portionwise, and the reaction mixture was stirred at 70° C. for 16 h. The reaction mixture was diluted with EtOAc and washed with a saturated solution of NaHCO3. The combined organic layers were dried over MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (2.35 g, 57%). MS (ESI) mass calcd. for C9H6BrFN2O, 255.96. m/z found 257.0 [M+H]+.
Step B: 4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid. Prepared analogous to intermediate 48, steps C and D, to give the title compound. MS (ESI) mass calcd. for C10H7FN2O3, 222.0. m/z found 223.0 [M+H]+.
Enantiopure Route A (2-azabicyclo[2.2.1]heptan-6-ol)
Intermediate B-1: (1S,4R)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.1]hept-5-ene




Intermediate B-1 was prepared according to the procedure of C. Chiu et al. [Synthetic Communications 1996, 26, 577-584] with the substitution of (+)-α-Methyl-benzylamine for (−)-α-Methyl-benzylamine and D-dibenzoyl tartaric acid for L-dibenzoyl tartaric acid. MS (ESI) mass calcd. for C14H17N, 199.1. m/z found 200.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 7.36-7.25 (m, 4H), 7.23-7.17 (m, 1H), 6.35-6.30 (m, 1H), 6.11 (dd, J=5.7, 2.0 Hz, 1H), 4.16-4.12 (m, 1H), 3.05 (q, J=6.5 Hz, 1H), 2.89 (dd, J=8.9, 3.1 Hz, 1H), 2.85-2.81 (m, 1H), 1.65-1.59 (m, 1H), 1.48-1.43 (m, 1H), 1.37-1.31 (m, 4H).
Intermediate B-2: (1S,4R,6S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.1]heptan-6-ol




Intermediate B-2 was synthesized according to the procedure of F. Carroll et al. [J Med. Chem. 1992, 35, 2184-2191] on a similar substrate. A 1 M solution of BH3-THF (1 M BH3-THF in THF, 359.3 mL, 359.3 mmol) was added dropwise via addition funnel to a stirred solution of intermediate B-1 (35.8 g, 179.6 mmol) in THF (359 mL) at 0° C. Upon complete addition of BH3-THF, the reaction mixture was stirred at 0° C. for 2 h. Then, excess BH3 was quenched with a solution of THF-H2O. A 3 M NaOH (132 mL) solution was added followed by the dropwise addition of H2O2 (30% w/w in H2O, 140 mL), and the reaction mixture was warmed to 40° C. and stirred for 1.5 h. The biphasic mixture was then cooled to room temperature and K2CO3 (17 g) added in one portion. The resulting mixture was concentrated under reduced pressure to remove THF and re-dissolved in DCM. The crude reaction mixture was washed with H2O and the aqueous phase extracted with DCM (3×). The combined organics were then washed with brine, dried with Na2SO4, filtered, and concentrated to give a clear oil, which was further purified by silica gel chromatography (5-10% MeOH (with 10% 2 M NH3) in DCM) to give intermediate B-2 as a clear oil (20.2 g, 93.0 mmol, 52%). MS (ESI) mass calcd. for C14H19NO, 217.2. m/z found 218.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 7.34-7.27 (m, 4H), 7.24-7.19 (m, 1H), 4.03 (d, J=6.9 Hz, 1H), 3.46 (q, J=6.5 Hz, 1H), 3.01 (s, 1H), 2.56-2.48 (m, 1H), 2.42-2.33 (m, 1H), 2.25 (dd, J=8.8, 1.3 Hz, 1H), 1.82 (ddd, J=13.1, 6.9, 2.2 Hz, 1H), 1.53-1.43 (m, 2H), 1.33-1.28 (m, 1H), 1.27 (d, J=6.5 Hz, 3H).
Intermediate B-3: (1S,4R,6S)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate




To a solution of intermediate B-2 (500 mg, 2.3 mmol) in EtOH (11.5 mL) was added Boc2O (603 mg, 2.76 mmol) and 10 wt % Pd/C wet Degussa (490 mg, 0.46 mmol). The reaction mixture was stirred under an atmosphere of H2 (balloon) at room temperature for 22 h. Then, the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated to a clear oil to give the title compound in quantitative yield, which was used without further purification. MS (ESI) mass calcd. for C11H19NO3, 213.1. m/z found 158.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.08-3.99 (m, 1H), 3.99-3.92 (m, 1H), 3.18-3.09 (m, 1H), 2.80 (dd, J=28.1, 9.2 Hz, 1H), 2.18-1.37 (m, 14H).
Intermediate B-4: (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate




To a solution of intermediate B-3 (7 g, 33 mmol) in EtOAc (219 mL) was added IBX (24.5 g, 39.4 mmol), and the heterogeneous reaction mixture was stirred at 80° C. overnight. Upon completion, the reaction mixture was then filtered through Celite, washed with EtOAc and concentrated to a white solid. The crude reaction mixture was re-dissolved in EtOAc and washed once with a 5% aqueous Na2CO3 solution. The aqueous layer was further extracted with EtOAc (2×) and the combined organics were washed with brine, dried with Na2SO4, filtered, and concentrated to afford intermediate B-4 as a light yellow solid (6.12 g, 28.9 mmol, 88%), which was used in the next step without further purification. MS (ESI) mass calcd. for C11H12NO3, 211.1. m/z found 156.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d) δ 4.32-4.04 (m, 1H), 3.45 (ddd, J=9.6, 3.1, 1.8 Hz, 1H), 3.25-3.04 (m, 1H), 2.89-2.77 (m, 1H), 2.21 (ddd, J=18.0, 4.6, 1.8 Hz, 1H), 2.04-1.96 (m, 1H), 1.95-1.82 (m, 1H), 1.75-1.66 (m, 1H), 1.45 (s, 9H).
Intermediate B-5: (1S,4R,6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate




A 1 M solution of L-Selectride (1 M in THF, 19.8 mL, 19.8 mmol) was added to a solution of intermediate B-4 (1.67 g, 7.91 mmol) in dry THF (40 mL) at −78° C., and the reaction mixture was stirred at that temperature for 3 h. Then, the reaction mixture was warmed to 0° C. and a 3 M NaOH (8.4 mL) solution was added followed by a solution of H2O2 (30% w/w in H2O, 4.3 mL). The resulting mixture was warmed to room temperature and stirred for 2 h. The biphasic mixture was then concentrated in vacuo to remove THF and the aqueous layer extracted with DCM (3×). The combined organics were washed with brine, dried with Na2SO4, filtered, and concentrated to an oil, which was further purified by silica gel chromatography (10-90% EtOAc in hexanes), to give intermediate B-2 as a white solid (1.16 g, 5.44 mmol, 67%). MS (ESI) mass calcd. for C11H19NO3, 213.1. m/z found 158.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.38-4.10 (m, 2H), 3.36 (br. s, 1H), 3.09 (dd, J=9.6, 1.4 Hz, 1H), 2.54-1.38 (m, 14H), 1.16-1.00 (m, 1H).
Intermediate B-5 can also be prepared from commercially available (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one. The procedure is as follows:
Enantiopure Route B (2-azabicyclo[2.2.1]heptan-6-ol)
Intermediate B-6: (1S,4R,6S)-2-benzyl-2-azabicyclo[2.2.1]heptan-6-ol




To a round bottom flask containing commercially available, (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one (2.0 g, 18.3 mmol), in THF (100 mL) at 0° C. was added a solution of LiAlH4 (1 M in THF, 40.3 mL, 40.3 mmol), and the reaction mixture was refluxed overnight. The reaction mixture was then cooled to 0° C. and carefully quenched by the dropwise addition of H2O (15 mL). Celite and solid Na2CO3 were added to the slurry and the reaction mixture was vigorously stirred at room temperature for 3 h. The slurry was then filtered and the solids washed with THF. Benzyl bromide (2.4 mL, 20.2 mmol) and an aqueous solution of Na2CO3 (3.2 g in 30 mL H2O) were added to the filtrate and the reaction mixture stirred at room temperature overnight. Upon completion of the reaction, the reaction mixture was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated to provide crude (1S,4R)-2-benzyl-2-azabicyclo[2.2.1]hept-5-ene as a yellow oil, which was directly hydroborated according to the procedure of F. Carroll et al. [J. Med. Chem. 1992, 35, 2184-2191]. The crude alcohol was purified by silica gel chromatography (0-15% MeOH (with 5% NH4OH) in DCM) to give intermediate B-6 as a clear oil (2.66 g, 13.1 mmol, 71% over 3 steps). MS (ESI) mass calcd for C13H17NO, 203.1. m/z found 204.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 7.39-7.28 (m, 4H), 7.26-7.21 (m, 1H), 4.18-4.09 (m, 1H), 3.76-3.66 (m, 2H), 3.06 (br. s, 1H), 2.51 (dt, J=9.0, 3.0 Hz, 1H), 2.44-2.35 (m, 2H), 1.90-1.81 (m, 1H), 1.68-1.53 (m, 2H), 1.38-1.30 (m, 1H).
Intermediate B-7: (1S,4R,6R)-2-benzyl-2-azabicyclo[2.2.1]heptan-6-ol




Intermediate B-7 was prepared from intermediate B-6 according to the procedure of F. Carroll et al. [J. Med. Chem. 1992, 35, 2184-2191]. MS (ESI) mass calcd for C13H17NO, 203.1. m/z found 204.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 7.37-7.22 (m, 5H), 4.56 (s, 1H), 4.05-3.94 (m, 1H), 3.80 (d, J=13.0 Hz, 1H), 3.62 (d, J=12.9 Hz, 1H), 3.20-3.11 (m, 1H), 2.77 (d, J=9.2 Hz, 1H), 2.45-2.34 (m, 2H), 1.88-1.79 (m, 1H), 1.76-1.64 (m, 1H), 1.30 (d, J=10.4 Hz, 1H), 0.99 (dt, J=13.3, 2.9 Hz, 1H).
Intermediate B-5: (1S,4R,6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate




To a solution of intermediate B-7 (3.41 g, 16.8 mmol) in EtOH (168 mL) was added Boc2O (5.49 g, 25.2 mmol) and 20 wt % Pd(OH)2/C (2.36 g, 3.36 mmol). The reaction mixture was stirred under an atmosphere of H2 (balloon) at room temperature overnight. Then, the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated to a clear oil, which was further purified by silica gel chromatography (10-60% EtOAc in hexanes), to give intermediate B-5 as a white solid (3.1 g, 1.5 mmol, 87%). [α]D20−11.2 (c 0.0065, MeOH). MS (ESI) mass calcd. for C11H19NO3, 213.1. m/z found 158.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.39-4.12 (m, 2H), 3.35 (br. s, 1H), 3.08 (dd, J=9.4, 1.4 Hz, 1H), 2.56-1.39 (m, 14H), 1.15-0.99 (m, 1H).
Racemic Route (2-azabicyclo[2.2.1]heptan-6-ol)
Intermediate B-8: (R/S)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate




Intermediate B-8 was prepared from commercially available (R/S)-tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate following the procedure of R. Nencka et. al. [Tetrahedron 2012, 68, 1286-1298]. MS (ESI) mass calcd. for C11H19NO3, 213.1. m/z found 158.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d) δ 4.39-4.08 (m, 2H), 3.36 (br. s, 1H), 3.10 (dd, J=9.6, 1.4 Hz, 1H), 2.56-1.41 (m, 14H), 1.17-1.01 (m, 1H).
Enantiopure Route (2-azabicyclo[2.2.1]heptan-6-amine)
Intermediate B-9: (1S,4R)-tert-butyl 6-(hydroxyimino)-2-azabicyclo[2.2.1]heptane-2-carboxylate




To a flask containing Intermediate B-4 (1.0 g, 4.7 mmol) dissolved in EtOH (20 mL) was added NEt3 (2.0 ml, 14.4 mmol), and hydroxylamine hydrochloride (789 mg, 2.40 mmol) and the reaction mixture was brought to reflux. Upon completion, the reaction mixture was concentrated, diluted with H2O, and the aqueous layer extracted with EtOAc (3×). The combined organics were then washed with H2O, brine, dried with MgSO4, filtered, and concentrated to provide intermediate B-9 as an off-white solid (1.018 g) which was used without further purification. MS (ESI) mass calcd. for C11H18N2O3, 226.1. m/z found 171.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d) δ 7.71 and 7.41 (2s, 1H), 4.62 and 4.48 (2s, 1H), 3.40-3.33 (m, 1H), 3.15-2.96 (m, 1H), 2.79-2.70 (m, 1H), 2.54-2.43 (m, 1H), 2.29-2.19 (m, 1H), 1.87-1.64 (m, 1H), 1.61-1.53 (m, 1H), 1.45 (s, 9H).
Intermediate B-10: (1S,4S,6R)-tert-butyl 6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylate




A mixture of NiCl2 (1.15 g, 8.84 mmol) and intermediate B-9 (1.0 g, 4.4 mmol) in MeOH (30 mL) was cooled to −35° C. and NaBH4 (3.34 g, 88.4 mmol) was added portion wise to the reaction mixture over 30 min. Upon complete addition of NaBH4, the reaction mixture was stirred for an additional 25 min and then warmed to room temperature. After 30 min at room temperature the reaction mixture was quenched with H2O and concentrated under reduced pressure to a dark brown residue, which was re-dissolved in a mixture of DCM and 15% aqueous NaOH solution, and the aqueous layer extracted with DCM (3×). The combined organics were dried with MgSO4, filtered, and concentrated to provide intermediate B-10 (209 mg). 5 N NH4OH solution was then added to the aqueous layer along with DCM, NaCl, and Celite and after several minutes of stirring the mixture was filtered to remove solids. The filtrate was then transferred to a separatory funnel, the layers separated, and the aqueous layer extracted with DCM (2×). The combined organics were dried with MgSO4, filtered, and concentrated to provide additional intermediate B-10 (582 mg) which was combined with the above fraction to provide intermediate B-10 (791 mg) as a brown oil which was used without further purification. MS (ESI) mass calcd. for C11H20N2O2, 212.2. m/z found 213.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 4.13-3.92 (m, 1H), 3.41-3.27 (m, 2H), 2.99 (dd, J=24.3, 9.6 Hz, 1H), 2.51-2.39 (m, 1H), 2.16-2.05 (m, 1H), 1.68-1.57 (m, 1H), 1.47 (s, 10H), 1.22-1.07 (m, 2H), 0.85-0.74 (m, 1H).
Route A (2-azabicyclo[2.2.1]heptan-6-ol and 2-azabicyclo[2.2.2]octan-6-amine)
Intermediate C-1: (R/S)-2-benzyl-2-azabicyclo[2.2.2]oct-5-ene




Intermediate C-1 was prepared according to the procedure of S. Larsen et al. [J. Am. Chem. Soc. 1985, 107, 1768-1769]. To a solution of phenylmethanamine (3.92 g, 27.3 mmol) in H2O (5 mL) was added aqueous formaldehyde (2.03 mL, 27.3 mmol, 37 wt. % in H2O). After 2 minutes, 1,3-cyclohexadiene (2 mL, 21 mmol) was added and the reaction mixture was heated to 55° C. for 4 days. The reaction mixture was cooled to room temperature and diluted with H2O and extracted with Et2O (2×). The organic layer was discarded and the aqueous layer was basified with solid KOH and further extracted with Et2O (2×). The organic layer was washed with brine, dried with MgSO4, filtered, and concentrated. The concentrate was further purified by silica gel chromatography (100% DCM to 100% MeOH (with 10% 2 M NH3) in DCM) to give intermediate C-1 as a brown oil, which contained minor impurities. Intermediate C-1 was used without further purification. MS (ESI) mass calcd. for C14H12N, 199.1. m/z found 200.1 [M+H]+.
Intermediate C-2: (R/S)-2-benzyl-2-azabicyclo[2.2.2]octan-6-ol




Intermediate C-2 was synthesized according to the procedure of F. Carroll et al. [J. Med. Chem. 1992, 35, 2184-2191] on a similar substrate. A 1 M solution of BH3-THF (1 M BH3-THF in THF, 1.11 L, 1.11 mol) was added dropwise via addition funnel to a stirred solution of intermediate C-1 (37 g, 186 mmol) in THF (250 mL) at 0° C. Upon complete addition of BH3-THF, the reaction mixture was stirred at 0° C. for 3 h. Then, excess BH3 was quenched with a solution of THF-H2O. A 4 M NaOH (100 mL) solution was added followed by the dropwise addition of H2O2 (30% w/w in H2O, 100 mL), and the reaction mixture was warmed to 40° C. and stirred overnight. The biphasic mixture was then cooled to room temperature and K2CO3 added portionwise. The resulting mixture was concentrated under reduced pressure to remove THF. Solid NaCl was added to the remaining aqueous layer and the crude mixture extracted with EtOAc (3×). The combined organics were then washed with brine, dried with Na2SO4, filtered, and concentrated to give a yellow-orange oil, which was further purified by silica gel chromatography (0-100% EtOAc in hexanes followed by 10% MeOH (with 10% 2 M NH3) in DCM) to give intermediate C-2 as a yellow oil (20.7 g, 95.3 mmol, 51%), which contained minor impurities. Intermediate C-2 was used without further purification. MS (ESI) mass calcd. for C14H19NO, 217.2. m/z found 218.2 [M+H]+.
Intermediate C-3: (R/S)-tert-Butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate




To a solution of intermediate C-2 (20.7 g, 95.3 mmol) in EtOH (477 mL) was added Boc2O (27.1 g, 124 mmol) and 10 wt % Pd/C wet Degussa (5 g, 4.77 mmol). The reaction mixture was stirred under an atmosphere of H2 (balloon) at room temperature for 48 h. Analysis of the crude reaction mixture showed that the majority of the mixture was the deprotected amine, 2-azabicyclo[2.2.2]octan-6-ol. An additional equivalent of Boc2O (27.1 g, 124 mmol) was added, and the reaction mixture was stirred at room temperature overnight. Then, the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated to a yellow oil to give intermediate C-3, which was used without further purification. MS (ESI) mass calcd. for C12H21NO3, 227.2. m/z found 172.2 [M+2H-tBu]+.
Intermediate C-4A: (R/S)-tert-Butyl 6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate




To a solution of intermediate C-3 (21.6 g, 95.0 mmol) in EtOAc (380 mL) was added IBX (31.9 g, 114 mmol), and the heterogeneous reaction mixture was stirred at 80° C. overnight. Upon completion, the reaction mixture was then filtered through Celite, washed with EtOAc and concentrated. The crude reaction mixture was re-dissolved in EtOAc and washed once with a 5% aqueous Na2CO3 solution. The aqueous layer was further extracted with EtOAc (2×) and the combined organics were washed with brine, dried with Na2SO4, filtered, and concentrated to a brown residue. The concentrate was further purified by silica gel chromatography (0-35% EtOAc in hexanes), to give intermediate C-4A as a yellow solid. MS (ESI) mass calcd. for C12H19NO3, 225.1. m/z found 170.1 [M+2H-tBu]+. Analytical HPLC using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). Rt=1.91 min at 280 nm.
Intermediate C-4B: (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate




The title compound was obtained as a single enantiomer by Chiral SFC purification of Intermediate C-4A performed using a Chiralpak IC column (5 μm, 250×20 mm), mobile phase of 20% iPrOH: 80% CO2, and a flow rate of 80 mL/min (Temperature=35° C.). Elution was monitored following absorbance at 250 nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5 μm, 150×4.6 mm), mobile phase of 20% iPrOH+(0.3% iPrNH2): 80% CO2, and a flow rate of 3 mL/min over 7 minutes (Temperature=35° C.). Elution was monitored following absorbance at 250 nm. Enantiopurity 100%, which elutes at one peak (1.56 min retention time). MS (ESI) mass calcd. for C12H19NO3, 225.1. m/z found 170.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.42-4.15 (m, 1H), 3.62-3.34 (m, 2H), 2.49-2.32 (m, 3H), 2.21-2.06 (m, 1H), 1.97-1.85 (m, 1H), 1.79-1.68 (m, 1H), 1.66-1.56 (m, 1H), 1.45 (s, 9H).
Intermediate C-4C: (1R,4S)-tert-butyl 6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate




The title compound was obtained as a single enantiomer by Chiral SFC purification of Intermediate C-4A performed using a Chiralpak IC column (5 μm, 250×20 mm), mobile phase of 20% iPrOH: 80% CO2, and a flow rate of 80 mL/min (Temperature=35° C.). Elution was monitored following absorbance at 250 nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5 μm, 150×4.6 mm), mobile phase of 20% iPrOH+(0.3% iPrNH2): 80% CO2, and a flow rate of 3 mL/min over 7 minutes (Temperature=35° C.). Elution was monitored following absorbance at 250 nm. Enantiopurity 100%, which elutes at one peak (2.18 min retention time). MS (ESI) mass calcd. for C12H19NO3, 225.1. m/z found 170.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.41-4.13 (m, 1H), 3.57-3.31 (m, 2H), 2.46-2.31 (m, 3H), 2.22-2.08 (m, 1H), 1.96-1.86 (m, 1H), 1.83-1.68 (m, 1H), 1.67-1.56 (m, 1H), 1.45 (s, 9H).
Intermediate C-5A: (R/S)-tert-Butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate




A 1 M solution of L-Selectride (1 M in THF, 1.7 mL, 1.7 mmol) was added to a solution of intermediate C-4A (150 mg, 0.666 mmol) in dry THF (3 mL) at −78° C., and the reaction mixture was stirred at that temperature for 3 h. Then, the reaction mixture was warmed to 0° C. and a 3 M NaOH (0.71 mL) solution was added followed by a solution of H2O2 (30% w/w in H2O, 0.37 mL). The resulting mixture was warmed to room temperature and stirred for 2 h. The biphasic mixture was then concentrated in vacuo to remove THF and the aqueous layer extracted with DCM (3×). The combined organics were washed with brine, dried with Na2SO4, filtered, and concentrated to an oil, which was further purified by silica gel chromatography (10-100% EtOAc in hexanes), to give intermediate C-5A as a white solid (114 mg, 0.502 mmol, 75%). MS (ESI) mass calcd. for C12H21NO3, 227.2. m/z found 172.2 [M+2H-tBu]+. 1H NMR (500 MHz, Methanol-d4) δ 3.97-3.86 (m, 2H), 3.38-3.20 (m, 2H), 2.09-2.00 (m, 1H), 1.96-1.87 (m, 1H), 1.87-1.79 (m, 1H), 1.62-1.48 (m, 3H), 1.46 (d, J=4.9 Hz, 9H), 1.43-1.37 (m, 1H).
Intermediate C-5B: (1S,4R,6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate




Intermediate C-5B was prepared analogous to Intermediate C-5A substituting racemic Intermediate C-4A for enantiopure Intermediate C-4B. MS (ESI) mass calcd. for C12H21NO3, 227.2. m/z found 172.1 [M+2H-tBu]+.
Intermediate C-6A: (R/S)-tert-butyl 6-(hydroxyimino)-2-azabicyclo[2.2.2]octane-2-carboxylate




To a flask containing Intermediate C-4A (324 mg, 1.44 mmol) dissolved in EtOH (5 mL) was added NEt3 (1 ml, 7.2 mmol), and hydroxylamine hydrochloride (300 mg, 4.32 mmol) and the reaction mixture was heated to 70° C. overnight. Upon completion, the reaction mixture was cooled to room temperature, concentrated, diluted with H2O, and the aqueous layer extracted with EtOAc (3×). The combined organics were then dried with MgSO4, filtered, and concentrated to provide intermediate C-6A as a light purple solid (351 mg) which was used without further purification. MS (ESI) mass calcd. for C12H20N2O3, 240.2. m/z found 184.1 [M+2H-tBu]+.
Intermediate C-6B: (1S,4R)-tert-butyl 6-(hydroxyimino)-2-azabicyclo[2.2.2]octane-2-carboxylate




Intermediate C-6B was prepared analogous to Intermediate C-6A substituting racemic Intermediate C-4A for enantiopure Intermediate C-4B. MS (ESI) mass calcd. for C12H20N2O3, 240.2. m/z found 241.2 [M+H]+.
Intermediate C-7A: (R/S)-tert-butyl 6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate




A mixture of NiCl2 (373 mg, 2.88 mmol) and intermediate C-6A (346 mg) in MeOH (12 mL) was cooled to −35° C. and NaBH4 (1.09 g, 28.8 mmol) was added portion wise to the reaction mixture. Upon complete addition of NaBH4, the reaction mixture was warmed to room temperature. After 2 h at room temperature the reaction mixture was quenched with H2O. Celite was added and the crude reaction mixture was stirred for 30 min. The crude reaction mixture was filtered and the filtrate concentrated under reduced pressure to a dark brown residue, which was re-dissolved in a mixture of DCM and 15% aqueous NaOH solution. The aqueous layer was extracted with DCM (3×). The combined organics were filtered through Celite, dried with MgSO4, filtered, and concentrated to provide intermediate C-7A (308 mg) as a brown oil which was used without further purification. MS (ESI) mass calcd. for C12H22N2O2, 226.2. m/z found 227.2 [M+H]+.
Intermediate C-7B: (1S,4R,6R)-tert-butyl 6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate




Intermediate C-7B was prepared analogous to Intermediate C-7A substituting racemic Intermediate C-6A for enantiopure Intermediate C-6B. MS (ESI) mass calcd. for C12H22N2O2, 226.2. m/z found 227.2 [M+H]+.
Alternative routes (2-azabicyclo[2.2.1]heptan-6-ol)
Intermediate C-8: (R/S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]oct-5-ene




Intermediate C-8 was prepared according to the procedure of C. Chiu et al. [Synthetic Communications 1996, 26, 577-584] on a similar substrate. To a solution of H2O (5.4 mL) and 12 M HCl (5 mL) was added (+)-α-methyl-benzylamine (6.95 mL, 54.6 mmol), and the reaction mixture was stirred at room temperature for 5 minutes. Then, aqueous formaldehyde (4.06 mL, 54.6 mmol, 37 wt. % in H2O) and 1,3-cyclohexadiene (4 mL, 42 mmol) were added and the reaction mixture heated to 55° C. for 4 days. The reaction mixture was cooled to room temperature and diluted with H2O and the crude reaction mixture extracted with Et2O (2×). The aqueous phase was basified with KOH, extracted with Et2O (2×), saturated with solid NaCl, and extracted once more with Et2O. The combined organics were dried with Na2SO4, filtered, and concentrated to give an orange oil, which was further purified by silica gel chromatography (0-10% MeOH (with 10% 2 M NH3) in DCM) to give intermediate C-8 as a yellow-orange oil (ca. 3:1 dr). Intermediate C-8 was carried forward as a mixture of diastereoisomers. MS (ESI) mass calcd. for C15H19N, 213.2. m/z found 214.2 [M+H]+.
Intermediate C-9: (R/S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]octan-6-ol




Intermediate C-9 was synthesized according to the procedure of F. Carroll et al. [J. Med. Chem. 1992, 35, 2184-2191] on a similar substrate. A 1 M solution of BH3-THF (1 M BH3-THF in THF, 68 mL, 68 mmol) was added dropwise via addition funnel to a stirred solution of intermediate C-8 (2.88 g, 13.5 mmol) in THF (42 mL) at 0° C. Upon complete addition of BH3-THF, the reaction mixture was stirred at 0° C. for 2 h. Then, excess BH3 was quenched with a solution of THF-H2O. A 4 M NaOH (8 mL) solution was added followed by the dropwise addition of H2O2 (30% w/w in H2O, 8 mL), and the reaction mixture was warmed to 40° C. and stirred for 2 h. The biphasic mixture was then cooled to room temperature and K2CO3 added in one portion. The resulting mixture was concentrated under reduced pressure to remove THF and re-dissolved in DCM. The crude reaction mixture was washed with H2O and the aqueous phase extracted with DCM (3×). The combined organics were then washed with brine, dried with Na2SO4, filtered, and concentrated and the concentrate was further purified by silica gel chromatography (0-10% MeOH (with 10% 2 M NH3) in DCM) to give intermediate C-9 as an orange-brown foam (1.35 g, 5.84 mmol, 43%). MS (ESI) mass calcd. for C15H21NO, 231.2. m/z found 232.2 [M+H]+.
Intermediate C-10: (R/S)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate




Intermediate C-10 was prepared analogous to Intermediate C-3 substituting racemic Intermediate C-2 for schlemic Intermediate C-9. MS (ESI) mass calcd. for C12H21NO3, 227.2. m/z found 172.2 [M+2H-tBu]+. Intermediate C-10 can be carried forward to Intermediate C-4A, which can be obtained as a single enantiomer (Intermediate C-4B or C-4C) by Chiral SFC purification as described above.
Intermediate C-11: (R/S)-2-benzyl-6-hydroxy-2-azabicyclo[2.2.2]octan-3-one




Intermediate C-11 was synthesized according to the procedure in U.S. Pat. No. 3,674,793. A mixture of 7-oxabicyclo[4.1.0]heptane-3-carboxylic acid methyl ester (268.0 g, 1.72 mol) and benzylamine (170.0 g, 1.58 mol) in ethanol (1.3 L) was heated to reflux for 20 h and the reaction mixture was evaporated. The oily residue was stirred at 200° C. for 2 h to distill off low-boiling byproducts. The resulting oil was cooled to room temperature, diluted with a solution of sodium hydroxide (51.0 g, 1.27 mol) in methanol (1.0 L) and heated to reflux for 10 min. The reaction mixture was cooled to room temperature and diluted with a mixture of brine (1.5 L) and water (750 mL). The aqueous layer was extracted with dichloromethane (3×) and the combined organic layers were dried with MgSO4, filtered, and concentrated. The oily residue was triturated with diisopropyl ether (400 mL) to give intermediate C-11 (190.0 g, 0.82 mol, 48%) as a white solid. MS (ESI) mass calcd. for C14H17NO2, 231.1. m/z found 232.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 7.43-7.12 (m, 5H), 4.99 (d, J=3.3 Hz, 1H), 4.48 (d, J=14.7 Hz, 1H), 4.39 (d, J=14.7 Hz, 1H), 3.76-3.61 (m, 1H), 3.31-3.23 (m, 1H), 2.38-2.24 (m, 1H), 2.15-1.91 (m, 2H), 1.79-1.51 (m, 2H), 1.45-1.16 (m, 2H).
Intermediate C-2: 2-benzyl-2-azabicyclo[2.2.2]octan-6-ol




To a suspension of lithium aluminum hydride (54.4 g, 1.43 mol) in THF (180 mL) under argon at 0° C. was added a solution of intermediate C-11 (170.0 g, 716.4 mmol) dropwise as a solution in THF (720 mL). The reaction mixture was allowed to warm to room temperature, then carefully heated to 60° C. and stirred for 2 h. The resulting suspension was cooled to 0° C. and diluted with diethyl ether (540 mL). To this suspension was added sodium sulfate decahydrate (450 g) in small portions. The mixture was stirred at room temperature for 16 h. The suspension was filtered and the filtrate evaporated. The residue was triturated with hexane (100 mL) to give intermediate C-2 (130.2 g, 0.60 mol, 84%) as a white solid. MS (ESI) mass calcd. for C14H19NO, 217.2. m/z found 218.3 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 7.41-7.25 (m, 4H), 7.25-7.10 (m, 1H), 4.50 (d, J=3.6 Hz, 1H), 3.97-3.86 (m, 1H), 3.71 (d, J=14.7 Hz, 1H), 3.66 (d, J=14.4 Hz, 1H), 2.61 (d, J=9.3 Hz, 1H), 2.48-2.32 (m, 2H), 1.94 (t, J=11.1 Hz, 1H), 1.82-1.66 (m, 2H), 1.66-1.56 (m, 1H), 1.52-1.37 (m, 2H), 1.32-1.15 (m, 1H). Intermediate C-2 can be carried forward to Intermediate C-4A, which can be obtained as a single enantiomer (Intermediate C-4B or C-4C) by Chiral SFC purification as described above.
Example 1
(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-8 (100 mg, 0.469 mmol) dissolved in DMF (3 mL) was added NaH (28 mg, 0.70 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyrazine (0.087 mL, 0.70 mmol) was then added and the mixture heated to 90° C. After heating at 90° C. for 3.5 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (151 mg, 0.420 mmol, 90%). MS (ESI) mass calcd. for C16H20F3N3O3, 359.1. m/z found 304.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d. compound present as a mixture of rotamers) δ 8.46-8.41 (m, 1H), 8.27-8.24 and 8.16-8.12 (2m, 1H), 5.45-5.30 (m, 1H), 4.63-4.48 (m, 1H), 3.48-3.33 (m, 1H), 3.28-3.13 (m, 1H), 2.67-2.54 (m, 1H), 2.32-2.19 (m, 1H), 1.85-1.04 (m, 12H).
Step B: (R/S)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (151 mg, 0.42 mmol) in EtOAc (1 mL) was added 4 M HCl in dioxane (6 mL). After 3.25 h, the reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C11H12F3N3O, 259.1. m/z found 260.1 [M+H]+.
Step C: (R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (43 mg) and intermediate A-1 (24 mg, 0.13 mmol) in DMF (1.5 mL) was added DIPEA (0.4 mL, 2.32 mmol) and HATU (48 mg, 0.13 mmol). Upon completion of the reaction, purification was performed using Agilent Prep Method X to give the title compound (9 mg). MS (ESI) mass calcd. for C20H12F3N6O2, 430.1. m/z found 431.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.80:0.20), major rotamer reported) δ 8.25 (s, 1H), 8.02-7.98 (m, 1H), 7.87-7.79 (m, 3H), 7.32 (ddd, J=8.2, 7.4, 1.5 Hz, 1H), 7.04 (dd, J=7.7, 1.5 Hz, 1H), 6.81 (t, J=7.5 Hz, 1H), 4.97 (dt, J=10.2, 3.3 Hz, 1H), 4.03-3.96 (m, 1H), 3.62 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5 Hz, 1H), 2.68-2.63 (m, 1H), 2.27-2.18 (m, 1H), 1.48 (dt, J=13.6, 3.6 Hz, 1H), 1.40 (d, J=10.6 Hz, 1H), 1.33-1.25 (m, 1H).
Example 2
(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 1 substituting intermediate A-1 with intermediate A-20. MS (ESI) mass calcd. for C20H18F3N7O2, 445.1. m/z found 446.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.30-8.27 (m, 1H), 8.05-8.00 (m, 2H), 7.83 (s, 2H), 7.11-7.07 (m, 1H), 5.01 (dt, J=10.2, 3.2 Hz, 1H), 4.27-4.23 (m, 1H), 3.70 (dt, J=11.0, 3.2 Hz, 1H), 3.49 (dd, J=11.0, 1.4 Hz, 1H), 2.72-2.67 (m, 1H), 2.30-2.21 (m, 4H), 1.60-1.48 (m, 3H).
Example 3
(R/S)-(3-ethoxyisoquinolin-4-yl)((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 1 substituting intermediate A-1 with intermediate A-21. MS (ESI) mass calcd. for C23H21F3N4O3, 458.2. m/z found 459.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.72 (d, J=0.8 Hz, 1H), 7.77-7.72 (m, 1H), 7.71-7.68 (m, 1H), 7.64-7.58 (m, 2H), 7.52-7.47 (m, 1H), 7.30 (ddd, J=8.1, 6.8, 1.1 Hz, 1H), 4.87 (dt, J=10.2, 3.4 Hz, 1H), 4.68-4.39 (m, 3H), 3.87 (dt, J=11.1, 3.2 Hz, 1H), 3.56 (dd, J=11.1, 1.6 Hz, 1H), 2.83-2.77 (m, 1H), 2.35-2.26 (m, 1H), 2.01-1.95 (m, 1H), 1.84-1.75 (m, 1H), 1.56-1.38 (m, 4H).
Example 4
(R/S)-5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 1 substituting intermediate A-1 with intermediate A-19. MS (ESI) mass calcd. for C20H18F3N2O2, 445.1. m/z found 446.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.34 (d, J=1.3 Hz, 1H), 8.00-7.95 (m, 2H), 7.84-7.80 (m, 2H), 7.62-7.59 (m, 1H), 5.10 (dt, J=10.3, 3.2 Hz, 1H), 4.27-4.24 (m, 1H), 3.71 (dt, J=11.0, 3.2 Hz, 1H), 3.49 (dd, J=11.0, 1.5 Hz, 1H), 2.76-2.70 (m, 1H), 2.34-2.22 (m, 4H), 1.71-1.54 (m, 3H).
Example 5
(R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-8 (200 mg, 0.94 mmol) dissolved in DMF (5 mL) was added NaH (56 mg, 1.41 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyridine (340 mg, 1.87 mmol) was then added and the mixture heated to 80° C. After heating at 80° C. for 5.75 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with H2O, and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-30% EtOAc in hexanes) gave the title compound (300 mg, 0.84 mmol, 89%). MS (ESI) mass calcd. for C12H21F3N2O3, 358.2. m/z found 359.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.47-8.37 (m, 1H), 7.84-7.69 (m, 1H), 6.87-6.68 (m, 1H), 5.45-5.29 (m, 1H), 4.63-4.52 (m, 1H), 3.47-3.34 (m, 1H), 3.26-3.11 (m, 1H), 2.66-2.52 (m, 1H), 2.31-2.16 (m, 1H), 1.80-1.09 (series of m, 12H).
Step B: (R/S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (300 mg, 0.84 mmol) in EtOAc (1 mL) was added 4 M HCl in dioxane (5 mL). After 7 h, the reaction was concentrated to give the title compound of step B (243 mg) which was used without further purification. MS (ESI) mass calcd. for C12H13F3N2O, 258.1. m/z found 259.1 [M+H]+.
Step C: (R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (30 mg) and intermediate A-14 (24 mg, 0.10 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (38 mg, 0.10 mmol). Upon completion, the reaction was diluted with H2O and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (40.3 mg). MS (ESI) mass calcd. for C23H19F4N3O2S, 477.1. m/z found 478.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.19-8.14 (m, 1H), 7.63-7.57 (m, 1H), 7.49-7.41 (m, 2H), 7.12-7.01 (m, 2H), 6.61-6.54 (m, 1H), 5.03 (dt, J=10.3, 3.2 Hz, 1H), 4.64-4.58 (m, 1H), 3.56-3.51 (m, 2H), 2.66-2.58 (m, 1H), 2.44 (s, 3H), 2.26-2.15 (m, 1H), 1.53 (d, J=10.8 Hz, 1H), 1.45-1.35 (m, 2H).
Example 6
(R/S)-(6-methylimidazo[2,1-b]thiazol-5-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 substituting intermediate A-14 with intermediate A-17. MS (ESI) mass calcd. for C19H17F3N4O2S, 422.1. m/z found 423.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.08 (br. s, 1H), 7.54-7.37 (m, 2H), 6.68 (d, J=4.5 Hz, 1H), 6.53-6.41 (m, 1H), 5.22-5.08 (m, 1H), 4.98-4.85 (m, 1H), 3.87-3.65 (m, 1H), 3.57-3.46 (m, 1H), 2.77-2.71 (m, 1H), 2.39 (s, 3H), 2.36-2.24 (m, 1H), 2.04-1.95 (m, 1H), 1.85 (d, J=10.5 Hz, 1H), 1.49 (dt, J=13.6, 3.5 Hz, 1H).
Example 7
(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-1. MS (ESI) mass calcd. for C21H18F3N5O2, 429.2. m/z found 430.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.02-7.99 (m, 1H), 7.87-7.74 (m, 4H), 7.35-7.29 (m, 1H), 7.03 (dd, J=7.7, 1.5 Hz, 1H), 6.84-6.78 (m, 2H), 5.00 (dt, J=10.1, 3.3 Hz, 1H), 4.07-4.03 (m, 1H), 3.61 (dt, J=11.0, 3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.5 Hz, 1H), 2.65-2.60 (m, 1H), 2.25-2.16 (m, 1H), 1.45-1.37 (m, 2H), 1.33-1.25 (m, 1H).
Example 8
(R/S)-(3-ethoxyisoquinolin-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-21 and additional purification using Shimadzu Prep Method X. MS (ESI) mass calcd. for C24H22F3N3O3, 457.2. m/z found 458.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.71 (s, 1H), 7.81-7.76 (m, 1H), 7.71-7.68 (m, 1H), 7.61 (d, J=8.2 Hz, 1H), 7.46 (ddd, J=8.4, 6.8, 1.3 Hz, 1H), 7.29-7.23 (buried m, 1H), 7.10 (dd, J=8.7, 2.5 Hz, 1H), 6.11 (d, J=8.6 Hz, 1H), 4.91 (dt, J=10.3, 3.4 Hz, 1H), 4.68-4.66 (m, 1H), 4.65-4.58 (m, 1H), 4.49-4.40 (m, 1H), 3.86 (dt, J=11.2, 3.2 Hz, 1H), 3.58 (dd, J=11.1, 1.7 Hz, 1H), 2.84-2.76 (m, 1H), 2.36-2.24 (m, 1H), 1.99-1.94 (m, 1H), 1.80 (d, J=10.4 Hz, 1H), 1.50 (dt, J=13.7, 3.8 Hz, 1H), 1.44 (t, J=7.1 Hz, 3H).
Example 9
(R/S)-(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-19. MS (ESI) mass calcd. for C21H19F3N6O2, 444.2. m/z found 445.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 7.98-7.95 (m, 1H), 7.95-7.92 (m, 1H), 7.82 (s, 2H), 7.71 (dd, J=8.8, 2.6 Hz, 1H), 7.67-7.64 (m, 1H), 6.88-6.83 (m, 1H), 5.02 (dt, J=10.2, 3.2 Hz, 1H), 4.28-4.21 (m, 1H), 3.68 (dt, J=10.9, 3.2 Hz, 1H), 3.45 (dd, J=11.0, 1.2 Hz, 1H), 2.71-2.64 (m, 1H), 2.28 (s, 3H), 2.28-2.17 (m, 1H), 1.59-1.46 (m, 3H).
Example 10
(R/S)-(7-ethoxyquinolin-8-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-25. MS (ESI) mass calcd. for C24H22F3N3O3, 457.2. m/z found 458.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.49 min (major rotamer) at 254 nm.
Example 11
(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-2. MS (ESI) mass calcd. for C23H18F4N4O2, 458.1. m/z found 459.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.14-8.10 (m, 1H), 7.79 (dd, J=8.8, 2.6 Hz, 1H), 7.30-7.26 (m, 1H), 7.10-7.03 (m, 1H), 6.95-6.81 (m, 3H), 5.06 (dt, J=10.2, 3.4 Hz, 1H), 4.27-4.23 (m, 1H), 3.34-3.30 (m, 2H), 2.57-2.51 (m, 1H), 2.25-2.14 (m, 1H), 1.46-1.40 (m, 1H), 1.36 (dt, J=13.6, 3.6 Hz, 1H), 0.94-0.87 (m, 1H).
Example 12
(R/S)-(4-methoxy-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




To the title compound of Example 5 step B (20 mg) and intermediate A-15 (15 mg, 0.066 mmol) was added DCM (0.8 mL) and DIPEA (0.05 mL, 0.29 mmol). T3P (0.11 mL, 0.18 mmol, 50% solution in DMF) was then added dropwise and the mixture heated to 45° C. Upon completion the reaction was quenched with saturated NaHCO3 solution and the aqueous layer extracted with EtOAc (3×). The combined organics were washed saturated NaHCO3 solution, brine, dried with MgSO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (9.3 mg). MS (ESI) mass calcd. for C24H21F3N4O3, 470.2. m/z found 471.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.78 (d, J=4.8 Hz, 2H), 8.11-8.09 (m, 1H), 7.83-7.77 (m, 1H), 7.70 (d, J=2.6 Hz, 1H), 7.20 (t, J=4.9 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.87-6.80 (m, 1H), 6.45 (dd, J=8.4, 2.7 Hz, 1H), 5.03 (dt, J=10.1, 3.3 Hz, 1H), 4.16-4.12 (m, 1H), 3.81 (s, 3H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.8, 1.4 Hz, 1H), 2.66-2.60 (m, 1H), 2.26-2.16 (m, 1H), 1.45-1.35 (m, 2H), 1.29-1.17 (m, 1H).
Example 13
(R/S)-4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-5. MS (ESI) mass calcd. for C22H20F3N5O3, 459.1. m/z found 460.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.11-8.07 (m, 1H), 7.84-7.75 (m, 3H), 7.37 (d, J=2.5 Hz, 1H), 6.96 (d, J=8.5 Hz, 1H), 6.81 (d, J=8.7 Hz, 1H), 6.37 (dd, J=8.5, 2.5 Hz, 1H), 5.01 (dt, J=10.1, 3.3 Hz, 1H), 4.08-4.01 (m, 1H), 3.80 (s, 3H), 3.58 (dt, J=10.9, 3.2 Hz, 1H), 3.39 (dd, J=10.9, 1.4 Hz, 1H), 2.65-2.58 (m, 1H), 2.25-2.14 (m, 1H), 1.45-1.35 (m, 2H), 1.30-1.22 (m, 1H).
An ORTEP of Example 13 is depicted in FIG. 1.
Example 14
(R/S)-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-10. MS (ESI) mass calcd. for C21H17F4N5O2, 447.1. m/z found 448.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.09-8.05 (m, 1H), 7.85-7.78 (m, 4H), 7.00 (ddd, J=9.0, 7.6, 2.9 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.78 (dd, J=8.1, 2.9 Hz, 1H), 5.02 (dt, J=10.2, 3.3 Hz, 1H), 4.06-4.01 (m, 1H), 3.59 (dt, J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.5 Hz, 1H), 2.66-2.60 (m, 1H), 2.28-2.17 (m, 1H), 1.47-1.37 (m, 2H), 1.34-1.27 (m, 1H).
An ORTEP of Example 14 is depicted in FIG. 2.
Example 15
(R/S)-2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-13. MS (ESI) mass calcd. for C22H20F3N5O3, 459.2. m/z found 460.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.00-7.95 (m, 1H), 7.82 (s, 2H), 7.73 (d, J=10.6 Hz, 1H), 7.46 (dd, J=8.2, 0.9 Hz, 1H), 7.28-7.21 (m, 1H), 6.75-6.71 (m, 1H), 6.42 (dd, J=8.4, 0.9 Hz, 1H), 4.82 (dt, J=10.2, 3.4 Hz, 1H), 4.18-4.12 (m, 1H), 3.63-3.58 (m, 1H), 3.57 (s, 3H), 3.37 (dd, J=11.0, 1.5 Hz, 1H), 2.58-2.52 (m, 1H), 2.19-2.09 (m, 1H), 1.74-1.66 (m, 1H), 1.45-1.37 (m, 1H), 1.32-1.23 (m, 1H).
Example 16
(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-16. MS (ESI) mass calcd. for C21H17F4N5O2, 447.1. m/z found 448.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 8.14-8.09 (m, 1H), 7.89 (s, 2H), 7.83-7.78 (m, 1H), 7.16 (ddd, J=9.9, 8.1, 1.6 Hz, 1H), 6.98-6.81 (m, 3H), 5.06 (dt, J=10.1, 3.3 Hz, 1H), 4.19-4.15 (m, 1H), 3.38-3.30 (m, 2H), 2.59-2.53 (m, 1H), 2.26-2.16 (m, 1H), 1.50-1.43 (m, 1H), 1.39-1.30 (m, 1H), 1.19-1.10 (m, 1H).
Example 17
(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-22. MS (ESI) mass calcd. for C22H20F3N5O2, 443.2. m/z found 444.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.15-8.11 (m, 1H), 7.86-7.77 (m, 3H), 7.24-7.19 (m, 1H), 6.99-6.82 (m, 3H), 5.09 (dt, J=10.1, 3.3 Hz, 1H), 4.25-4.19 (m, 1H), 3.31-3.23 (m, 2H), 2.57-2.50 (m, 1H), 2.27-2.11 (m, 4H), 1.53-1.47 (m, 1H), 1.37-1.28 (m, 1H), 1.27-1.21 (m, 1H).
Example 18
(R/S)-(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-11. MS (ESI) mass calcd. for C21H17F4N5O2, 447.1. m/z found 448.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.04-8.02 (m, 1H), 7.85-7.72 (m, 4H), 7.32-7.26 (m, 1H), 6.92-6.88 (m, 1H), 6.61 (td, J=8.4, 1.0 Hz, 1H), 5.00-4.94 (m, 1H), 4.03-4.00 (m, 1H), 3.65 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5 Hz, 1H), 2.68-2.60 (m, 1H), 2.28-2.17 (m, 1H), 1.46-1.37 (m, 2H), 1.31-1.25 (m, 1H).
Example 19
(R/S)-(5-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-7. MS (ESI) mass calcd. for C23H18F4N4O2, 458.1. m/z found 459.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.77 (d, J=4.9 Hz, 2H), 8.22 (dd, J=8.8, 5.6 Hz, 1H), 8.11-8.06 (m, 1H), 7.82 (dd, J=8.7, 2.5 Hz, 1H), 7.19 (t, J=4.9 Hz, 1H), 6.98 (ddd, J=8.8, 7.9, 2.7 Hz, 1H), 6.85 (d, J=8.8 Hz, 1H), 6.77 (dd, J=8.6, 2.7 Hz, 1H), 5.03 (dt, J=10.1, 3.4 Hz, 1H), 4.16-4.11 (m, 1H), 3.66 (dt, J=10.8, 3.2 Hz, 1H), 3.42 (dd, J=10.8, 1.5 Hz, 1H), 2.70-2.63 (m, 1H), 2.30-2.19 (m, 1H), 1.50-1.39 (m, 2H), 1.35-1.27 (m, 1H).
Example 20
(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(−6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-23. MS (ESI) mass calcd. for C23H18F4N4O2, 458.1. m/z found 459.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.84:0.16), major rotamer reported) δ 8.80 (d, J=4.8 Hz, 2H), 8.12-8.09 (m, 1H), 7.93 (dd, J=9.9, 2.6 Hz, 1H), 7.83-7.78 (m, 1H), 7.25-7.21 (m, 1H), 7.01 (dd, J=8.4, 5.6 Hz, 1H), 6.85-6.81 (m, 1H), 6.63-6.55 (m, 1H), 5.03 (dt, J=10.1, 3.3 Hz, 1H), 4.16-4.09 (m, 1H), 3.65 (dt, J=10.8, 3.3 Hz, 1H), 3.46-3.36 (m, 1H), 2.69-2.62 (m, 1H), 2.29-2.17 (m, 1H), 1.48-1.37 (m, 2H), 1.31-1.23 (m, 1H).
Example 21
(R/S)-(2-(4H-1,2,4-triazol-4-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-9. MS (ESI) mass calcd. for C21H18F3N5O2, 429.1. m/z found 430.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.84:0.16), major rotamer reported) δ 8.44 (s, 2H), 8.03-7.95 (m, 1H), 7.80 (dd, J=8.9, 2.5 Hz, 1H), 7.44-7.34 (m, 1H), 7.30-7.24 (m, 1H), 7.08-6.92 (m, 2H), 6.83 (d, J=8.7 Hz, 1H), 5.04-4.94 (m, 1H), 3.90 (br. s, 1H), 3.47-3.32 (m, 2H), 2.65-2.57 (m, 1H), 2.26-2.13 (m, 1H), 1.52-1.33 (m, 2H), 1.05-0.86 (m, 1H).
Example 22
(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-20. MS (ESI) mass calcd. for C21H19F3N6O2, 444.2. m/z found 445.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.05-7.98 (m, 2H), 7.83 (s, 2H), 7.71-7.66 (m, 1H), 7.10-7.05 (m, 1H), 6.86-6.80 (m, 1H), 5.01-4.93 (m, 1H), 4.28-4.22 (m, 1H), 3.68 (dt, J=10.9, 3.2 Hz, 1H), 3.46 (dd, J=10.9, 1.2 Hz, 1H), 2.67-2.62 (m, 1H), 2.28-2.16 (m, 4H), 1.53-1.42 (m, 3H).
Example 23
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




The title compound, absolute configuration confirmed by Example 25, was obtained as a single enantiomer by Chiral SFC purification of Example 22 performed using a Chiralpak IC column (5 um 250×21 mm), mobile phase of 20% EtOH: 80% CO2, and a flow rate of 40 mL/min (Temperature=40° C.). Elution was monitored following absorbance at 270 nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5 um 250×4.6 mm), mobile phase of 20% EtOH: 80% CO2, and a flow rate of 2 mL/min over 45 minutes (Temperature=40° C.). Elution was monitored following absorbance at 270 nm (enantiopurity>98%) which elutes as two peaks with an initial minor peak followed by a second major peak (due to rotamers), 6.77 min and 23.40 min retention time). MS (ESI) mass calcd. for C21H19F3N6O2, 444.2. m/z found 445.2 [M+H]+. 1H NMR data is in agreement with Example 22.
Example 24
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




The title compound, absolute configuration confirmed by Example 25, was obtained as a single enantiomer by Chiral SFC purification of Example 22 performed using a Chiralpak IC column (5 um 250×21 mm), mobile phase of 20% EtOH: 80% CO2, and a flow rate of 40 mL/min (Temperature=40° C.). Elution was monitored following absorbance at 270 nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5 um 250×4.6 mm), mobile phase of 20% EtOH: 80% CO2, and a flow rate of 2 mL/min over 45 minutes (Temperature=40° C.). Elution was monitored following absorbance at 270 nm (enantiopurity>98%) which elutes as two peaks with an initial minor peak followed by a second major peak (due to rotamers), 7.75 min and 11.79 min retention time). MS (ESI) mass calcd. for C21H19F3N6O2, 444.2. m/z found 445.2 [M+H]+. 1H NMR data is in agreement with Example 22.
Example 25
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (422 mg, 1.98 mmol) dissolved in DMF (8 mL) was added NaH (119 mg, 2.97 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyridine (718 mg, 3.96 mmol) was then added and the mixture heated to 80° C. After heating at 80° C. for 4.75 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with H2O, and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound (622 mg, 1.74 mmol, 88%). MS (ESI) mass calcd. for C12H21F3N2O3, 358.2. m/z found 359.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, compound present as a mixture of rotamers (0.75:0.25)) δ 8.44-8.37 (m, 1H), 7.80-7.74 (m, 0.75H), 7.73-7.66 (m, 0.25H), 6.82-6.77 (m, 0.75H), 6.73-6.68 (m, 0.25H), 5.44-5.37 (m, 0.25H), 5.34 (dt, J=10.1, 3.2 Hz, 0.75H), 4.58-4.53 (m, 1H), 3.44-3.34 (m, 1H), 3.20 (dd, J=9.6, 1.3 Hz, 0.75H), 3.13 (d, J=9.5 Hz, 0.25H), 2.61-2.52 (m, 1H), 2.29-2.15 (m, 1H), 1.79-1.58 (m, 2H), 1.47-1.23 (m, 3H), 1.12 (s, 7H).
Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (622 mg, 1.74 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (10 mL). After 2 h, the reaction was concentrated to give the title compound of step B (507 mg) which was used without further purification. MS (ESI) mass calcd. for C12H13F3N2O, 258.1. m/z found 259.1 [M+H]+.
Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
To the title compound of step B (100 mg) and intermediate A-20 (84 mg, 0.37 mmol) in DMF (4 mL) was added DIPEA (0.3 mL, 1.74 mmol) and HATU (142 mg, 0.37 mmol). Upon completion, the reaction was diluted with H2O and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (112 mg). The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (Sum 250×4.6 mm), mobile phase of 20% EtOH: 80% CO2, and a flow rate of 2 mL/min over 45 minutes (Temperature=40° C.). Elution was monitored following absorbance at 270 nm (100% single enantiomer) which elutes as two peaks with an initial minor peak followed by a second major peak (due to rotamers), 7.69 min and 11.90 min retention time). MS (ESI) mass calcd. for C21H19F3N6O2, 444.2. m/z found 445.2 [M+H]+. 1H NMR data is in agreement with Example 22.
Example 26
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-23. MS (ESI) mass calcd. for C23H18F4N4O2, 458.1. m/z found 459.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.80 (d, J=4.8 Hz, 2H), 8.13-8.07 (m, 1H), 7.95-7.90 (m, 1H), 7.84-7.78 (m, 1H), 7.23 (t, J=4.8 Hz, 1H), 7.01 (dd, J=8.4, 5.6 Hz, 1H), 6.87-6.81 (m, 1H), 6.59 (ddd, J=8.5, 7.9, 2.7 Hz, 1H), 5.03 (dt, J=10.1, 3.3 Hz, 1H), 4.15-4.10 (m, 1H), 3.65 (dt, J=10.8, 3.2 Hz, 1H), 3.44-3.38 (m, 1H), 2.69-2.62 (m, 1H), 2.29-2.18 (m, 1H), 1.48-1.37 (m, 2H), 1.34-1.23 (m, 1H).
Example 27
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-2. MS (ESI) mass calcd. for C23H18F4N4O2, 458.1. m/z found 459.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.14-8.08 (m, 1H), 7.79 (dd, J=8.8, 2.5 Hz, 1H), 7.30-7.26 (m, 1H), 7.10-7.02 (m, 1H), 6.95-6.80 (m, 3H), 5.06 (dt, J=10.3, 3.4 Hz, 1H), 4.28-4.22 (m, 1H), 3.34-3.30 (m, 2H), 2.56-2.51 (m, 1H), 2.25-2.15 (m, 1H), 1.45-1.40 (m, 1H), 1.36 (dt, J=13.6, 3.6 Hz, 1H), 0.95-0.86 (m, 1H).
Example 28
(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-19. MS (ESI) mass calcd. for C21H19F3N6O2, 444.2. m/z found 445.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 7.98-7.92 (m, 2H), 7.83 (s, 2H), 7.75-7.69 (m, 1H), 7.67-7.63 (m, 1H), 6.89-6.83 (m, 1H), 5.02 (dt, J=10.3, 3.2 Hz, 1H), 4.27-4.21 (m, 1H), 3.69 (dt, J=10.9, 3.2 Hz, 1H), 3.51-3.42 (m, 1H), 2.70-2.64 (m, 1H), 2.33-2.16 (m, 4H), 1.58-1.46 (m, 3H).
Example 29
(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-3. MS (ESI) mass calcd. C21H19F3N6O2, 444.2. m/z found 445.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.06-8.02 (m, 1H), 7.88 (s, 2H), 7.80 (dd, J=8.7, 2.5 Hz, 1H), 7.31-7.24 (m, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.61 (d, J=7.8 Hz, 1H), 4.98 (dt, J=10.1, 3.3 Hz, 1H), 4.06-4.02 (m, 1H), 3.62 (dt, J=11.0, 3.2 Hz, 1H), 3.41 (dd, J=10.9, 1.5 Hz, 1H), 2.68-2.61 (m, 1H), 2.56 (s, 3H), 2.27-2.14 (m, 1H), 1.48-1.40 (m, 2H), 1.37-1.29 (m, 1H).
Example 30
(3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-28. MS (ESI) mass calcd. C20H17F3N6O2, 430.1. m/z found 431.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.80:0.20), major rotamer reported) δ 8.17 (dd, J=8.4, 1.5 Hz, 1H), 7.95-7.91 (m, 1H), 7.88-7.81 (m, 3H), 7.72 (dd, J=8.7, 2.6 Hz, 1H), 7.20 (dd, J=8.3, 4.7 Hz, 1H), 6.86 (d, J=8.8 Hz, 1H), 5.03 (dt, J=10.2, 3.2 Hz, 1H), 4.27-4.23 (m, 1H), 3.74-3.68 (m, 1H), 3.47 (dd, J=11.0, 1.3 Hz, 1H), 2.71-2.66 (m, 1H), 2.29-2.19 (m, 1H), 1.64-1.48 (m, 3H).
Example 31
(3-fluoro-2-methoxyphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-18. MS (ESI) mass calcd. C20H18F4N2O3, 410.1. m/z found 411.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.01-7.97 (m, 1H), 7.74-7.71 (m, 1H), 6.92 (ddd, J=11.5, 8.1, 1.7 Hz, 1H), 6.79 (d, 8.7 Hz, 1H), 6.67-6.49 (m, 2H), 5.07 (dt, J=10.1, 3.2 Hz, 1H), 4.43-4.38 (m, 1H), 3.90 (d, J=1.7 Hz, 3H), 3.69 (dt, J=11.1, 3.3 Hz, 1H), 3.45 (dd, J=11.1, 1.5 Hz, 1H), 2.76-2.70 (m, 1H), 2.33-2.21 (m, 1H), 1.90-1.83 (m, 1H), 1.75-1.69 (m, 1H), 1.44 (dt, J=13.5, 3.6 Hz, 1H).
Example 32
(3-methyl-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-27. MS (ESI) mass calcd. C23H20F3N3O3, 443.1. m/z found 444.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.07-8.03 (m, 1H), 7.81-7.73 (m, 2H), 7.30-7.25 (m, 1H), 7.18-7.13 (m, 1H), 6.91-6.80 (m, 3H), 5.04 (dt, J=10.2, 3.2 Hz, 1H), 4.22-4.17 (m, 1H), 3.49-3.41 (m, 1H), 3.40-3.33 (m, 1H), 2.63-2.57 (m, 1H), 2.44 (s, 3H), 2.26-2.16 (m, 1H), 1.49 (d, J=10.4 Hz, 1H), 1.41-1.26 (m, 2H).
Example 33
(3-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-33. MS (ESI) mass calcd. C21H17F4N5O2, 447.1. m/z found 448.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.76:0.24), major rotamer reported) δ 8.20-8.15 (m, 1H), 7.92-7.88 (m, 1H), 7.87-7.80 (m, 2H), 7.24-7.16 (m, 1H), 7.07-6.99 (m, 1H), 6.92-6.85 (m, 2H), 5.14 (dt, J=9.9, 3.2 Hz, 1H), 4.28-4.24 (m, 1H), 3.37-3.31 (m, 1H), 3.30-3.24 (m, 1H), 2.62-2.56 (m, 1H), 2.32-2.21 (m, 1H), 1.42-1.31 (m, 2H), 0.94-0.89 (m, 1H).
Example 34
(6-methyl-2-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-4. MS (ESI) mass calcd. C21H19F3N6O2, 444.2. m/z found 445.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.44 (d, J=1.2 Hz, 1H), 8.09-8.05 (m, 1H), 7.84-7.78 (m, 2H), 7.28 (d, J=7.8 Hz, 1H), 6.88-6.83 (m, 1H), 6.65 (d, J=7.8 Hz, 1H), 5.05 (dt, J=10.1, 3.3 Hz, 1H), 4.13-4.06 (m, 1H), 3.73 (dt, J=11.0, 3.2 Hz, 1H), 3.38 (dd, J=10.9, 1.5 Hz, 1H), 2.72-2.65 (m, 1H), 2.50 (s, 3H), 2.31-2.21 (m, 1H), 1.73-1.67 (m, 1H), 1.51-1.40 (m, 2H).
Example 35
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-16. MS (ESI) mass calcd. C21H17F4N5O2, 447.1. m/z found 448.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.14-8.08 (m, 1H), 7.89 (s, 2H), 7.80 (dd, J=8.7, 2.5 Hz, 1H), 7.16 (ddd, J=9.9, 8.2, 1.6 Hz, 1H), 6.98-6.81 (m, 3H), 5.06 (dt, J=10.1, 3.3 Hz, 1H), 4.21-4.13 (m, 1H), 3.39-3.30 (m, 2H), 2.60-2.52 (m, 1H), 2.26-2.15 (m, 1H), 1.51-1.43 (m, 1H), 1.39-1.30 (m, 1H), 1.20-1.10 (m, 1H).
Example 36
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-1. MS (ESI) mass calcd. C21H18F3N5O2, 429.1. m/z found 430.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.04-7.98 (m, 1H), 7.89-7.74 (m, 4H), 7.36-7.28 (m, 1H), 7.02 (dd, J=7.7, 1.5 Hz, 1H), 6.85-6.77 (m, 2H), 4.99 (dt, J=10.2, 3.3 Hz, 1H), 4.10-4.00 (m, 1H), 3.61 (dt, J=10.9, 3.3 Hz, 1H), 3.40 (dd, J=10.9, 1.5 Hz, 1H), 2.67-2.58 (m, 1H), 2.26-2.15 (m, 1H), 1.47-1.23 (m, 3H).
Example 37
(3-ethoxy-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-8. MS (ESI) mass calcd. C21H22F3N3O3, 421.2. m/z found 422.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 7.92-7.88 (m, 1H), 7.71-7.66 (m, 1H), 6.92 (d, J=8.5 Hz, 1H), 6.87-6.82 (m, 2H), 5.00 (dt, J=10.2, 3.3 Hz, 1H), 4.68-4.63 (m, 1H), 4.05-3.85 (m, 2H), 3.72 (dt, J=11.0, 3.2 Hz, 1H), 3.51 (dd, J=11.0, 1.6 Hz, 1H), 2.74-2.68 (m, 1H), 2.31-2.16 (m, 4H), 1.96-1.88 (m, 1H), 1.78-1.70 (m, 1H), 1.48 (dt, J=13.5, 3.6 Hz, 1H), 1.43-1.35 (m, 3H).
Example 38
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-6 and substituting purification by Agilent Prep Method X by silica gel chromatography (15-80% EtOAc (with 10% MeOH) in hexanes). MS (ESI) mass calcd. C23H18F4N4O2, 458.1. m/z found 459.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.81 (d, J=4.9 Hz, 2H), 8.11-8.05 (m, 1H), 8.05-8.00 (m, 1H), 7.77 (dd, J=8.7, 2.3 Hz, 1H), 7.31-7.27 (m, 1H), 7.23 (t, J=4.8 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 6.72-6.64 (m, 1H), 4.97 (dt, J=10.1, 3.4 Hz, 1H), 4.14-4.09 (m, 1H), 3.68 (dt, J=10.9, 3.2 Hz, 1H), 3.46 (dd, J=10.9, 1.5 Hz, 1H), 2.65 (s, 1H), 2.28-2.18 (m, 1H), 1.48-1.38 (m, 2H), 1.25-1.18 (m, 1H).
Example 39
(2-methoxy-6-(1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-30. MS (ESI) mass calcd. C23H21F3N4O3, 458.2. m/z found 459.3 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.00 (s, 1H), 7.75 (dd, J=8.7, 2.6 Hz, 1H), 7.62-7.57 (m, 1H), 7.34-7.26 (m, 1H), 7.25-7.21 (m, 1H), 6.76 (d, J=8.7 Hz, 1H), 6.53 (d, J=2.0 Hz, 1H), 6.46 (d, J=8.4 Hz, 1H), 4.84 (dt, J=10.2, 3.4 Hz, 1H), 4.15 (s, 1H), 3.54-3.46 (m, 4H), 3.34 (d, J=10.8 Hz, 1H), 2.49 (s, 1H), 2.19-2.07 (m, 1H), 1.55-1.22 (m, 3H).
Example 40
(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-24. MS (ESI) mass calcd. C24H21F3N4O3, 470.2. m/z found 471.1 [M+H]+. Analytical HPLC using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). Rt=2.01 and 2.24 min (major rotamers) at 254 nm.
Example 41
(2-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-31. MS (ESI) mass calcd. C24H23F3N4O2, 456.2. m/z found 457.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.74:0.26), major rotamer reported) δ 7.95-7.90 (m, 1H), 7.75 (dd, J=9.0, 1.7 Hz, 1H), 7.39 (s, 1H), 7.30-7.27 (m, 1H), 7.13 (dd, J=7.7, 0.7 Hz, 1H), 7.03 (dd, J=7.7, 0.8 Hz, 1H), 6.91-6.87 (m, 1H), 6.80 (d, J=8.8 Hz, 1H), 4.96-4.91 (m, 1H), 4.05-4.03 (m, 1H), 3.61 (s, 3H), 3.39-3.35 (m, 1H), 3.34-3.29 (m, 1H), 2.54-2.49 (m, 1H), 2.19-2.10 (m, 1H), 2.08 (s, 3H), 1.44-1.34 (m, 2H), 0.95-0.89 (m, 1H).
Example 42
(1H-indol-7-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-29 and substituting purification by Agilent Prep Method X by silica gel chromatography (0-60% EtOAc (with 10% MeOH) in hexanes). MS (ESI) mass calcd. C21H18F3N3O2, 401.1. m/z found 402.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.82 (s, 1H), 7.92 (br. s, 1H), 7.62 (dd, J=8.9, 2.7 Hz, 1H), 7.32 (d, J=7.9 Hz, 1H), 7.21 (t, J=2.8 Hz, 1H), 6.93 (d, J=7.3 Hz, 1H), 6.69 (t, J=7.5 Hz, 1H), 6.57 (d, J=8.7 Hz, 1H), 6.32-6.25 (m, 1H), 5.06 (dt, J=10.0, 3.1 Hz, 1H), 4.67 (br. s, 1H), 3.60-3.53 (m, 1H), 3.52-3.44 (m, 1H), 2.70-2.62 (m, 1H), 2.29-2.17 (m, 1H), 2.06-1.99 (m, 1H), 1.73 (d, J=10.2 Hz, 1H), 1.30 (dt, J=13.4, 3.5 Hz, 1H).
Example 43
(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-10. MS (ESI) mass calcd. for C21H17F4N5O2, 447.2. m/z found 448.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.09-8.03 (m, 1H), 7.84-7.81 (m, 1H), 7.81-7.78 (m, 3H), 7.05-6.95 (m, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.78 (dd, J=8.1, 2.9 Hz, 1H), 5.01 (dt, J=10.1, 3.3 Hz, 1H), 4.07-3.99 (m, 1H), 3.58 (dt, J=11.0, 3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.5 Hz, 1H), 2.67-2.60 (m, 1H), 2.29-2.17 (m, 1H), 1.46-1.37 (m, 2H), 1.33-1.27 (m, 1H).
Example 44
(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-12. MS (ESI) mass calcd. for C21H17F4N5O2, 447.2. m/z found 448.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.13-8.07 (m, 1H), 7.83 (s, 2H), 7.81-7.78 (m, 1H), 7.63 (dd, J=9.5, 2.5 Hz, 1H), 7.02 (dd, J=8.5, 5.9 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.52 (td, J=8.1, 2.5 Hz, 1H), 5.01 (dt, J=10.2, 3.3 Hz, 1H), 4.03 (s, 1H), 3.63 (dt, J=11.0, 3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.4 Hz, 1H), 2.68-2.61 (m, 1H), 2.28-2.16 (m, 1H), 1.46-1.38 (m, 2H), 1.38-1.28 (m, 1H).
Example 45
(2-bromo-3-fluorophenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-32. MS (ESI) mass calcd. for C19H15BrF4N2O2, 458.0. m/z found 459.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.03 (s, 1H), 7.78 (dd, J=8.7, 2.5 Hz, 1H), 6.94 (td, J=8.3, 1.5 Hz, 1H), 6.87-6.81 (m, 1H), 6.73 (br. s, 1H), 6.63 (br. s, 1H), 5.15-5.06 (m, 1H), 4.23 (br. s, 1H), 3.73 (dt, J=11.1, 3.3 Hz, 1H), 3.45 (dd, J=11.0, 1.6 Hz, 1H), 2.80-2.71 (m, 1H), 2.37-2.25 (m, 1H), 1.99-1.89 (m, 1H), 1.84-1.71 (m, 1H), 1.46 (dt, J=13.6, 3.6 Hz, 1H).
Example 46
(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-11. MS (ESI) mass calcd. for C21H17F4N5O2, 447.2. m/z found 448.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.05-8.00 (m, 1H), 7.83 (s, 2H), 7.80-7.77 (m, 1H), 7.77-7.72 (m, 1H), 7.32-7.27 (m, 1H), 6.89 (d, J=8.8 Hz, 1H), 6.60 (td, J=8.4, 1.0 Hz, 1H), 4.96 (dt, J=10.1, 3.4 Hz, 1H), 4.06-3.96 (m, 1H), 3.64 (dt, J=10.9, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5 Hz, 1H), 2.69-2.60 (m, 1H), 2.28-2.16 (m, 1H), 1.51-1.34 (m, 2H), 1.30-1.22 (m, 1H).
Example 47
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.474 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1.0 mL) and 5-bromo-2-fluoropyridine (0.078 mL, 0.76 mmol) was then added and the mixture heated to 70° C. After heating at 70° C. for 3.25 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with H2O, and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound (149 mg, 0.40 mmol, 85%). MS (ESI) mass calcd. for C16H21BrN2O3, 368.1. m/z found 369.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, compound is present a mixture of rotamers (0.75:0.25)) δ 8.20-8.11 (m, 1H), 7.63 (dd, J=8.8, 2.6 Hz, 0.75H), 7.58 (dd, J=8.8, 2.6 Hz, 0.25H), 6.63 (dd, J=8.8, 0.7 Hz, 0.75H), 6.57-6.52 (m, 0.25H), 5.29 (dt, J=9.8, 3.0 Hz, 0.25H), 5.22 (dt, J=10.1, 3.2 Hz, 0.75H), 4.57-4.49 (m, 1H), 3.43-3.31 (m, 1H), 3.19 (dd, J=9.5, 1.3 Hz, 0.75H), 3.15-3.09 (m, 0.25H), 2.59-2.50 (m, 1H), 2.26-2.13 (m, 1H), 1.77-1.66 (m, 1H), 1.65-1.56 (m, 1H), 1.43 (s, 2H), 1.41-1.23 (m, 1H), 1.16 (s, 7H).
Step B: (1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (149 mg, 0.404 mmol) in EtOAc (1.5 mL) was added 4M HCl in dioxane (5 mL). After 3.25 h, the reaction was concentrated to give the title compound of step B (128 mg) which was used without further purification. MS (ESI) mass calcd. for C11H13BrN2O, 268.0. m/z found 269.0 [M+H]+.
Step C: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-6 (24 mg, 0.11 mmol) in DMF (1.5 mL) was added DIPEA (0.25 mL, 1.45 mmol) and HATU (41 mg, 0.11 mmol). Upon completion the reaction was diluted with H2O and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (20 mg). MS (ESI) mass calcd. C22H18BrFN4O2, 468.1. m/z found 469.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.79:0.21), major rotamer reported) δ 8.80 (d, J=4.8 Hz, 2H), 8.08 (d, J=8.0 Hz, 1H), 7.77 (d, J=2.5 Hz, 1H), 7.64 (dd, J=8.8, 2.5 Hz, 1H), 7.39-7.30 (m, 1H), 7.23 (t, J=4.9 Hz, 1H), 6.81-6.72 (m, 2H), 4.86 (dt, J=10.1, 3.3 Hz, 1H), 4.11-4.02 (m, 1H), 3.65 (dt, J=10.9, 3.1 Hz, 1H), 3.44 (dd, J=10.8, 1.5 Hz, 1H), 2.66-2.59 (m, 1H), 2.25-2.15 (m, 1H), 1.42-1.34 (m, 2H), 1.22-1.13 (m, 1H).
Example 48
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-2. MS (ESI) mass calcd. C22H18BrFN4O2, 468.1. m/z found 469.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported)1H NMR (400 MHz, Chloroform-d) δ 8.85 (d, J=4.9 Hz, 2H), 7.90-7.83 (m, 1H), 7.66 (dd, J=8.8, 2.5 Hz, 1H), 7.29-7.26 (m, 1H), 7.16-7.07 (m, 1H), 7.05-6.96 (m, 1H), 6.91 (dd, J=7.5, 1.3 Hz, 1H), 6.67 (d, J=8.7 Hz, 1H), 4.96 (dt, J=10.1, 3.3 Hz, 1H), 4.27-4.16 (m, 1H), 3.34-3.24 (m, 2H), 2.52 (s, 1H), 2.23-2.11 (m, 1H), 1.40 (d, J=10.8 Hz, 1H), 1.31 (dt, J=13.5, 3.6 Hz, 1H), 0.98-0.87 (m, 1H).
Example 49
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-1. MS (ESI) mass calcd. C20H18BrN5O2, 439.1. m/z found 440.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 7.85 (dd, J=8.2, 1.1 Hz, 1H), 7.81 (s, 2H), 7.75 (dd, J=2.5, 0.7 Hz, 1H), 7.64 (dd, J=8.7, 2.6 Hz, 1H), 7.41-7.35 (m, 1H), 7.05 (dd, J=7.7, 1.5 Hz, 1H), 6.91 (td, J=7.6, 1.2 Hz, 1H), 6.65 (d, J=8.7 Hz, 1H), 4.89 (dt, J=10.2, 3.3 Hz, 1H), 4.05-3.97 (m, 1H), 3.59 (dt, J=10.9, 3.2 Hz, 1H), 3.38 (dd, J=10.9, 1.4 Hz, 1H), 2.63-2.56 (m, 1H), 2.23-2.12 (m, 1H), 1.41-1.33 (m, 2H), 1.29-1.23 (m, 1H).
Example 50
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-20. MS (ESI) mass calcd. C20H19BrN6O2, 454.1. m/z found 455.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.03 (d, J=8.4 Hz, 1H), 7.82 (s, 2H), 7.70 (dd, J=2.6, 0.7 Hz, 1H), 7.56 (dd, J=8.8, 2.6 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 6.66 (dd, J=8.6, 0.7 Hz, 1H), 4.82 (dt, J=10.2, 3.3 Hz, 1H), 4.23-4.16 (m, 1H), 3.65 (dt, J=11.0, 3.2 Hz, 1H), 3.43 (dd, J=10.9, 1.5 Hz, 1H), 2.63-2.58 (m, 1H), 2.30 (s, 3H), 2.23-2.11 (m, 1H), 1.48-1.33 (m, 3H).
Example 51
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.474 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1.0 mL) and 2-fluoro-3-(trifluoromethyl)pyridine (0.091 mL, 0.76 mmol) was then added and the mixture heated to 70° C. After heating at 70° C. for 3 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-35% EtOAc in hexanes) gave the title compound (87 mg, 0.24 mmol, 51%) as a white solid. MS (ESI) mass calcd. for C17H21F3N2O3, 358.2. m/z found 303.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.68:0.0.32), major rotamer reported) δ 8.35-8.25 (m, 1H), 7.90-7.82 (m, 1H), 6.96 (dd, J=7.5, 5.0 Hz, 1H), 5.32 (dt, J=10.1, 3.1 Hz, 1H), 4.64-4.58 (m, 1H), 3.42 (dt, J=9.5, 3.1 Hz, 1H), 3.15 (d, J=9.5 Hz, 1H), 2.61-2.56 (m, 1H), 2.27-2.15 (m, 1H), 1.76-1.66 (m, 1H), 1.63 (br. s, 1H), 1.48 (dt, J=13.5, 3.5 Hz, 1H), 1.08 (s, 9H).
Step B: (1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (86 mg, 0.24 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL). After 2 h, the reaction was concentrated to give the title compound of step B (76.5 mg) as a white solid and used without further purification. MS (ESI) mass calcd. for C12H13F3N2O, 258.1. m/z found 259.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (25 mg) and intermediate A-1 (18 mg, 0.093 mmol) in DMF (0.8 mL) was added DIPEA (75 μL, 0.44 mmol) and HATU (36 mg, 0.093 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-60% EtOAc in hexanes) gave the title compound (29 mg). MS (ESI) mass calcd. C21H18F3N5O2, 429.1. m/z found 430.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.76:0.24), major rotamer reported) δ 7.93-7.82 (m, 4H), 7.81 (s, 2H), 7.07 (dd, J=7.7, 1.5 Hz, 1H), 6.93-6.86 (m, 1H), 6.75 (td, J=7.6, 1.2 Hz, 1H), 5.04 (dt, J=10.2, 3.4 Hz, 1H), 4.15-4.04 (m, 1H), 3.66 (dt, J=10.9, 3.3 Hz, 1H), 3.38 (dd, J=10.9, 1.4 Hz, 1H), 2.66-2.60 (m, 1H), 2.27-2.15 (m, 1H), 1.48 (dt, J=13.3, 3.6 Hz, 1H), 1.44-1.37 (m, 1H), 1.36-1.28 (m, 1H).
Example 52
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 51 substituting intermediate A-1 with intermediate A-20. MS (ESI) mass calcd. C21H19F3N6O2, 444.2. m/z found 445.0 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.72:0.28), major rotamer reported) δ 8.01 (d, J=8.5 Hz, 1H), 7.83-7.78 (m, 4H), 7.05 (d, J=8.4 Hz, 1H), 6.85-6.78 (m, 1H), 4.97 (dt, J=10.4, 3.3 Hz, 1H), 4.31 (br. s, 1H), 3.70 (dt, J=10.9, 3.3 Hz, 1H), 3.42 (d, J=10.9 Hz, 1H), 2.66-2.62 (m, 1H), 2.23-2.14 (m, 1H), 2.10 (s, 3H), 1.58-1.15 (m, 3H).
Example 53
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (9 mL) was added Pd(OAc)2 (24 mg, 0.035 mmol) and racemic BINAP (22 mg, 0.035 mmol) at room temperature and the reaction mixture was purged with N2 for 5 min. Then, 2-chloro-5-(trifluoromethyl)pyridine (159 mg, 0.874 mmol), intermediate B-10 (204 mg), and sodium tert-butoxide (121 mg, 1.22 mmol) were added and the reaction mixture heated to 70° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and the filter pad washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (198 mg, 0.554 mmol, 63%). MS (ESI) mass calcd. for C12H22F3N3O2, 357.2. m/z found 358.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.33 (s, 1H), 7.55 (d, J=8.8 Hz, 1H), 6.37 (d, J=8.8 Hz, 1H), 5.11-4.97 (m, 1H), 4.41 (s, 1H), 4.27-4.18 (m, 1H), 3.44-3.36 (m, 1H), 3.08 (d, J=9.7 Hz, 1H), 2.62-2.55 (m, 1H), 2.39-2.26 (m, 1H), 1.68-1.61 (m, 1H), 1.45-1.43 (m, 1H), 1.48 and 1.22 (two s, 9H).
Step B: Step B: (1S,4R,6R)—N-(5-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (198 mg, 0.554 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (14 mL). After 1 h, the reaction was concentrated to give the title compound of step B (183 mg), which was used without further purification. MS (ESI) mass calcd. for C12H14F3N3, 257.1. m/z found 258.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (30 mg) and intermediate A-1 (19 mg, 0.10 mmol) in DMF (1 mL) was added DIPEA (94 μL, 0.55 mmol) and HATU (38 mg, 0.10 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with 4:1 EtOAc/hexanes (3×X). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (25-100% EtOAc (with 10% MeOH) in hexanes) gave the title compound (20 mg). MS (ESI) mass calcd. C21H19F3N6O, 428.2. m/z found 429.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6, Compound presents as a mixture of rotamers, major rotamer reported) δ 8.10 (s, 2H), 7.94-7.77 (m, 1H), 7.70 (d, J=8.1 Hz, 1H), 7.67-7.49 (m, 2H), 7.28 (td, J=7.7, 1.5 Hz, 1H), 6.96-6.82 (m, 1H), 6.77-6.56 (m, 2H), 3.96 (br. s, 1H), 3.64 (br. s, 1H), 3.33-3.25 (m, 1H), 3.23-3.14 (m, 1H), 2.15-2.00 (m, 1H), 1.44-1.33 (m, 1H), 1.23-1.03 (m, 2H), *1H buried under DMSO-d6 peak.
Example 54
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-20 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. C21H20F3N7O, 443.2. m/z found 444.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=5.92 min (major rotamer) at 254 nm.
Example 55
(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-22 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. C22H21F3N6O, 442.2. m/z found 443.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.85 min (major rotamer) at 254 nm.
Example 56
(7-ethoxyquinolin-8-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-25 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. C24H23F3N4O2, 456.2. m/z found 457.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.45 min (major rotamer) at 254 nm.
Example 57
(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-10. MS (ESI) mass calcd. C21H18F4N6O, 446.1. m/z found 447.1 [M+H]+. 1H NMR (400 MHz, Methanol-d4) δ 7.95 (s, 2H), 7.91-7.84 (m, 1H), 7.81 (dd, J=9.0, 4.7 Hz, 1H), 7.56 (d, J=8.1 Hz, 1H), 7.12-7.02 (m, 1H), 6.78-6.67 (m, 1H), 6.67-6.47 (m, 1H), 4.02-3.91 (m, 1H), 3.85 (br. s, 1H), 3.42 (dt, J=11.1, 3.2 Hz, 1H), 3.30-3.27 (m, 1H), 2.63-2.55 (m, 1H), 2.26-2.14 (m, 1H), 1.51-1.40 (m, 1H), 1.28-1.16 (m, 2H).
Example 58
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-7 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. C23H19F4N5O, 457.2. m/z found 458.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6, Compound presents as a mixture of rotamers (0.90:0.10), major rotamer reported) δ 8.87 (d, J=4.9 Hz, 2H), 8.03 (dd, J=8.8, 5.6 Hz, 1H), 7.88 (br. s, 1H), 7.64-7.49 (m, 2H), 7.45 (t, J=4.9 Hz, 1H), 7.04 (td, J=8.6, 2.8 Hz, 1H), 6.70-6.53 (m, 2H), 3.96 (br. s, 1H), 3.73 (br. s, 1H), 3.23-3.13 (m, 1H), 2.15-2.02 (m, 1H), 1.37 (d, J=9.7 Hz, 1H), 1.21-0.99 (m, 3H). *1H buried under DMSO-d6 peak.
Example 59
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-10 (44 mg) and 2-chloro-5-(trifluoromethyl)pyrazine (45 mg, 0.25 mmol) dissolved in DMF (2 mL) was added K2CO3 (43 mg, 0.31 mmol) and the mixture heated to 70° C. After heating at 70° C. for 3.5 h, the mixture was cooled to room temperature, diluted with H2O, and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-45% EtOAc in hexanes) gave the title compound (31 mg, 0.087 mmol, 42%). MS (ESI) mass calcd. for C16H21F2N4O2, 358.2. m/z found 303.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d) δ 8.38-8.25 (m, 1H), 7.93-7.76 (m, 1H), 6.25-6.12 and 5.57-5.44 (2m, 1H), 4.50-4.38 (m, 1H), 4.34-4.11 (m, 1H), 3.46-3.33 (m, 1H), 3.16-3.01 (m, 1H), 2.66-2.57 (m, 1H), 2.42-2.29 (m, 1H), 1.95-0.80 (m, 12H).
Step B: (1S,4R,6R)—N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (31 mg, 0.087 mmol) in EtOAc (0.5 mL) was added 4M HCl in dioxane (4 mL). After 1.5 h additional 4 M HCl in dioxane (2 mL) was added. After an additional 1.25 h, the reaction was concentrated to give the title compound of step B (31 mg) which was used without further purification. MS (ESI) mass calcd. for C11H13F3N4, 258.1. m/z found 259.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (29 mg) and intermediate A-1 (18 mg, 0.096 mmol) in DMF (2.0 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (37 mg, 0.096 mmol). Upon completion the reaction was diluted with H2O and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (8 mg). MS (ESI) mass calcd. C20H18F3N7O, 429.2. m/z found 430.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.27 min (major rotamer) at 254 nm.
Example 60
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (218 mg, 1.03 mmol) in MeCN (5 mL) was added 2-chloro-5-(trifluoromethyl)pyrimidine (225 mg, 1.23 mmol) and Et3N (0.21 mL, 1.54 mmol), and the reaction mixture was sealed and heated to 90° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H2O. The reaction mixture was extracted with EtOAc (3×). The combined organics were concentrated and the concentrate subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (263 mg, 0.734 mmol, 71%). MS (ESI) mass calcd. for C16H21F3N4O2; 358.2. m/z found 303.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 8.54-8.36 (m, 2H), 6.18-6.09 and 5.82-5.71 (two m, 1H), 4.49-4.36 (m, 1H), 4.34-4.23 (m, 1H), 3.45-3.31 (m, 1H), 3.12 (3.00, 1H), 2.63-2.55 (m, 1H), 2.38-2.27 (m, 1H), 1.77-1.18 (m, 12H), 1.12-1.02 (m, 1H).
Step B: (1S,4R,6R)—N-(5-(trifluoromethyl)pyrimidin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (263 mg, 0.73 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (6 mL), and the reaction mixture was stirred at room temperature for 5 h. The reaction was concentrated to give the title compound of step B (230 mg), which was used without further purification. MS (ESI) mass calcd. for C11H13F3N4, 258.1. m/z found 259.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (35 mg) and intermediate A-1 (25 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (50 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Agilient Prep Method X to give the title compound (34 mg). MS (ESI): mass calcd. for C20H18F3N7O, 429.2. m/z found, 430.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.18 min (major rotamer) at 254 nm.
Example 61
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C20H19F3N8O, 444.2. m/z found, 445.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.23 (s, 1H), 8.16 (d, J=8.4 Hz, 1H), 7.92 (s, 1H), 7.86 (s, 2H), 7.73 (s, 1H), 7.32 (d, J=8.4 Hz, 1H), 4.34-4.29 (m, 1H), 4.19-4.11 (m, 1H), 3.72 (dt, J=11.0, 3.2 Hz, 1H), 3.33 (dd, J=11.1, 1.6 Hz, 1H), 2.83-2.77 (m, 1H), 2.60 (s, 3H), 2.49-2.39 (m, 1H), 2.00-1.93 (m, 1H), 1.75-1.69 (m, 1H), 1.21 (dt, J=13.2, 3.6 Hz, 1H).
Example 62
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C20H19F3N8O, 444.2. m/z found, 445.9 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.73:0.27), major rotamer reported) δ 8.52-8.44 (m, 1H), 8.36-8.30 (m, 1H), 8.21 (d, J=8.5 Hz, 1H), 7.99 (s, 2H), 7.39 (d, J=8.5 Hz, 1H), 4.24-4.15 (m, 1H), 4.12-4.00 (m, 1H), 3.60 (dt, J=11.1, 3.3 Hz, 1H), 3.35-3.32 (m, 1H), 2.75-2.70 (m, 1H), 2.48 (s, 3H), 2.43-2.30 (m, 1H), 1.76-1.62 (m, 2H), 1.39-1.29 (m, 1H).
Example 63
(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 64
(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 65
(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 66
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H19F4N5O, 457.2. m/z found, 458.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H), 7.93 (s, 1H), 7.57 (dd, J=8.9, 2.5 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.10-7.03 (m, 1H), 6.91-6.83 (m, 1H), 6.84-6.76 (m, 1H), 6.60-6.52 (m, 1H), 4.17 (s, 1H), 4.14-4.03 (m, 1H), 3.23 (s, 2H), 2.57-2.49 (m, 1H), 2.27-2.17 (m, 1H), 1.54 (d, J=11.3 Hz, 1H), 1.26-1.17 (m, 1H), 1.04 (d, J=10.0 Hz, 1H).
Example 67
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 8.12 (s, 1H), 7.72 (d, J=1.4 Hz, 1H), 7.37 (t, J=5.0 Hz, 1H), 7.18-7.11 (m, 1H), 7.07 (d, J=7.5 Hz, 1H), 4.52 (s, 1H), 4.41-4.28 (m, 1H), 3.59-3.48 (m, 1H), 3.24 (d, J=11.6 Hz, 1H), 2.79-2.69 (m, 1H), 2.49-2.38 (m, 1H), 1.81-1.71 (m, 2H), 1.15-1.05 (m, 1H). 1H buried under solvent.
Example 68
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.9 [M+H]+. 1H NMR (600 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d, J=4.9 Hz, 2H), 8.55-8.50 (m, 1H), 8.24-8.19 (m, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.16-7.08 (m, 1H), 7.06-6.96 (m, 1H), 6.89 (d, J=7.8 Hz, 1H), 4.16 (s, 1H), 4.14-4.07 (m, 1H), 3.28-3.26 (m, 1H), 3.26-3.21 (m, 1H), 2.58-2.52 (m, 1H), 2.24-2.14 (m, 1H), 1.54 (d, J=10.0 Hz, 1H), 1.34-1.28 (m, 1H), 1.09-1.01 (m, 1H).
Example 69
(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 70
(3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 71
(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 72
(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 73
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-2. The enantiomeric purity of the title compound was confirmed by analytical SFC using a Chiralpak AZ-H column (5 μm, 250×4.6 mm), mobile phase of 35% EtOH+(0.2% TEA): 65% CO2, and a flow rate of 2 mL/min over 45 minutes (Temperature=40° C.). Elution was monitored following absorbance at 220 nm Enantiopurity 100%, which elutes as a major peak (Rt=10.8 min) MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.18 min (major rotamer) at 254 nm.
Example 74
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-2. MS (ESI): mass calcd. for C23H19F4N5O2, 473.2. m/z found, 474.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.39 min (major rotamer) at 254 nm.
Example 75
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 76
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (196 mg, 0.862 mmol) dissolved in DMF (7 mL) was added NaH (69 mg, 1.7 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyridine (250 mg, 1.38 mmol) was then added and the mixture stirred at room temperature for 90 min. The reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (250 mg, 0.671 mmol, 78%). MS (ESI) mass calcd. for C18H23F3N2O3, 372.2. m/z found 373.0 [M+H]+.
Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (250 mg, 0.671 mmol) in EtOAc (8 mL) was added 4 M HCl in dioxane (0.84 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was then concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C13H15F3N2O, 272.1. m/z found 273.1 [M+H]+.
Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (35 mg) and intermediate A-40 (75 mg, 0.15 mmol, 42% purity) in DMF (1 mL) was added DIPEA (0.13 mL, 0.77 mmol) and HATU (54 mg, 0.14 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with MeOH and subjected directly to purification using Agilent Prep Method X to give the title compound (28 mg). MS (ESI): mass calcd. for C22H21F3N6O2, 458.2. m/z found, 459.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.14 min (major rotamer) at 254 nm.
Example 77
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (52 mg, 0.23 mmol) dissolved in DMF (2 mL) was added NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyrazine (45 μL, 0.37 mmol) was then added and the mixture stirred at room temperature for 1 h. The reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (75 mg, 0.20 mmol, 88%). MS (ESI) mass calcd. for C12H22F3N3O3, 373.1. m/z found 317.9 [M+2H-tBu]+.
Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (75 mg, 0.20 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.25 mL), and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed unreacted starting material. An additional equivalent of 4M HCl in dioxane (0.25 mL) was added and the reaction mixture stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (55 mg), which was used without further purification. MS (ESI) mass calcd. for C12H14F3N3O, 273.1. m/z found 274.1 [M+H]+.
Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (27 mg) and intermediate A-40 (58 mg, 0.12 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.59 mmol) and HATU (41 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was diluted with MeOH and the crude reaction mixture subjected directly to purification via Agilent Prep Method X to give the title compound (5.2 mg). MS (ESI): mass calcd. for C21H20F3N7O2, 459.2. m/z found, 460.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.28-8.24 (m, 1H), 8.15-8.11 (m, 1H), 8.08-8.02 (m, 1H), 7.83-7.79 (s, 2H), 7.13-7.09 (d, J=8.3 Hz, 1H), 5.03-4.94 (m, 1H), 3.84-3.75 (m, 2H), 3.68-3.58 (m, 1H), 2.77-2.63 (m, 1H), 2.29-2.24 (s, 3H), 2.25-2.18 (m, 3H), 1.93-1.81 (m, 1H), 1.71-1.62 (m, 1H), 1.50-1.43 (m, 1H).
Example 78
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 79
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 80
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-2. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 472.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.44 min (major rotamer) at 254 nm.
Example 81
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 82
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 83
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octane-2-carboxylate. To a microwave vial containing intermediate C-7B (193 mg, 0.853 mmol) in MeCN (4 mL) was added 2-chloro-5-(trifluoromethyl)pyrazine (0.1 mL, 0.82 mmol) and Et3N (0.14 mL, 1.02 mmol), and the reaction mixture was sealed and heated to reflux bench top overnight. Upon completion of the reaction, the crude reaction mixture was concentrated and subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (245 mg, 0.658 mmol, 77%) MS (ESI) mass calcd. for C17H23F3N4O2; 372.2. m/z found 373.2 [M+H]+.
Step B: (1S,4R,6R)—N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.2]octan-6-amine.xHCl. To the title compound of step A (245 mg, 0.658 mmol) in EtOAc (8 mL) was added 4M HCl in dioxane (0.82 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (179 mg), which was used without further purification. MS (ESI) mass calcd. for C12H15F3N4, 272.1. m/z found 273.1 [M+H]+.
Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (35 mg) and intermediate A-40 (75 mg, 0.15 mmol, 42% purity) in DMF (1.3 mL) was added DIPEA (0.13 mL, 0.77 mmol) and HATU (54 mg, 0.14 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was diluted with MeOH and the crude reaction mixture subjected directly to purification via Agilent Prep Method X to give the title compound (26 mg). MS (ESI): mass calcd. for C21H21F3N8O, 458.2. m/z found, 459.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=5.97 min (major rotamer) at 254 nm.
Example 84
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 85
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-(6-2H)-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 27 where the reduction of intermediate B-5 is carried out with NaBD4 instead of L-Selectride. MS (ESI): mass calcd. for C23H12DF4N4O2, 459.1. m/z found, 460.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.91 (d, J=5.0 Hz, 2H), 8.19-8.13 (m, 1H), 7.96 (dd, J=8.7, 2.6 Hz, 1H), 7.50 (t, J=5.0 Hz, 1H), 7.18-7.13 (m, 1H), 7.06-6.97 (m, 2H), 6.88 (dd, J=7.6, 1.1 Hz, 1H), 4.33-4.23 (m, 1H), 3.27-3.24 (m, 2H), 2.59-2.53 (m, 1H), 2.30-2.21 (m, 1H), 1.54 (d, J=10.6 Hz, 1H), 1.37 (dd, J=13.5, 3.6 Hz, 1H), 1.01-0.91 (m, 1H).
Example 86
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]-(3-2H,2H)-heptan-2-yl)methanone




Prepared analogous to Example 27 where the Diels-Alder reaction to intermediate B-1 is carried out with formaldehyde-d2 instead of formaldehyde. MS (ESI): mass calcd. for C23H16D2F4N4O2, 460.1. m/z found, 461.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.15-8.09 (m, 1H), 7.79 (dd, J=8.8, 2.5 Hz, 1H), 7.30-7.27 (m, 1H), 7.10-7.03 (m, 1H), 6.96-6.86 (m, 2H), 6.84 (d, J=8.7 Hz, 1H), 5.07 (dt, J=10.1, 3.3 Hz, 1H), 4.31-4.19 (m, 1H), 2.56-2.48 (m, 1H), 2.27-2.12 (m, 1H), 1.46-1.40 (m, 1H), 1.36 (dt, J=13.6, 3.6 Hz, 1H), 0.96-0.86 (m, 1H).
Example 87
(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-39. MS (ESI): mass calcd. for C20H17F3N6O2, 430.1. m/z found, 431.2 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.43 (dd, J=4.8, 1.8 Hz, 1H), 8.18-8.11 (m, 1H), 8.11-8.02 (m, 2H), 7.95 (dd, J=8.6, 2.5 Hz, 1H), 7.71-7.55 (m, 1H), 7.12-6.90 (m, 2H), 5.08 (dt, J=10.1, 3.2 Hz, 1H), 4.01 (s, 1H), 3.57 (dt, J=11.1, 3.2 Hz, 1H), 3.35 (dd, J=11.1, 1.7 Hz, 1H), 2.75-2.64 (m, 1H), 2.37-2.24 (m, 1H), 1.57 (d, J=10.4 Hz, 1H), 1.53-1.35 (m, 2H).
Example 88
(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-38. MS (ESI): mass calcd. for C21H19F3N6O2, 444.2. m/z found, 445.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.90:0.10), major rotamer reported) δ 8.26-8.21 (m, 1H), 8.19-8.14 (m, 1H), 8.05 (s, 2H), 7.98 (dd, J=8.7, 2.6 Hz, 1H), 7.50-7.46 (m, 1H), 6.99 (d, J=8.8 Hz, 1H), 5.06 (dt, J=10.4, 3.2 Hz, 1H), 4.05-3.97 (m, 1H), 3.54 (dt, J=11.0, 3.2 Hz, 1H), 3.35 (dd, J=11.1, 1.6 Hz, 1H), 2.68-2.62 (m, 1H), 2.32-2.19 (m, 1H), 2.08 (s, 3H), 1.56 (d, J=10.7 Hz, 1H), 1.47-1.35 (m, 2H).
Example 89
(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-34. MS (ESI): mass calcd. for C23H18F4N4O2, 458.1. m/z found, 459.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.85-8.80 (m, 2H), 8.17 (dd, J=8.1, 1.3 Hz, 1H), 8.09-8.03 (m, 1H), 7.95 (dd, J=8.8, 2.6 Hz, 1H), 7.39-7.31 (m, 1H), 7.05-6.96 (m, 2H), 6.92 (td, J=7.5, 1.2 Hz, 1H), 5.11 (dt, J=10.2, 3.3 Hz, 1H), 4.16-4.10 (m, 1H), 3.61 (dt, J=10.9, 3.2 Hz, 1H), 3.35-3.33 (m, 1H), 2.74-2.65 (m, 1H), 2.36-2.26 (m, 1H), 1.59-1.53 (m, 1H), 1.46 (dt, J=13.4, 3.7 Hz, 1H), 1.41-1.32 (m, 1H).
Example 90
(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-35. MS (ESI): mass calcd. for C23H17F5N4O2, 476.1. m/z found, 477.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.81:0.19), major rotamer reported) δ 8.88 (d, J=0.7 Hz, 2H), 8.21-8.15 (m, 1H), 7.96 (dd, J=8.8, 2.6 Hz, 1H), 7.19-7.13 (m, 1H), 7.07-6.99 (m, 2H), 6.91 (dd, J=7.6, 0.9 Hz, 1H), 5.17 (dt, J=10.2, 3.3 Hz, 1H), 4.31-4.21 (m, 1H), 3.35-3.32 (m, 1H), 3.27-3.23 (m, 1H), 2.63-2.59 (m, 1H), 2.32-2.25 (m, 1H), 1.65-1.56 (m, 1H), 1.39 (dt, J=13.6, 3.6 Hz, 1H), 1.20-1.05 (m, 1H).
Example 91
(2-(5-fluoropyrimidin-2-yl)-3-methylphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-36. MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 473.1 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.81:0.19), major rotamer reported) δ 8.85 (d, J=0.8 Hz, 2H), 8.21-8.10 (m, 1H), 7.96 (dd, J=8.8, 2.6 Hz, 1H), 7.25-7.18 (m, 1H), 7.08-6.96 (m, 1H), 6.96-6.79 (m, 2H), 5.17 (dt, J=10.2, 3.3 Hz, 1H), 4.33-4.23 (m, 1H), 3.27-3.16 (m, 2H), 2.58 (s, 1H), 2.33-2.22 (m, 4H), 1.62-1.56 (m, 1H), 1.37 (dt, J=13.5, 3.6 Hz, 1H), 1.21-1.02 (m, 1H).
Example 92
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-41. MS (ESI): mass calcd. for C23H20F3N5O2, 455.2. m/z found, 456.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.87 (d, J=4.9 Hz, 2H), 8.47 (d, J=8.2 Hz, 1H), 8.05-7.99 (m, 1H), 7.86 (dd, J=8.8, 2.5 Hz, 1H), 7.42 (t, J=4.9 Hz, 1H), 7.22 (d, J=8.2 Hz, 1H), 6.91-6.87 (m, 1H), 4.99 (dt, J=10.3, 3.4 Hz, 1H), 4.32-4.25 (m, 1H), 3.66 (dt, J=10.9, 3.2 Hz, 1H), 3.39 (dd, J=10.9, 1.6 Hz, 1H), 2.71-2.66 (m, 1H), 2.33-2.24 (m, 1H), 2.19 (s, 3H), 1.62-1.54 (m, 1H), 1.49 (dt, J=13.4, 3.7 Hz, 1H), 1.44-1.32 (m, 1H).
Example 93
(3-phenylpyrazin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-43. MS (ESI): mass calcd. for C23H19F3N4O2, 440.1. m/z found, 441.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.52 (d, J=2.4 Hz, 1H), 8.04-8.01 (m, 1H), 7.93 (d, J=2.5 Hz, 1H), 7.89 (dd, J=8.8, 2.7 Hz, 1H), 7.75-7.71 (m, 2H), 7.56-7.53 (m, 3H), 6.91-6.84 (m, 1H), 4.95 (dt, J=10.3, 3.3 Hz, 1H), 4.11-3.99 (m, 1H), 3.38-3.34 (m, 2H), 2.57-2.52 (m, 1H), 2.27-2.12 (m, 1H), 1.45-1.35 (m, 2H), 0.68-0.59 (m, 1H).
Example 94
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (50 mg, 0.23 mmol) dissolved in DMF (1 mL) was added NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-fluoro-6-(trifluoromethyl)pyridine (0.045 mL, 0.38 mmol) was then added and the mixture stirred overnight at room temperature. The mixture was quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (29 mg, 0.080 mmol, 34%) as a clear oil. MS (ESI) mass calcd. for C12H21F3N2O3, 358.2. m/z found 303.1 [M+2H-tBu]+.
Step B: (1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (28 mg, 0.078 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (0.1 mL). After 4 h, the reaction was concentrated to give the title compound of step B (23 mg) as a pink solid and used without further purification. MS (ESI) mass calcd. for C12H13F3N2O, 258.1. m/z found 259.1 [M+H]+.
Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (23 mg) and intermediate A-2 (25 mg, 0.094 mmol) in DMF (1.1 mL) was added DIPEA (81 μL, 0.47 mmol) and HATU (33 mg, 0.086 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (15 mg). MS (ESI): mass calcd. for C23H18F4N4O2, 458.1. m/z found, 459.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.84:0.16), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 7.95-7.88 (m, 1H), 7.48 (t, J=5.0 Hz, 1H), 7.33 (d, J=7.5 Hz, 1H), 7.17-7.10 (m, 2H), 7.05-6.99 (m, 1H), 6.86 (dd, J=7.9, 1.0 Hz, 1H), 5.12 (dt, J=10.2, 3.3 Hz, 1H), 4.29-4.25 (m, 1H), 3.26 (t, J=3.0 Hz, 1H), 3.25 (s, 1H), 2.58 (s, 1H), 2.32-2.24 (m, 1H), 1.60 (d, J=10.1 Hz, 1H), 1.38 (dt, J=13.5, 3.6 Hz, 1H), 1.11-1.05 (m, 1H).
Example 95
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-4-(trifluoromethyl)pyridine (0.10 mL, 0.76 mmol) was then added and the mixture heated to 70° C. After heating at 70° C. for 3 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (16 mg, 0.045 mmol, 10%) as a yellow-brown solid. MS (ESI) mass calcd. for C17H21F3N2O3, 358.2. m/z found 359.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.34-8.23 (m, 1H), 7.12-7.04 (m, 1H), 7.01-6.92 (m, 1H), 5.35 (dt, J=10.1, 3.2 Hz, 1H), 4.56-4.49 (m, 1H), 3.41 (dt, J=9.5, 3.1 Hz, 1H), 3.27-3.17 (m, 1H), 2.60-2.55 (m, 1H), 2.28-2.16 (m, 1H), 1.80-1.71 (m, 1H), 1.68-1.62 (m, 1H), 1.53-0.93 (m, 10H).
Step B: (1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (16 mg, 0.045 mmol) in EtOAc (0.1 mL) was added 4M HCl in dioxane (0.1 mL). After 3 h, the reaction was concentrated to give the title compound of step B (16 mg) and used without further purification. MS (ESI) mass calcd. for C12H13F3N2O, 258.1. m/z found 259.2 [M+H]+.
Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (16 mg) and intermediate A-2 (13 mg, 0.060 mmol) in DMF (0.6 mL) was added DIPEA (56 μL, 0.33 mmol) and HATU (23 mg, 0.060 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (3.4 mg). MS (ESI): mass calcd. for C23H18F4N4O2, 458.1. m/z found, 459.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.80:0.20), major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H), 8.07 (d, J=5.3 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.20-7.11 (m, 3H), 7.03-6.97 (m, 1H), 6.91-6.87 (m, 1H), 5.16 (dt, J=10.2, 3.3 Hz, 1H), 4.28-4.23 (m, 1H), 3.28-3.24 (m, 2H), 2.61-2.54 (m, 1H), 2.32-2.20 (m, 1H), 1.56 (d, J=10.6 Hz, 1H), 1.38 (dt, J=13.6, 3.6 Hz, 1H), 1.04-0.96 (m, 1H).
Example 96
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-fluoro-3-(trifluoromethyl)pyridine (0.10 mL, 0.76 mmol) was then added and the mixture heated to 70° C. After heating at 70° C. for 3 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-35% EtOAc in hexanes) gave the title compound (87 mg, 0.24 mmol, 51%) as a white solid. MS (ESI) mass calcd. for C12H21F3N2O3, 358.2. m/z found 303.1 [M+2H-tBu]+. 1H NMR (400 MHz, Chloroform-d) δ 8.35-8.25 (m, 1H), 7.90-7.82 (m, 1H), 6.96 (dd, J=7.5, 5.0 Hz, 1H), 5.32 (dt, J=10.1, 3.1 Hz, 1H), 4.64-4.58 (m, 1H), 3.42 (dt, J=9.5, 3.1 Hz, 1H), 3.15 (d, J=9.5 Hz, 1H), 2.61-2.56 (m, 1H), 2.27-2.15 (m, 1H), 1.76-1.66 (m, 2H), 1.48 (dt, J=13.5, 3.5 Hz, 1H), 1.08 (s, 9H).
Step B: (1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (86 mg, 0.24 mmol) in EtOAc (0.9 mL) was added 4M HCl in dioxane (3 mL). After 2 h, the reaction was concentrated to give the title compound of step B (77 mg) and used without further purification. MS (ESI) mass calcd. for C12H13F3N2O, 258.1. m/z found 259.1 [M+H]+.
Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (28 mg) and intermediate A-2 (23 mg, 0.11 mmol) in DMF (1 mL) was added DIPEA (98 μL, 0.57 mmol) and HATU (40 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (5.4 mg). MS (ESI): mass calcd. for C23H18F4N4O2, 458.1. m/z found, 459.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.86:0.14), major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H), 8.05-8.01 (m, 2H), 7.49 (t, J=5.0 Hz, 1H), 7.17-7.11 (m, 1H), 7.08-7.04 (m, 1H), 6.96-6.90 (m, 1H), 6.77 (dd, J=7.6, 1.1 Hz, 1H), 5.20 (dt, J=10.2, 3.3 Hz, 1H), 4.32-4.28 (m, 1H), 3.29-3.26 (m, 1H), 3.25-3.20 (m, 1H), 2.60-2.54 (m, 1H), 2.29-2.21 (m, 1H), 1.53 (d, J=10.4 Hz, 1H), 1.40 (dt, J=13.6, 3.6 Hz, 1H), 0.95-0.89 (m, 1H).
Example 97
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (70 mg, 0.33 mmol) and 2,3-difluoro-5-(trifluoromethyl)pyridine (90 mg, 0.49 mmol) dissolved in DMF (3 mL) was added NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil) and the reaction mixture was stirred overnight at room temperature after which analysis of the reaction mixture showed mainly starting material. Additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) was then added and the reaction mixture heated to 70° C. and stirred overnight after which analysis of the reaction mixture still showed starting material remaining Additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) was again added and the reaction mixture was heated at 70° C. for an additional 4.5 hours before additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) was added and the reaction stirred overnight. After this time analysis still showed incomplete conversion however the reaction was cooled to room temperature and quenched with H2O. The aqueous layer was extracted with EtOAc (3×) and the combined organics were washed with 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound. MS (ESI) mass calcd. for C17H20F4N2O3, 376.1. m/z found 321.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.67:0.33), major rotamer reported) δ 8.21-8.18 (m, 1H), 7.51 (dd, J=9.5, 2.1 Hz, 1H), 5.37 (dt, J=10.1, 3.2 Hz, 1H), 4.57-4.50 (m, 1H), 3.41 (dt, J=9.5, 3.1 Hz, 1H), 3.22 (dd, J=9.5, 1.4 Hz, 1H), 2.62-2.57 (m, 1H), 2.30-2.19 (m, 1H), 1.77-1.73 (m, 1H), 1.67-1.63 (m, 1H), 1.48 (dt, J=13.7, 3.6 Hz, 1H), 1.12 (s, 9H).
Step B: (1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (130 mg, 0.345 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL) and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (114 mg) as a yellow oil and used without further purification. MS (ESI) mass calcd. for C12H12F4N2O, 276.1. m/z found 277.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (28.5 mg) and intermediate A-1 (19 mg, 0.1 mmol) in DMF (0.9 mL) was added DIPEA (0.13 mL, 0.73 mmol) and HATU (38 mg, 0.1 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (18 mg). MS (ESI): mass calcd. for C21H17F4N5O2, 447.1. m/z found, 448.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 7.87 (s, 1H), 7.81 (s, 2H), 7.57-7.50 (m, 2H), 7.37-7.30 (m, 2H), 6.96 (t, J=7.5 Hz, 1H), 5.05 (dt, J=10.1, 3.4 Hz, 1H), 4.03 (s, 1H), 3.64 (dt, J=11.0, 3.2 Hz, 1H), 3.42 (dd, J=10.9, 1.4 Hz, 1H), 2.72-2.62 (m, 1H), 2.36-2.20 (m, 1H), 1.51-1.36 (m, 3H).
Example 98
(1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 97 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C21H18F4N6O2, 462.1. m/z found, 463.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.79:0.21), major rotamer reported) δ 8.00 (d, J=8.4 Hz, 1H), 7.81 (s, 2H), 7.72-7.69 (m, 1H), 7.39 (dd, J=9.4, 2.1 Hz, 1H), 7.07 (d, J=8.4 Hz, 1H), 4.96 (dt, J=10.3, 3.3 Hz, 1H), 4.47-4.40 (m, 1H), 3.72 (dt, J=11.0, 3.2 Hz, 1H), 3.48 (dd, J=11.0, 1.4 Hz, 1H), 2.72-2.64 (m, 1H), 2.29-2.21 (m, 4H), 1.66-1.61 (m, 1H), 1.57-1.50 (m, 2H).
Example 99
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 97 substituting intermediate A-1 with intermediate A-37. MS (ESI): mass calcd. for C23H18F4N4O2, 458.1. m/z found, 459.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.79 (d, J=4.8 Hz, 2H), 8.21-8.18 (m, 1H), 7.89-7.84 (m, 1H), 7.57-7.52 (m, 1H), 7.36-7.29 (m, 1H), 7.29-7.26 (m, 1H), 7.20 (t, J=4.8 Hz, 1H), 7.01 (td, J=7.5, 1.3 Hz, 1H), 5.06 (dt, J=10.0, 3.3 Hz, 1H), 4.17-4.11 (m, 1H), 3.69 (dt, J=10.8, 3.2 Hz, 1H), 3.43 (dd, J=10.8, 1.5 Hz, 1H), 2.72-2.65 (m, 1H), 2.37-2.23 (m, 1H), 1.51-1.43 (m, 2H), 1.42-1.30 (m, 1H).
Example 100
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 97 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H12F5N4O2, 476.1. m/z found, 477.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.85 (d, J=4.8 Hz, 2H), 8.00-7.94 (m, 1H), 7.55 (dd, J=9.5, 2.1 Hz, 1H), 7.30-7.27 (m, 1H), 7.19 (dd, J=7.1, 1.7 Hz, 1H), 7.13-7.03 (m, 2H), 5.10 (dt, J=10.0, 3.3 Hz, 1H), 4.31-4.24 (m, 1H), 3.45-3.29 (m, 2H), 2.65-2.53 (m, 1H), 2.35-2.23 (m, 1H), 1.48 (d, J=9.9 Hz, 1H), 1.40 (dt, J=13.6, 3.7 Hz, 1H), 1.18-0.99 (m, 1H).
Example 101
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-5-methylpyridine (0.08 mL, 0.76 mmol) was then added and the mixture heated to 70° C. After heating at 70° C. for 3 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-35% EtOAc in hexanes) gave the title compound (16 mg, 0.053 mmol, 11%) as a white solid. MS (ESI) mass calcd. for C12H24N2O3, 304.2. m/z found 305.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 7.97-7.89 (m, 1H), 7.37 (dd, J=8.4, 2.5 Hz, 1H), 6.61 (d, J=8.5 Hz, 1H), 5.25 (dt, J=10.1, 3.2 Hz, 1H), 4.56-4.48 (m, 1H), 3.38 (dt, J=9.5, 3.1 Hz, 1H), 3.19 (d, J=9.5 Hz, 1H), 2.59-2.52 (m, 1H), 2.23 (s, 3H), 2.20-2.14 (m, 1H), 1.76-1.68 (m, 1H), 1.65-1.60 (m, 1H), 1.35 (dt, J=13.4, 3.6 Hz, 1H), 1.14 (s, 9H).
Step B: (1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (16 mg, 0.053 mmol) in EtOAc (0.1 mL) was added 4M HCl in dioxane (0.1 mL). After 3 h, the reaction was concentrated to give the title compound of step B (15 mg) and used without further purification. MS (ESI) mass calcd. for C12H16N2O, 204.1. m/z found 205.2 [M+H]+.
Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (16 mg) and intermediate A-2 (16 mg, 0.07 mmol) in DMF (1 mL) was added DIPEA (69 μL, 0.40 mmol) and HATU (28 mg, 0.073 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (6 mg). MS (ESI): mass calcd. for C23H21FN4O2, 404.2. m/z found, 405.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 7.69-7.65 (m, 1H), 7.52 (dd, J=8.4, 2.5 Hz, 1H), 7.48 (t, J=4.9 Hz, 1H), 7.21-7.14 (m, 1H), 7.07-7.00 (m, 1H), 6.92 (dd, J=7.6, 1.1 Hz, 1H), 6.74 (d, J=8.4 Hz, 1H), 5.02 (dt, J=10.1, 3.3 Hz, 1H), 4.25-4.19 (m, 1H), 3.26-3.18 (m, 2H), 2.57-2.53 (m, 1H), 2.25 (s, 3H), 2.24-2.19 (m, 1H), 1.56-1.51 (m, 1H), 1.34-1.28 (m, 1H), 1.08-1.02 (m, 1H).
Example 102
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) dissolved in DMF (5 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-fluoropyridine (0.10 mL, 1.13 mmol) was then added and the mixture heated to 70° C. After heating at 70° C. for 7 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-30% EtOAc in hexanes) gave the title compound (73 mg, 0.25 mmol, 36%) as a colorless solid. MS (ESI) mass calcd. for C16H22N2O3, 290.2. m/z found 291.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.11 (ddd, J=5.1, 2.0, 0.8 Hz, 1H), 7.59-7.50 (m, 1H), 6.89-6.80 (m, 1H), 6.70 (dt, J=8.4, 0.9 Hz, 1H), 5.29 (dt, J=10.1, 3.2 Hz, 1H), 4.61-4.49 (m, 1H), 3.39 (dt, J=9.5, 3.1 Hz, 1H), 3.20 (dd, J=9.5, 1.3 Hz, 1H), 2.59-2.50 (m, 1H), 2.26-2.15 (m, 1H), 1.76-1.69 (m, 1H), 1.67-1.63 (m, 1H), 1.38 (dt, J=13.3, 3.6 Hz, 1H), 1.12 (s, 9H).
Step B: (1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (73 mg, 0.25 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred overnight. Then, the reaction was concentrated to give the title compound of step B (68 mg) and used without further purification. MS (ESI) mass calcd. for C11H14N2O, 190.1. m/z found 191.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (23 mg) and intermediate A-1 (18 mg, 0.094 mmol) in DMF (1 mL) was added DIPEA (0.17 mL, 0.99 mmol) and HATU (36 mg, 0.094 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (22 mg). MS (ESI): mass calcd. for C20H19N5O2, 361.2. m/z found, 362.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 7.84 (dd, J=8.3, 1.2 Hz, 1H), 7.82-7.77 (m, 3H), 7.60-7.54 (m, 1H), 7.36-7.28 (m, 1H), 7.16 (dd, J=7.8, 1.5 Hz, 1H), 6.88 (td, J=7.6, 1.2 Hz, 1H), 6.82-6.77 (m, 1H), 6.74 (d, J=8.3 Hz, 1H), 5.03 (dt, J=10.3, 3.2 Hz, 1H), 4.06-3.97 (m, 1H), 3.60 (dt, J=10.9, 3.3 Hz, 1H), 3.39 (dd, J=10.8, 1.4 Hz, 1H), 2.68-2.56 (m, 1H), 2.27-2.13 (m, 1H), 1.48-1.31 (m, 3H).
Example 103
(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 102 substituting intermediate A-1 with intermediate A-3. MS (ESI): mass calcd. for C20H20N6O2, 376.2. m/z found, 377.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.92:0.08), major rotamer reported) δ 7.86 (s, 2H), 7.82-7.78 (m, 1H), 7.60-7.54 (m, 1H), 7.40 (d, J=7.7 Hz, 1H), 6.85-6.79 (m, 1H), 6.74-6.64 (m, 2H), 4.98 (dt, J=10.1, 3.2 Hz, 1H), 4.05-3.97 (m, 1H), 3.61 (dt, J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.8, 1.4 Hz, 1H), 2.65-2.59 (m, 1H), 2.56 (s, 3H), 2.25-2.15 (m, 1H), 1.48-1.33 (m, 3H).
Example 104
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 102 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H19FN4O2, 390.1. m/z found, 391.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 8.84 (d, J=4.9 Hz, 2H), 7.92-7.85 (m, 1H), 7.63-7.56 (m, 1H), 7.28-7.24 (m, 2H), 7.09-6.96 (m, 2H), 6.85-6.80 (m, 1H), 6.76 (dt, J=8.3, 0.9 Hz, 1H), 5.10 (dt, J=10.0, 3.3 Hz, 1H), 4.26-4.15 (m, 1H), 3.34-3.30 (m, 2H), 2.59-2.48 (m, 1H), 2.27-2.15 (m, 1H), 1.45 (d, J=11.0 Hz, 1H), 1.32 (dt, J=13.4, 3.6 Hz, 1H), 1.13-1.01 (m, 1H).
Example 105
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-3. MS (ESI): mass calcd. for C20H19BrN6O2, 454.1. m/z found, 455.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.93:0.07), major rotamer reported) δ 7.87 (s, 2H), 7.76 (d, J=2.6 Hz, 1H), 7.64 (dd, J=8.7, 2.6 Hz, 1H), 7.29 (d, J=7.8 Hz, 1H), 6.69 (d, J=7.7 Hz, 1H), 6.62 (d, J=8.7 Hz, 1H), 4.83 (dt, J=10.3, 3.3 Hz, 1H), 4.05-3.94 (m, 1H), 3.59 (dt, J=11.0, 3.2 Hz, 1H), 3.38 (d, J=11.0 Hz, 1H), 2.66-2.56 (m, 4H), 2.23-2.10 (m, 1H), 1.44-1.33 (m, 2H), 1.32-1.23 (m, 1H).
Example 106
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-16. MS (ESI): mass calcd. for C20H17BrFN5O2, 457.1. m/z found, 458.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 7.87 (s, 2H), 7.85 (dd, J=2.6, 0.7 Hz, 1H), 7.66 (dd, J=8.7, 2.5 Hz, 1H), 7.24-7.17 (m, 1H), 7.07-6.98 (m, 1H), 6.91 (dt, J=7.7, 1.2 Hz, 1H), 6.66 (dd, J=8.8, 0.7 Hz, 1H), 4.95 (dt, J=10.1, 3.3 Hz, 1H), 4.19-4.10 (m, 1H), 3.35-3.30 (m, 2H), 2.60-2.49 (m, 1H), 2.24-2.12 (m, 1H), 1.48-1.41 (m, 1H), 1.31 (dt, J=13.5, 3.6 Hz, 1H), 1.21-1.09 (m, 1H).
Example 107
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-12. MS (ESI): mass calcd. for C20H17BrFN5O2, 457.1. m/z found, 458.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 7.85 (d, J=2.6 Hz, 1H), 7.82 (s, 2H), 7.71-7.61 (m, 2H), 7.05 (dd, J=8.5, 5.9 Hz, 1H), 6.68-6.58 (m, 2H), 4.91 (dt, J=10.1, 3.3 Hz, 1H), 4.00 (s, 1H), 3.61 (dt, J=10.9, 3.3 Hz, 1H), 3.38 (dd, J=10.9, 1.4 Hz, 1H), 2.69-2.59 (m, 1H), 2.26-2.14 (m, 1H), 1.47-1.25 (m, 3H).
Example 108
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-10. MS (ESI): mass calcd. for C20H17BrFN5O2, 457.1. m/z found, 458.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.91:0.09), major rotamer reported) δ 7.84-7.81 (m, 2H), 7.80 (s, 2H), 7.68 (dd, J=8.8, 2.6 Hz, 1H), 7.07 (ddd, J=9.0, 7.6, 2.9 Hz, 1H), 6.81 (dd, J=8.1, 2.9 Hz, 1H), 6.66 (d, J=8.8 Hz, 1H), 4.90 (dt, J=10.2, 3.4 Hz, 1H), 4.04-4.00 (m, 1H), 3.56 (dt, J=11.0, 3.2 Hz, 1H), 3.37 (dd, J=11.0, 1.5 Hz, 1H), 2.65-2.57 (m, 1H), 2.25-2.13 (m, 1H), 1.50-1.32 (m, 2H), 1.32-1.23 (m, 1H).
Example 109
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-11. MS (ESI): mass calcd. for C20H17BrFN5O2, 457.1. m/z found, 458.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 7.83 (s, 2H), 7.79-7.76 (m, 1H), 7.75 (dt, J=8.2, 1.0 Hz, 1H), 7.63 (dd, J=8.8, 2.5 Hz, 1H), 7.39-7.31 (m, 1H), 6.76-6.66 (m, 2H), 4.85 (dt, J=10.1, 3.4 Hz, 1H), 4.01-3.92 (m, 1H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.42 (dd, J=10.9, 1.5 Hz, 1H), 2.64-2.58 (m, 1H), 2.24-2.14 (m, 1H), 1.42-1.31 (m, 2H), 1.30-1.17 (m, 1H).
Example 110
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-23. MS (ESI): mass calcd. for C22H18BrFN4O2, 468.1. m/z found, 469.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.79 (d, J=4.9 Hz, 2H), 7.93 (dd, J=10.0, 2.7 Hz, 1H), 7.86 (dd, J=2.6, 0.6 Hz, 1H), 7.67 (dd, J=8.8, 2.6 Hz, 1H), 7.22 (t, J=4.9 Hz, 1H), 7.04 (dd, J=8.4, 5.6 Hz, 1H), 6.70-6.64 (m, 2H), 4.93 (dt, J=10.1, 3.3 Hz, 1H), 4.09-4.04 (m, 1H), 3.63 (dt, J=10.9, 3.1 Hz, 1H), 3.43-3.34 (m, 1H), 2.66-2.59 (m, 1H), 2.26-2.15 (m, 1H), 1.46-1.33 (m, 2H), 1.31-1.23 (m, 1H).
Example 111
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-7. MS (ESI): mass calcd. for C22H18BrFN4O2, 468.1. m/z found, 469.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.76 (d, J=4.9 Hz, 2H), 8.23 (dd, J=8.8, 5.6 Hz, 1H), 7.83 (dd, J=2.6, 0.7 Hz, 1H), 7.68 (dd, J=8.8, 2.6 Hz, 1H), 7.18 (t, J=4.9 Hz, 1H), 7.08-7.02 (m, 1H), 6.81 (dd, J=8.6, 2.7 Hz, 1H), 6.68 (d, J=8.8 Hz, 1H), 4.93 (dt, J=10.0, 3.3 Hz, 1H), 4.14-4.06 (m, 1H), 3.64 (dt, J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.7, 1.5 Hz, 1H), 2.69-2.61 (m, 1H), 2.30-2.15 (m, 1H), 1.47-1.35 (m, 2H), 1.34-1.24 (m, 1H).
Example 112
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) dissolved in DMF (5 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 5-chloro-2-fluoropyridine (0.11 mL, 1.13 mmol) was then added and the mixture heated to 70° C. After heating at 70° C. for 7 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound (149 mg, 0.46 mmol, 65%) as a colorless solid. MS (ESI) mass calcd. for C16H21ClN2O3, 324.1. m/z found 325.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, only major rotamer reported) δ 8.06 (d, J=2.6 Hz, 1H), 7.51 (dd, J=8.8, 2.7 Hz, 1H), 6.66 (d, J=8.7 Hz, 1H), 5.22 (dt, J=10.1, 3.2 Hz, 1H), 4.52-4.49 (m, 1H), 3.38 (dt, J=9.6, 3.1 Hz, 1H), 3.18 (dd, J=9.5, 1.3 Hz, 1H), 2.58-2.54 (m, 1H), 2.23-2.12 (m, 1H), 1.75-1.68 (m, 1H), 1.64-1.59 (m, 1H), 1.36 (dt, J=13.4, 3.6 Hz, 1H), 1.15 (s, 9H).
Step B: (1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (149 mg, 0.46 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 3 h. Then, the reaction was concentrated to give the title compound of step B (129 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for C11H13ClN2O, 224.1. m/z found 225.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (32 mg) and intermediate A-1 (25 mg, 0.14 mmol) in DMF (1 mL) was added DIPEA (0.25 mL, 1.5 mmol) and HATU (51 mg, 0.135 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (34 mg). MS (ESI): mass calcd. for C20H18ClN5O2, 395.1. m/z found, 396.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 7.85 (dd, J=8.2, 1.1 Hz, 1H), 7.81 (s, 2H), 7.67 (d, J=2.6 Hz, 1H), 7.53 (dd, J=8.8, 2.7 Hz, 1H), 7.40-7.34 (m, 1H), 7.07 (dd, J=7.6, 1.5 Hz, 1H), 6.91 (td, J=7.5, 1.2 Hz, 1H), 6.69 (d, J=8.8 Hz, 1H), 4.90 (dt, J=10.1, 3.3 Hz, 1H), 4.07-3.97 (m, 1H), 3.59 (dt, J=10.9, 3.2 Hz, 1H), 3.38 (dd, J=10.8, 1.4 Hz, 1H), 2.65-2.56 (m, 1H), 2.26-2.12 (m, 1H), 1.42-1.34 (m, 2H), 1.31-1.23 (m, 1H).
Example 113
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-10. MS (ESI): mass calcd. for C20H17ClFN5O2, 413.1. m/z found, 414.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.92:0.08), major rotamer reported) δ 7.85-7.79 (m, 3H), 7.72 (d, J=2.7 Hz, 1H), 7.56 (dd, J=8.8, 2.7 Hz, 1H), 7.11-7.01 (m, 1H), 6.81 (dd, J=8.2, 2.9 Hz, 1H), 6.70 (d, J=8.7 Hz, 1H), 4.91 (dt, J=10.1, 3.4 Hz, 1H), 4.11-3.98 (m, 1H), 3.56 (dt, J=10.9, 3.2 Hz, 1H), 3.37 (dd, J=10.9, 1.5 Hz, 1H), 2.68-2.56 (m, 1H), 2.26-2.13 (m, 1H), 1.47-1.32 (m, 2H), 1.32-1.22 (m, 1H).
Example 114
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C20H19ClN6O2, 410.1. m/z found, 411.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.04 (d, J=8.4 Hz, 1H), 7.83 (s, 2H), 7.61 (d, J=2.7 Hz, 1H), 7.44 (dd, J=8.8, 2.7 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 6.70 (d, J=8.8 Hz, 1H), 4.83 (dt, J=10.2, 3.3 Hz, 1H), 4.22-4.14 (m, 1H), 3.65 (dt, J=10.9, 3.2 Hz, 1H), 3.43 (dd, J=11.0, 1.4 Hz, 1H), 2.63-2.58 (m, 1H), 2.29 (s, 3H), 2.23-2.13 (m, 1H), 1.48-1.32 (m, 3H).
Example 115
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H18ClFN4O2, 424.1. m/z found, 425.1 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.84:0.16), major rotamer reported) δ 8.90 (d, J=4.9 Hz, 2H), 7.80 (d, J=2.8 Hz, 1H), 7.69 (dd, J=8.8, 2.7 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.26-7.18 (m, 1H), 7.14-7.05 (m, 1H), 6.95-6.81 (m, 2H), 5.02 (dt, J=10.1, 3.3 Hz, 1H), 4.29-4.20 (m, 1H), 3.28-3.17 (m, 2H), 2.59-2.50 (m, 1H), 2.29-2.17 (m, 1H), 1.52 (d, J=10.6 Hz, 1H), 1.33 (dt, J=13.5, 3.6 Hz, 1H), 1.04-0.89 (m, 1H).
Example 116
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-34. MS (ESI): mass calcd. for C22H18ClFN4O2, 424.1. m/z found, 425.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.81 (d, J=0.6 Hz, 2H), 8.21-8.15 (m, 1H), 7.73-7.67 (m, 2H), 7.44-7.39 (m, 1H), 7.02-6.99 (m, 2H), 6.85 (d, J=8.7 Hz, 1H), 5.00 (dt, J=10.2, 3.3 Hz, 1H), 4.13-4.06 (m, 1H), 3.60 (dt, J=11.0, 3.2 Hz, 1H), 3.34-3.32 (m, 1H), 2.71-2.64 (m, 1H), 2.31-2.22 (m, 1H), 1.58-1.50 (m, 1H), 1.41 (dt, J=13.3, 3.6 Hz, 1H), 1.38-1.33 (m, 1H).
Example 117
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-35. MS (ESI): mass calcd. for C22H17ClF2N4O2, 442.1. m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.82:0.18), major rotamer reported) δ 8.87 (d, J=0.7 Hz, 2H), 7.82 (dd, J=2.7, 0.7 Hz, 1H), 7.70 (dd, J=8.8, 2.7 Hz, 1H), 7.24-7.18 (m, 1H), 7.13-7.06 (m, 1H), 6.93 (dd, J=7.6, 1.4 Hz, 1H), 6.87 (dd, J=8.8, 0.7 Hz, 1H), 5.06 (dt, J=10.1, 3.3 Hz, 1H), 4.26-4.20 (m, 1H), 3.26-3.20 (m, 1H), 2.61-2.57 (m, 1H), 2.31-2.22 (m, 1H), 1.61-1.55 (m, 1H), 1.35 (dt, J=13.5, 3.6 Hz, 1H), 1.17-1.09 (m, 1H). 1H buried under solvent peak.
Example 118
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (200 mg, 0.94 mmol) dissolved in DMF (3 mL) was added NaH (41 mg, 1.03 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2,5-difluoropyridine (0.11 mL, 1.22 mmol) was then added and the mixture heated to 60° C. After heating at 60° C. for 3 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-30% EtOAc in hexanes) gave the title compound (193 mg, 0.63 mmol, 67%) as a colorless solid. MS (ESI) mass calcd. for C16H21FN2O3, 308.2. m/z found 309.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, only major rotamer reported) δ 7.95 (d, J=3.1 Hz, 1H), 7.37-7.30 (m, 1H), 6.67 (dd, J=9.0, 3.6 Hz, 1H), 5.21 (dt, J=10.2, 3.2 Hz, 1H), 4.53-4.50 (m, 1H), 3.39 (dt, J=9.6, 3.1 Hz, 1H), 3.19 (dd, J=9.5, 1.4 Hz, 1H), 2.58-2.53 (m, 1H), 2.24-2.12 (m, 1H), 1.77-1.69 (m, 1H), 1.64-1.59 (m, 1H), 1.36 (dt, J=13.4, 3.6 Hz, 1H), 1.15 (s, 9H).
Step B: (1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (193 mg, 0.63 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 2 h. The reaction was concentrated to give the title compound of step B (182 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for C11H13FN2O, 208.1. m/z found 209.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (32 mg) and intermediate A-1 (27 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (31 mg). MS (ESI): mass calcd. for C20H18FN5O2, 379.1. m/z found, 380.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 7.85 (dd, J=8.2, 1.1 Hz, 1H), 7.81 (s, 2H), 7.60 (d, J=3.1 Hz, 1H), 7.39-7.31 (m, 2H), 7.12 (dd, J=7.7, 1.5 Hz, 1H), 6.92 (td, J=7.6, 1.2 Hz, 1H), 6.70 (dd, J=9.0, 3.6 Hz, 1H), 4.91 (dt, J=10.1, 3.3 Hz, 1H), 4.04-3.95 (m, 1H), 3.59 (dt, J=10.9, 3.2 Hz, 1H), 3.38 (dd, J=11.0, 1.4 Hz, 1H), 2.65-2.58 (m, 1H), 2.24-2.13 (m, 1H), 1.44-1.20 (m, 3H).
Example 119
((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 118 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C20H19FN6O2, 394.2. m/z found, 395.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.03 (d, J=8.4 Hz, 1H), 7.82 (s, 2H), 7.53 (d, J=3.1 Hz, 1H), 7.29-7.22 (m, 1H), 7.13 (d, J=8.4 Hz, 1H), 6.71 (dd, J=9.0, 3.7 Hz, 1H), 4.84 (dt, J=10.3, 3.2 Hz, 1H), 4.19-4.15 (m, 1H), 3.65 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.8, 1.4 Hz, 1H), 2.63-2.58 (m, 1H), 2.30 (s, 3H), 2.23-2.13 (m, 1H), 1.47-1.33 (m, 3H).
Example 120
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 118 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H18F2N4O2, 408.1. m/z found, 409.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 7.70 (d, J=3.1 Hz, 1H), 7.40-7.32 (m, 1H), 7.28-7.27 (m, 1H), 7.15-7.05 (m, 1H), 7.06-6.94 (m, 2H), 6.72 (dd, J=9.0, 3.6 Hz, 1H), 4.98 (dt, J=10.0, 3.3 Hz, 1H), 4.26-4.15 (m, 1H), 3.35-3.26 (m, 2H), 2.60-2.48 (m, 1H), 2.25-2.14 (m, 1H), 1.42 (d, J=10.3 Hz, 1H), 1.30 (dt, J=13.4, 3.5 Hz, 1H), 1.00-0.92 (m, 1H).
Example 121
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (200 mg, 0.94 mmol) dissolved in DMF (3 mL) was added NaH (41 mg, 1.03 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-5-(difluoromethyl)pyridine (0.15 mL, 1.22 mmol) was then added and the mixture heated to 60° C. After heating at 60° C. for 3 h, the mixture was cooled to room temperature, quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (76 mg, 0.22 mmol, 24%) as a colorless solid. MS (ESI) mass calcd. for C12H22F2N2O3, 340.2. m/z found 341.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, only major rotamer reported) δ 8.27-8.23 (m, 1H), 7.72 (dd, J=8.7, 2.5 Hz, 1H), 6.83-6.46 (m, 2H), 5.32 (dt, J=10.1, 3.2 Hz, 1H), 4.57-4.52 (m, 1H), 3.40 (dt, J=9.6, 3.1 Hz, 1H), 3.20 (dd, J=9.5, 1.3 Hz, 1H), 2.61-2.55 (m, 1H), 2.26-2.15 (m, 1H), 1.77-1.71 (m, 1H), 1.67-1.60 (m, 1H), 1.40 (dt, J=13.5, 3.8 Hz, 1H), 1.12 (s, 9H).
Step B: (1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (76 mg, 0.22 mmol) in EtOAc (4 mL) was added 4M HCl in dioxane (1 mL) and the reaction mixture was stirred at room temperature for 2 h. The reaction was concentrated to give the title compound of step B (74 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for C12H14F2N2O, 240.1. m/z found 241.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (24 mg) and intermediate A-1 (20 mg, 0.095 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (36 mg, 0.095 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (29 mg). MS (ESI): mass calcd. for C21H19F2N5O2, 411.2. m/z found, 412.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 7.88-7.85 (m, 1H), 7.83 (dd, J=8.3, 1.1 Hz, 1H), 7.81 (s, 2H), 7.77-7.70 (m, 1H), 7.34-7.28 (m, 1H), 7.05 (dd, J=7.6, 1.5 Hz, 1H), 6.85-6.79 (m, 2H), 6.60 (t, J=56.0 Hz, 1H), 5.00 (dt, J=10.2, 3.3 Hz, 1H), 4.09-3.99 (m, 1H), 3.60 (dt, J=11.0, 3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.4 Hz, 1H), 2.66-2.56 (m, 1H), 2.28-2.13 (m, 1H), 1.44-1.35 (m, 2H), 1.33-1.25 (m, 1H).
Example 122
((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 121 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C21H20F2N6O2, 426.2. m/z found, 427.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.86:0.14), major rotamer reported) δ 8.01 (d, J=8.4 Hz, 1H), 7.87-7.81 (m, 3H), 7.64 (dd, J=8.7, 2.4 Hz, 1H), 7.06 (d, J=8.4 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.57 (t, J=56.0 Hz, 1H), 4.95 (dt, J=10.4, 3.3 Hz, 1H), 4.25-4.17 (m, 1H), 3.67 (dt, J=11.0, 3.2 Hz, 1H), 3.46 (dd, J=11.0, 1.4 Hz, 1H), 2.68-2.61 (m, 1H), 2.27-2.16 (m, 4H), 1.50-1.40 (m, 3H).
Example 123
((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 121 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H19F3N4O2, 440.1. m/z found, 441.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 7.98-7.92 (m, 1H), 7.75 (dd, J=8.6, 2.4 Hz, 1H), 7.29-7.26 (m, 1H), 7.09-7.02 (m, 1H), 6.96-6.88 (m, 2H), 6.83 (d, J=8.6 Hz, 1H), 6.61 (t, J=55.9 Hz, 1H), 5.07 (dt, J=10.1, 3.3 Hz, 1H), 4.27-4.20 (m, 1H), 3.35-3.28 (m, 2H), 2.59-2.51 (m, 1H), 2.25-2.12 (m, 1H), 1.43 (d, J=10.3 Hz, 1H), 1.35 (dt, J=13.5, 3.5 Hz, 1H), 1.01-0.89 (m, 1H).
Example 124
(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (125 mg, 0.59 mmol) dissolved in DMF (5 mL) was added NaH (47 mg, 1.17 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-5-(trifluoromethyl)pyrazine (0.12 mL, 0.94 mmol) was then added and the reaction mixture stirred overnight at room temperature. Then, the mixture was quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (89 mg, 0.25 mmol, 42%) as a colorless solid. MS (ESI) mass calcd. for C16H20F3N3O3, 359.2. m/z found 304.0 [M+2H-tBu]+. 1H NMR (500 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.35-8.26 (m, 1H), 5.49-5.39 (m, 1H), 4.59-4.53 (m, 1H), 3.39 (dt, J=9.6, 3.2 Hz, 1H), 3.15 (d, J=9.5 Hz, 1H), 2.67-2.62 (m, 1H), 2.37-2.22 (m, 1H), 1.80-1.73 (m, 3H), 1.08 (s, 9H).
Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (89 mg, 0.25 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.3 mL) and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (80 mg) as a yellow oil and used without further purification. MS (ESI) mass calcd. for C11H12F3N3O, 259.1. m/z found 260.1 [M+H]+.
Step C: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (24 mg) and intermediate A-10 (20 mg, 0.097 mmol) in DMF (1 mL) was added DIPEA (84 μL, 0.49 mmol) and HATU (34 mg, 0.089 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Gilson Prep Method X to give the title compound (17 mg). MS (ESI): mass calcd. for C20H16F4N6O2, 448.1. m/z found, 449.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.83:0.17), major rotamer reported) δ 8.40 (s, 1H), 8.23 (s, 1H), 7.96 (s, 2H), 7.90 (dd, J=9.0, 4.7 Hz, 1H), 7.22-7.14 (m, 1H), 6.87 (d, J=8.1 Hz, 1H), 5.10 (dt, J=10.2, 3.3 Hz, 1H), 4.02 (s, 1H), 3.52 (dt, J=10.9, 3.3 Hz, 1H), 3.35 (dd, J=11.1, 1.6 Hz, 1H), 2.71-2.63 (m, 1H), 2.35-2.24 (m, 1H), 1.59-1.51 (m, 1H), 1.49 (dt, J=13.5, 3.7 Hz, 1H), 1.46-1.21 (m, 1H).
Example 125
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-40. MS (ESI): mass calcd. for C20H18F3N7O2, 445.1. m/z found, 446.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.28 (d, J=1.3 Hz, 1H), 8.19-8.14 (m, 2H), 8.00 (s, 2H), 7.29 (d, J=8.5 Hz, 1H), 5.08 (dt, J=10.4, 3.2 Hz, 1H), 4.25-4.20 (m, 1H), 3.61 (dt, J=11.0, 3.2 Hz, 1H), 3.41 (dd, J=11.0, 1.6 Hz, 1H), 2.75-2.67 (m, 1H), 2.36-2.27 (m, 1H), 2.22 (s, 3H), 1.66-1.59 (m, 1H), 1.60-1.49 (m, 2H).
Example 126
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-2. MS (ESI): mass calcd. for C22H17F4N5O2, 459.1. m/z found, 460.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.76:0.24), major rotamer reported) δ 8.91 (d, J=5.0 Hz, 2H), 8.42 (d, J=1.3 Hz, 1H), 8.26-8.23 (m, 1H), 7.50 (t, J=5.0 Hz, 1H), 7.21-7.15 (m, 1H), 7.07-7.00 (m, 1H), 6.95 (dd, J=7.6, 1.2 Hz, 1H), 5.14 (dt, J=10.2, 3.3 Hz, 1H), 4.33-4.24 (m, 1H), 3.29-3.27 (m, 2H), 2.63-2.56 (m, 1H), 2.34-2.25 (m, 1H), 1.56 (d, J=11.1 Hz, 1H), 1.44 (dt, J=13.7, 3.6 Hz, 1H), 1.05-0.91 (m, 1H).
Example 127
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-23. MS (ESI): mass calcd. for C22H17F4N5O2, 459.1. m/z found, 460.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.80:0.20), major rotamer reported) δ 8.88 (d, J=4.9 Hz, 2H), 8.40 (s, 1H), 8.20 (s, 1H), 7.92 (dd, J=10.1, 2.7 Hz, 1H), 7.46-7.41 (m, 1H), 7.08 (dd, J=8.4, 5.5 Hz, 1H), 6.66 (td, J=8.2, 2.7 Hz, 1H), 5.09 (dt, J=10.2, 3.3 Hz, 1H), 4.11 (s, 1H), 3.60 (dt, J=11.0, 3.2 Hz, 1H), 3.36 (dd, J=11.0, 1.6 Hz, 1H), 2.74-2.65 (m, 1H), 2.35-2.27 (m, 1H), 1.56-1.47 (m, 2H), 1.35-1.27 (m, 1H).
Example 128
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-7. MS (ESI): mass calcd. for C22H17F4N5O2, 459.1. m/z found, 460.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 8.40 (s, 1H), 8.26 (dd, J=8.8, 5.5 Hz, 1H), 8.22 (s, 1H), 7.39 (t, J=4.9 Hz, 1H), 7.15-7.09 (m, 1H), 6.78 (dd, J=8.6, 2.7 Hz, 1H), 5.11 (dt, J=10.2, 3.4 Hz, 1H), 4.14 (s, 1H), 3.61 (dt, J=11.0, 3.2 Hz, 1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.74-2.66 (m, 1H), 2.36-2.26 (m, 1H), 1.58-1.54 (m, 1H), 1.52 (dt, J=13.6, 3.6 Hz, 1H), 1.40-1.33 (m, 1H).
Example 129
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-6. MS (ESI): mass calcd. for C22H17F4N5O2, 459.1. m/z found, 460.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.74:0.26), major rotamer reported) δ 8.88 (d, J=4.9 Hz, 2H), 8.35-8.33 (m, 1H), 8.17-8.12 (m, 2H), 7.43 (t, J=4.9 Hz, 1H), 7.41-7.35 (m, 1H), 6.70-6.64 (m, 1H), 5.07 (dt, J=10.2, 3.4 Hz, 1H), 4.13-4.10 (m, 1H), 3.64 (dt, J=11.0, 3.2 Hz, 1H), 3.39 (dd, J=11.0, 1.6 Hz, 1H), 2.72-2.68 (m, 1H), 2.36-2.27 (m, 1H), 1.87-1.83 (m, 1H), 1.55-1.53 (m, 1H), 1.32-1.25 (m, 1H).
Example 130
(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-37. MS (ESI): mass calcd. for C22H18F3N5O2, 441.1. m/z found, 442.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.38 (s, 1H), 8.16 (dd, J=8.0, 1.2 Hz, 1H), 8.11 (s, 1H), 7.44-7.33 (m, 2H), 7.01 (dd, J=7.7, 1.4 Hz, 1H), 6.91 (t, J=7.5, 1.3 Hz, 1H), 5.08 (dt, J=10.2, 3.3 Hz, 1H), 4.12 (s, 1H), 3.58 (dt, J=10.9, 3.2 Hz, 1H), 3.37 (dd, J=10.9, 1.6 Hz, 1H), 2.73-2.66 (m, 1H), 2.35-2.22 (m, 1H), 1.56-1.48 (m, 2H), 1.28-1.21 (m, 1H).
Example 131
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (106 mg, 0.497 mmol) and 2-chloro-5-methylpyrimidine (93 mg, 0.72 mmol) dissolved in DMF (2 mL) was added NaH (40 mg, 0.99 mmol, 60% dispersion in mineral oil), and the reaction mixture was stirred at room temperature for 2 h. Then, the mixture was quenched with H2O, diluted with EtOAc and the aqueous layer extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate via silica gel chromatography (0-60% EtOAc in hexanes) gave the title compound (129 mg, 0.422 mmol, 85%) as a colorless solid. MS (ESI) mass calcd. for C16H23N3O3, 305.2. m/z found 306.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.68:0.32), major rotamer reported) δ 8.29 (s, 2H), 5.22-5.14 (m, 1H), 4.59-4.51 (m, 1H), 3.37 (dt, J=9.5, 3.1 Hz, 1H), 3.20 (dd, J=9.4, 1.4 Hz, 1H), 2.55-2.51 (m, 1H), 2.21 (s, 3H), 2.17-2.11 (m, 1H), 1.69-1.67 (m, 1H), 1.63-1.59 (m, 1H), 1.54-1.47 (m, 1H), 1.07 (s, 9H).
Step B: (1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (129 mg, 0.422 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 1 h. The reaction was concentrated to give the title compound of step B (147 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for C11H15N3O, 205.1. m/z found 206.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (34 mg) and intermediate A-1 (29 mg, 0.16 mmol) in DMF (0.8 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (59 mg, 0.16 mmol), and the reaction mixture was stirred at room temperature for 6 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (20 mg). MS (ESI): mass calcd. for C20H20N6O2, 376.2. m/z found, 377.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.11 (s, 2H), 7.83 (dd, J=8.2, 1.1 Hz, 1H), 7.80 (s, 2H), 7.30-7.26 (m, 1H), 7.20 (dd, J=7.7, 1.5 Hz, 1H), 6.82 (t, J=7.6 Hz, 1H), 4.92 (dt, J=10.2, 3.3 Hz, 1H), 4.15-3.99 (m, 1H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.41 (d, J=10.8 Hz, 1H), 2.65-2.60 (m, 1H), 2.24-2.20 (m, 4H), 1.53 (dt, J=13.5, 3.4 Hz, 1H), 1.41 (d, J=3.2 Hz, 2H).
Example 132
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 131 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C20H21N7O2, 391.2. m/z found, 392.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.74:0.26), major rotamer reported) δ 8.04 (d, J=8.4 Hz, 1H), 8.03 (d, J=0.9 Hz, 2H), 7.80 (s, 2H), 7.07 (d, J=8.4 Hz, 1H), 4.81 (dt, J=10.3, 3.4 Hz, 1H), 4.38-4.29 (m, 1H), 3.72 (dt, J=10.9, 3.2 Hz, 1H), 3.46 (dd, J=10.9, 1.5 Hz, 1H), 2.67-2.65 (m, 1H), 2.25 (s, 3H), 2.24-2.19 (m, 1H), 2.16 (s, 3H), 1.66-1.61 (m, 1H), 1.57-1.52 (m, 1H), 1.51-1.47 (m, 1H).
Example 133
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 131 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H20FN5O2, 405.2. m/z found, 406.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.75:0.25), major rotamer reported) δ 8.83 (d, J=4.9 Hz, 2H), 8.18 (d, J=0.9 Hz, 2H), 7.26-7.24 (m, 1H), 7.08 (dd, J=7.5, 1.2 Hz, 1H), 7.05-7.00 (m, 1H), 6.95-6.91 (m, 1H), 5.00 (dt, J=10.2, 3.3 Hz, 1H), 4.31-4.22 (m, 1H), 3.36-3.32 (m, 2H), 2.61-2.50 (m, 1H), 2.22 (s, 3H), 1.52-1.41 (m, 2H), 1.12-1.07 (m, 1H). 1H buried under water peak.
Example 134
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 131 substituting intermediate A-1 with intermediate A-47. MS (ESI): mass calcd. for C22H22N6O2, 402.2. m/z found, 403.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.60:0.40), major rotamer reported) δ 8.76 (d, J=4.8 Hz, 2H), 8.28 (dd, J=2.2, 0.8 Hz, 1H), 8.03 (d, J=0.9 Hz, 2H), 7.81 (dd, J=2.2, 0.8 Hz, 1H), 7.19 (t, J=4.8 Hz, 1H), 4.88 (dt, J=10.3, 3.4 Hz, 1H), 4.45-4.38 (m, 1H), 3.76 (dt, J=10.8, 3.2 Hz, 1H), 3.45 (dd, J=10.7, 1.4 Hz, 1H), 2.72-2.64 (m, 1H), 2.31 (s, 3H), 2.20 (s, 3H), 1.74-1.53 (m, 3H). 1H buried under solvent.
Example 135
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (120 mg, 0.563 mmol) and 2-chloro-5-ethylpyrimidine (128 mg, 0.9 mmol), dissolved in DMF (4 mL), was added NaH (29 mg, 0.73 mmol, 60% dispersion in mineral oil) and the mixture stirred at room temperature for 1 h. The reaction mixture was quenched with H2O, diluted with EtOAc and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (160 mg, 0.501 mmol, 89%) as a colorless solid. MS (ESI) mass calcd. for C12H25N3O3, 319.2. m/z found 320.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, only major rotamer reported) δ 8.34 (s, 2H), 5.21 (dt, J=10.3, 3.4 Hz, 1H), 4.60-4.55 (m, 1H), 3.40 (dt, J=9.5, 3.1 Hz, 1H), 3.23 (dd, J=9.5, 1.4 Hz, 1H), 2.61-2.55 (m, 3H), 2.22-2.15 (m, 1H), 1.75-1.69 (m, 1H), 1.65-1.62 (m, 1H), 1.55 (dt, J=13.5, 3.8 Hz, 1H), 1.25-1.22 (m, 3H), 1.09 (s, 9H).
Step B: (1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (160 mg, 0.501 mmol) in EtOAc (1.5 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 1 h. Then, the reaction was concentrated to give the title compound of step B (148 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for C12H12N3O, 219.1. m/z found 220.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (37 mg) and intermediate A-1 (30 mg, 0.16 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.6 mmol) and HATU (61 mg, 0.16 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (33 mg). MS (ESI): mass calcd. for C21H22N6O2, 390.2. m/z found, 391.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), only major rotamer reported) δ 8.14-7.16 (m, 7H), 6.79 (t, J=7.6 Hz, 1H), 4.92 (dt, J=10.3, 3.3 Hz, 1H), 4.05 (s, 1H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.41 (d, J=10.8 Hz, 1H), 2.65-2.59 (m, 1H), 2.54 (q, J=7.6 Hz, 2H), 2.28-2.12 (m, 1H), 1.85-1.76 (m, 1H), 1.70-1.63 (m, 1H), 1.53 (dt, J=13.3, 3.2 Hz, 1H), 1.26 (t, J=7.6 Hz, 3H).
Example 136
((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 135 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C21H23N7O2, 405.2. m/z found, 406.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.69:0.31), only major rotamer reported) δ 8.08-8.01 (m, 3H), 7.80 (s, 2H), 7.05 (d, J=8.5 Hz, 1H), 4.82 (dt, J=10.3, 3.4 Hz, 1H), 4.47-4.30 (m, 1H), 3.73 (dt, J=10.8, 3.2 Hz, 1H), 3.47 (dd, J=10.9, 1.5 Hz, 1H), 2.70-2.65 (m, 1H), 2.55-2.45 (m, 2H), 2.27-2.16 (m, 4H), 1.65 (dt, J=13.3, 3.7 Hz, 1H), 1.64-1.47 (m, 2H), 1.27-1.18 (m, 3H).
Example 137
((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 135 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H22FN5O2, 419.2. m/z found, 420.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.78:0.22), only major rotamer reported) δ 8.84 (d, J=4.9 Hz, 2H), 8.20 (s, 2H), 7.07 (dd, J=7.5, 1.2 Hz, 1H), 7.01-6.97 (m, 1H), 6.94-6.89 (m, 1H), 5.00 (dt, J=10.1, 3.3 Hz, 1H), 4.31-4.22 (m, 1H), 3.37-3.29 (m, 2H), 2.57 (q, J=7.6 Hz, 3H), 2.25-2.16 (m, 1H), 1.53-1.44 (m, 2H), 1.27 (t, J=7.6 Hz, 3H), 1.15-1.06 (m, 1H). 1H buried under solvent.
Example 138
((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 135 substituting intermediate A-1 with intermediate A-41. MS (ESI): mass calcd. for C23H24N6O2, 416.2. m/z found, 417.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.63:0.37), only major rotamer reported) δ 8.74 (d, J=4.8 Hz, 2H), 8.38 (d, J=8.1 Hz, 1H), 8.00 (s, 2H), 7.17 (t, J=4.8 Hz, 1H), 7.04 (d, J=8.2 Hz, 1H), 4.81 (dt, J=10.4, 3.4 Hz, 1H), 4.51-4.46 (m, 1H), 3.80 (dt, J=10.8, 3.2 Hz, 1H), 3.47 (dd, J=10.6, 1.4 Hz, 1H), 2.72-2.66 (m, 1H), 2.48 (q, J=7.6 Hz, 2H), 2.28-2.17 (m, 4H), 1.67 (dt, J=13.3, 3.7 Hz, 1H), 1.61-1.54 (m, 2H), 1.21 (t, J=7.7 Hz, 3H).
Example 139
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (106 mg, 0.457 mmol) and 3-chloro-6-(trifluoromethyl)pyridazine (120 mg, 0.66 mmol) dissolved in DMF (2 mL) was added NaH (40 mg, 0.99 mmol, 60% dispersion in mineral oil), and the reaction mixture was stirred at room temperature for 2 h. Then, the mixture was quenched with saturated NH4Cl solution, diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, brine, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (189 mg) as an off-white solid. MS (ESI) mass calcd. for C16H20F3N3O3, 359.2. m/z found 304.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.74:0.26), major rotamer reported) δ 7.70 (d, J=9.2 Hz, 1H), 7.07 (d, J=9.2 Hz, 1H), 5.59 (dt, J=10.1, 3.1 Hz, 1H), 4.76-4.67 (m, 1H), 3.43 (dt, J=9.6, 3.1 Hz, 1H), 3.23-3.17 (m, 1H), 2.64-2.60 (m, 1H), 2.34-2.26 (m, 1H), 1.81-1.76 (m, 1H), 1.68-1.65 (m, 1H), 1.50-1.45 (m, 1H), 1.10 (s, 9H).
Step B: (1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (189 mg, 0.53 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 6 h. The reaction was concentrated to give the title compound of step B (146 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for C11H12F3N3O, 259.1. m/z found 260.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (34 mg) and intermediate A-1 (24 mg, 0.126 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48 mg, 0.126 mmol), and the reaction mixture was stirred at room temperature for 1 h. Analysis of the reaction mixture showed unreacted starting material and additional intermediate A-1 (10 mg) was added. The reaction mixture was stirred for an additional 15 minutes at room temperature. The reaction was then quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were concentrated and subjected directly to purification using Agilent Prep Method X to give the title compound (33 mg). MS (ESI): mass calcd. for C20H17F3N6O2, 430.1. m/z found, 431.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.08 min (major rotamer) at 254 nm.
Example 140
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 139 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C20H18F3N7O2, 445.1. m/z found, 446.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.04 (d, J=8.4 Hz, 1H), 7.81 (s, 2H), 7.62 (d, J=9.1 Hz, 1H), 7.15 (dd, J=9.2, 0.7 Hz, 1H), 7.11 (d, J=8.5 Hz, 1H), 5.31 (dt, J=10.1, 3.3 Hz, 1H), 4.46-4.41 (m, 1H), 3.70 (dt, J=11.0, 3.2 Hz, 1H), 3.47 (dd, J=11.0, 1.5 Hz, 1H), 2.73-2.68 (m, 1H), 2.37-2.28 (m, 1H), 2.23 (s, 3H), 1.63-1.58 (m, 1H), 1.57-1.49 (m, 2H).
Example 141
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 139 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H17F4N5O2, 459.1. m/z found, 460.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 7.73 (d, J=9.2 Hz, 1H), 7.28 (t, J=4.9 Hz, 1H), 7.15 (dd, J=9.2, 0.7 Hz, 1H), 7.12-7.09 (m, 1H), 7.09-7.04 (m, 1H), 6.98 (dd, J=7.5, 1.3 Hz, 1H), 5.39 (dt, J=9.9, 3.3 Hz, 1H), 4.40-4.31 (m, 1H), 3.41-3.33 (m, 1H), 3.32 (dd, J=11.0, 1.3 Hz, 1H), 2.66-2.57 (m, 1H), 2.41-2.33 (m, 1H), 1.53-1.48 (m, 1H), 1.38 (dt, J=13.7, 3.6 Hz, 1H), 1.20-1.10 (m, 1H).
Example 142
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 139 substituting intermediate A-1 with intermediate A-41. MS (ESI): mass calcd. for C22H19F3N6O2, 456.2. m/z found, 457.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.77 (d, J=4.8 Hz, 2H), 8.39 (d, J=8.1 Hz, 1H), 7.64 (d, J=9.2 Hz, 1H), 7.23-7.19 (m, 2H), 7.09 (d, J=8.1 Hz, 1H), 5.34 (dt, J=10.1, 3.3 Hz, 1H), 4.47-4.42 (m, 1H), 3.75 (dt, J=10.9, 3.2 Hz, 1H), 3.49 (dd, J=10.8, 1.3 Hz, 1H), 2.75-2.70 (m, 1H), 2.38-2.28 (m, 1H), 2.20 (s, 3H), 1.58-1.51 (m, 3H).
Example 143
(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-3. MS (ESI): mass calcd. for C21H20F3N7O, 443.2. m/z found, 444.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=5.80 min (major rotamer) at 254 nm.
Example 144
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-16. MS (ESI): mass calcd. for C21H18F4N6O, 446.1. m/z found, 447.1 [M+H]+. 1H NMR (500 MHz, Methanol-4 Compound present as a mixture of rotamers, major rotamer reported) δ 8.00 (s, 2H), 7.91 (s, 1H), 7.58 (dd, J=8.9, 2.6 Hz, 1H), 7.23-7.16 (m, 1H), 6.92-6.84 (m, 1H), 6.80 (d, J=7.6 Hz, 1H), 6.64-6.53 (m, 1H), 4.15-3.93 (m, 2H), 3.27-3.18 (m, 2H), 2.56-2.50 (m, 1H), 2.28-2.14 (m, 1H), 1.55 (d, J=10.2 Hz, 1H), 1.29-1.09 (m, 2H).
Example 145
(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-12. MS (ESI): mass calcd. for C21H18F4N6O, 446.1. m/z found, 447.1 [M+H]+. Analytical HPLC using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). Rt=2.05 min at 254 nm.
Example 146
(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-11. MS (ESI): mass calcd. for C21H18F4N6O, 446.1. m/z found, 447.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 7.98 (s, 2H), 7.78 (s, 1H), 7.75 (dt, J=8.3, 0.9 Hz, 1H), 7.56 (dd, J=8.8, 2.4 Hz, 1H), 7.35-7.27 (m, 1H), 6.66-6.56 (m, 1H), 6.49 (t, J=8.6 Hz, 1H), 3.98-3.89 (m, 1H), 3.88-3.82 (m, 1H), 3.49 (dt, J=11.0, 3.2 Hz, 1H), 3.34-3.32 (m, 1H), 2.63-2.55 (m, 1H), 2.27-2.15 (m, 1H), 1.44 (d, J=10.1 Hz, 1H), 1.32-1.19 (m, 2H).
Example 147
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-6. MS (ESI): mass calcd. for C23H19F4N5O, 457.2. m/z found, 458.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.06 (dd, J=7.9, 1.0 Hz, 1H), 7.83-7.73 (m, 1H), 7.56 (dd, J=8.9, 2.4 Hz, 1H), 7.41 (t, J=4.9 Hz, 1H), 7.31-7.24 (m, 1H), 6.66-6.59 (m, 1H), 6.58-6.53 (m, 1H), 3.99-3.90 (m, 2H), 3.55 (dt, J=10.9, 3.2 Hz, 1H), 3.35-3.32 (m, 1H), 2.64-2.58 (m, 1H), 2.26-2.16 (m, 1H), 1.44 (d, J=10.4 Hz, 1H), 1.33-1.26 (m, 1H), 1.19-1.13 (m, 1H).
Example 148
(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-37. MS (ESI): mass calcd. for C23H20F3N5O, 439.2. m/z found, 440.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.84 (d, J=4.9 Hz, 2H), 8.13 (dd, J=7.9, 1.2 Hz, 1H), 7.87-7.78 (m, 1H), 7.65-7.54 (m, 1H), 7.38 (t, J=4.9 Hz, 1H), 7.29 (td, J=7.7, 1.4 Hz, 1H), 6.98-6.87 (m, 1H), 6.87-6.76 (m, 1H), 6.66-6.49 (m, 1H), 4.08-3.92 (m, 1H), 3.52 (dt, J=10.9, 3.3 Hz, 1H), 2.66-2.59 (m, 1H), 2.30-2.19 (m, 1H), 1.54-1.45 (m, 1H), 1.35-1.19 (m, 3H). 1H buried under solvent peak.
Example 149
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-47. MS (ESI): mass calcd. for C23H21F3N6O, 454.2. m/z found, 455.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.89:0.11), only major rotamer reported) δ 8.82 (d, J=4.9 Hz, 2H), 8.41-8.37 (m, 1H), 8.33 (dd, J=2.1, 0.9 Hz, 1H), 8.26-8.22 (m, 1H), 7.70-7.58 (m, 1H), 7.45 (dd, J=8.9, 2.5 Hz, 1H), 7.28 (t, J=4.9 Hz, 1H), 6.38 (d, J=8.8 Hz, 1H), 4.32-4.28 (m, 1H), 4.22-4.11 (m, 1H), 3.72 (dt, J=10.9, 3.2 Hz, 1H), 3.32 (dd, J=10.9, 1.5 Hz, 1H), 2.83-2.72 (m, 1H), 2.46-2.36 (m, 4H), 1.94-1.87 (m, 1H), 1.71 (d, J=10.0 Hz, 1H), 1.20 (dt, J=13.0, 3.5 Hz, 1H).
Example 150
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-41. MS (ESI): mass calcd. for C23H21F3N6O, 454.2. m/z found, 455.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.91:0.09), only major rotamer reported) δ 8.79 (d, J=4.9 Hz, 2H), 8.45 (d, J=8.1 Hz, 1H), 8.31-8.23 (m, 1H), 7.70-7.59 (m, 1H), 7.47 (dd, J=8.8, 2.5 Hz, 1H), 7.29 (d, J=8.1 Hz, 1H), 7.24 (t, J=4.9 Hz, 1H), 6.44 (d, J=8.8 Hz, 1H), 4.26-4.21 (m, 1H), 4.13 (s, 1H), 3.73 (dt, J=10.8, 3.2 Hz, 1H), 3.31 (dd, J=10.8, 1.5 Hz, 1H), 2.82-2.73 (m, 1H), 2.62 (s, 3H), 2.51-2.37 (m, 1H), 1.98-1.85 (m, 1H), 1.70 (d, J=10.2 Hz, 1H), 1.20 (dt, J=13.5, 3.5 Hz, 1H).
Example 151
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-46. MS (ESI): mass calcd. for C23H21F3N6O, 454.2. m/z found, 455.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=5.33 min (major rotamer) at 254 nm.
Example 152
(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-51. MS (ESI): mass calcd. for C22H19F4N5O2, 461.1. m/z found, 462.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 7.84 (s, 1H), 7.70 (dd, J=9.1, 2.6 Hz, 1H), 7.59-7.53 (m, 1H), 7.02 (dd, J=8.5, 5.3 Hz, 1H), 6.72 (td, J=8.2, 2.6 Hz, 1H), 6.62-6.47 (m, 1H), 4.06-3.97 (m, 2H), 3.61 (dt, J=11.1, 3.2 Hz, 1H), 3.41-3.35 (m, 1H), 2.76-2.67 (m, 1H), 2.44 (s, 3H), 2.34-2.23 (m, 1H), 1.74-1.60 (m, 2H), 1.35-1.26 (m, 1H).
Example 153
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




To the title compound of example 53 (10 mg, 0.023 mmol) dissolved in DMF (0.5 mL) was added NaOtBu (2.5 mg, 0.026 mmol). After 5 minutes, MeI (1.5 μL, 0.025 mmol) was added and the reaction mixture as stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (2×). The combined organics were washed with H2O, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (3 mg) as a brown solid. MS (ESI): mass calcd. for C22H21F3N6O, 442.2. m/z found, 443.1 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.06 (s, 1H), 7.95 (s, 2H), 7.80 (d, J=8.3 Hz, 1H), 7.68-7.60 (m, 1H), 7.35-7.25 (m, 1H), 7.00-6.90 (m, 1H), 6.82-6.75 (m, 1H), 6.65 (d, J=8.9 Hz, 1H), 4.58-4.46 (m, 1H), 3.88 (s, 1H), 3.49-3.42 (m, 2H), 3.11 (s, 3H), 2.69 (s, 1H), 2.09-1.98 (m, 1H), 1.99-1.88 (m, 1H), 1.49 (d, J=9.9 Hz, 1H), 1.27-1.17 (m, 1H).
Example 154
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-16 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C22H20F4N6O, 460.2. m/z found, 461.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 7.98 (s, 3H), 7.76-7.70 (m, 1H), 7.65 (dd, J=9.1, 2.5 Hz, 1H), 7.33-7.26 (m, 1H), 6.70 (d, J=9.1 Hz, 1H), 6.59-6.50 (m, 1H), 4.49-4.40 (m, 1H), 3.99-3.93 (m, 1H), 3.51 (dt, J=11.4, 3.0 Hz, 1H), 3.43 (dd, J=11.4, 1.6 Hz, 1H), 3.09 (d, J=1.3 Hz, 3H), 2.69 (s, 1H), 2.08-1.93 (m, 2H), 1.46 (d, J=9.7 Hz, 1H), 1.19-1.12 (m, 1H).
Example 155
(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-10 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C22H20F4N6O, 460.2. m/z found, 461.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.08 (s, 1H), 7.95 (s, 2H), 7.79 (dd, J=9.0, 4.7 Hz, 1H), 7.63 (dd, J=9.1, 2.6 Hz, 1H), 7.07-6.99 (m, 1H), 6.69 (dd, J=8.1, 2.9 Hz, 1H), 6.66 (d, J=9.1 Hz, 1H), 4.52-4.44 (m, 1H), 3.92-3.87 (m, 1H), 3.44-3.40 (m, 2H), 3.10 (s, 3H), 2.70-2.65 (m, 1H), 2.08-1.99 (m, 1H), 1.97-1.90 (m, 1H), 1.52-1.45 (m, 1H), 1.19-1.11 (m, 1H).
Example 156
((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-40 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C22H22F3N7O, 457.2. m/z found, 458.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.09 (d, J=8.4 Hz, 1H), 8.07 (s, 1H), 7.97 (s, 2H), 7.66 (dd, J=9.1, 2.6 Hz, 1H), 7.17 (d, J=8.4 Hz, 1H), 6.68 (d, J=9.1 Hz, 1H), 4.72-4.63 (m, 1H), 3.95-3.87 (m, 1H), 3.54 (dt, J=11.4, 3.1 Hz, 1H), 3.51-3.42 (m, 1H), 3.12 (s, 3H), 2.77-2.69 (m, 1H), 2.15 (s, 3H), 2.11-1.99 (m, 1H), 1.92-1.80 (m, 1H), 1.57 (d, J=10.4 Hz, 1H), 1.47-1.38 (m, 1H).
Example 157
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-2 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C24H21F4N5O, 471.2. m/z found, 472.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.90:0.10), major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H), 8.20-8.12 (m, 1H), 7.66 (dd, J=9.1, 2.6 Hz, 1H), 7.49 (t, J=4.9 Hz, 1H), 7.09-7.00 (m, 1H), 6.87-6.80 (m, 1H), 6.72-6.66 (m, 2H), 4.62-4.53 (m, 1H), 4.15-4.08 (m, 1H), 3.36 (dd, J=11.5, 1.6 Hz, 1H), 3.20 (dt, J=11.5, 3.2 Hz, 1H), 3.10 (s, 3H), 2.66-2.57 (m, 1H), 2.08-1.98 (m, 1H), 1.90 (dt, J=13.8, 3.7 Hz, 1H), 1.54 (d, J=10.1 Hz, 1H), 0.95-0.87 (m, 1H).
Example 158
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-7 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C24H21F4N5O, 471.2. m/z found, 472.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.83 (d, J=4.9 Hz, 2H), 8.15 (dd, J=8.8, 5.5 Hz, 1H), 8.08 (s, 1H), 7.63 (dd, J=9.1, 2.6 Hz, 1H), 7.38 (t, J=4.9 Hz, 1H), 6.98 (ddd, J=8.8, 8.1, 2.7 Hz, 1H), 6.66 (d, J=9.1 Hz, 1H), 6.58 (dd, J=8.4, 2.7 Hz, 1H), 4.55-4.45 (m, 1H), 4.02-3.95 (m, 1H), 3.51 (dt, J=11.3, 3.1 Hz, 1H), 3.48-3.41 (m, 1H), 3.14 (s, 3H), 2.75-2.67 (m, 1H), 2.10-2.00 (m, 1H), 1.99-1.92 (m, 1H), 1.49 (d, J=10.1 Hz, 1H), 1.19-1.09 (m, 1H).
Example 159
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-6 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C24H21F4N5O, 471.2. m/z found, 472.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.02 (dd, J=7.8, 1.0 Hz, 1H), 7.98 (s, 1H), 7.63 (dd, J=9.2, 2.6 Hz, 1H), 7.42 (t, J=4.9 Hz, 1H), 7.28-7.22 (m, 1H), 6.68 (d, J=9.2 Hz, 1H), 6.63-6.58 (m, 1H), 4.48-4.40 (m, 1H), 4.08-4.00 (m, 1H), 3.55 (dt, J=11.3, 3.0 Hz, 1H), 3.46-3.41 (m, 1H), 3.11-3.09 (m, 3H), 2.72-2.68 (m, 1H), 2.07-1.94 (m, 2H), 1.48-1.42 (m, 1H), 1.07-1.02 (m, 1H).
Example 160
(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




To the title compound of Example 66 (38 mg, 0.066 mmol) dissolved in DMF (1.3 mL) was added NaOtBu (7 mg, 0.072 mmol). After 5 minutes, EtI (5.5 μL, 0.069 mmol) was added and the reaction mixture as stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material (Example 66) still remained. NaH (5 mg, 0.13 mmol, 60% dispersion in mineral oil) and additional EtI (5.5 μL, 0.069 mmol) were added to the reaction flask, and the reaction mixture was stirred at room temperature for 2 h. Then, the mixture was diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (2×). The combined organics were washed with H2O, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (16 mg) as a white solid. MS (ESI): mass calcd. for C25H23F4N5O, 485.2. m/z found, 486.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H), 8.12 (s, 1H), 7.63 (dd, J=9.0, 2.6 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.03-6.96 (m, 1H), 6.83-6.76 (m, 1H), 6.71-6.64 (m, 2H), 4.48-4.39 (m, 1H), 4.13 (s, 1H), 3.88-3.75 (m, 1H), 3.36-3.32 (m, 2H), 3.16 (dt, J=11.4, 3.2 Hz, 1H), 2.61 (s, 1H), 2.14-2.05 (m, 1H), 1.83-1.75 (m, 1H), 1.53 (d, J=10.1 Hz, 1H), 1.17 (t, J=7.0 Hz, 3H), 0.86-0.79 (m, 1H).
Example 161
((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




To the title compound of Example 66 (30 mg, 0.053 mmol) dissolved in DMF (1 mL) was added NaH (6 mg, 0.16 mmol, 60% dispersion in mineral oil). After 10 minutes, (bromomethyl)cyclopropane (10 μL, 0.11 mmol) was added and the reaction mixture as stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (2×). The combined organics were washed with H2O, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Gilson Prep Method X to give the title compound (19 mg) as a white solid. MS (ESI): mass calcd. for C22H25F4N5O, 511.2. m/z found, 512.3 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 8.13 (s, 1H), 7.61 (dd, J=9.1, 2.6 Hz, 1H), 7.48 (t, J=5.0 Hz, 1H), 7.02-6.95 (m, 1H), 6.85-6.78 (m, 1H), 6.75 (d, J=9.1 Hz, 1H), 6.68 (dd, J=7.6, 1.1 Hz, 1H), 4.51-4.41 (m, 1H), 4.20-4.10 (m, 1H), 3.85-3.73 (m, 1H), 3.28-3.23 (m, 1H), 3.20-3.11 (m, 1H), 2.63-2.58 (m, 1H), 2.19-2.08 (m, 1H), 1.90-1.82 (m, 1H), 1.57-1.51 (m, 1H), 1.29 (s, 1H), 0.99-0.90 (m, 1H), 0.86-0.77 (m, 1H), 0.62-0.49 (m, 2H), 0.49-0.42 (m, 1H), 0.37-0.28 (m, 1H).
Example 162
N-((1S,4R,6R)-2-(3-fluoro-2-(pyrimidin-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)acetamide




To the title compound of Example 66 (30 mg, 0.053 mmol) was added Ac2O (0.1 mL, 1.05 mmol), and the reaction mixture as stirred at 100° C. overnight. Then, the mixture was concentrated and the concentrate was purified directly using Gilson Prep Method X to give the title compound. MS (ESI): mass calcd. for C25H21F4N5O2, 499.2. m/z found, 500.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.79:0.21), major rotamer reported) δ 9.02-8.98 (m, 1H), 8.89 (d, J=4.9 Hz, 2H), 8.31 (dd, J=8.1, 2.5 Hz, 1H), 7.64-7.46 (m, 4H), 7.38-7.32 (m, 1H), 4.55-4.48 (m, 1H), 4.38-4.33 (m, 1H), 3.08 (dt, J=11.1, 3.2 Hz, 1H), 2.68 (d, J=11.2 Hz, 1H), 2.39 (s, 1H), 1.91-1.81 (m, 1H), 1.75 (s, 3H), 1.52 (d, J=10.4 Hz, 1H), 0.96-0.90 (m, 1H), 0.69-0.61 (m, 1H).
Example 163
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((2-methoxyethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




To the title compound of Example 66 (43 mg, 0.094 mmol) dissolved in DMF (2 mL) was added NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil). After 10 minutes, 2-chloroethyl methyl ether (26 μL, 0.28 mmol) was added and the reaction mixture as stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material (Example 66) still remained. NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil) and additional 2-chloroethyl methyl ether (26 μL, 0.28 mmol) were added to the reaction flask, and the reaction mixture was stirred at 50° C. for 3 h. Then, the mixture was diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (2×). The combined organics were washed with H2O, dried with Na2SO4, filtered, and concentrated. Purification of the concentrate was performed using Gilson Prep Method X to give the title compound (10 mg) as an off-white solid. MS (ESI): mass calcd. for C26H25F4N5O2, 515.2. m/z found, 516.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H), 8.16 (s, 1H), 7.61 (dd, J=9.1, 2.6 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.03-6.96 (m, 1H), 6.84-6.77 (m, 1H), 6.74 (d, J=8.9 Hz, 1H), 6.71 (dd, J=7.6, 1.1 Hz, 1H), 4.46-4.36 (m, 1H), 4.16 (s, 1H), 4.04-3.90 (m, 1H), 3.61-3.43 (m, 3H), 3.38-3.32 (m, 3H), 3.16 (dt, J=12.1, 3.1 Hz, 1H), 2.65-2.56 (m, 1H), 2.14-2.02 (m, 1H), 1.91-1.82 (m, 1H), 1.54 (d, J=10.3 Hz, 1H), 0.83 (d, J=10.3 Hz, 1H). 1H buried under solvent peak.
Example 164
(2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 165
(6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 166
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing 5-bromo-2-iodopyridine (669 mg, 2.36 mmol) and degassed THF (12 mL) was added NaOtBu (453 mg, 4.71 mmol), Xantphos (98 mg, 0.17 mmol) and Pd2(dba)3 (86 mg, 0.094 mmol). The reaction mixture was purged with N2 for 10 minutes and then intermediate B-10 (500 mg, 2.36 mmol) was added and the reaction mixture heated to 90° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound of step A (91 mg). Further flushing of the column with 0-10% MeOH (with 10% 2 M NH3) in DCM gave (1S,4R,6R)—N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine (483 mg). (1S,4S,6R)-tert-butyl 6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate: MS (ESI) mass calcd. for C16H22BrN3O2, 367.1. m/z found 370.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 7.98 (d, J=2.5 Hz, 1H), 7.49 (dd, J=9.0, 2.5 Hz, 1H), 6.51 (d, J=8.9 Hz, 1H), 4.46-4.41 (m, 1H), 4.12-4.05 (m, 1H), 3.29-3.27 (m, 1H), 3.07 (d, J=9.6 Hz, 1H), 2.57-2.51 (m, 1H), 2.27-2.18 (m, 1H), 1.70-1.67 (m, 2H), 1.18-1.09 (m, 10H). (1S,4R,6R)—N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine: 1H NMR (500 MHz, Methanol-d4) δ 8.11 (dd, J=2.5, 0.7 Hz, 1H), 7.58 (dd, J=8.9, 2.5 Hz, 1H), 6.65 (dd, J=8.9, 0.7 Hz, 1H), 4.44 (dd, J=3.1, 2.0 Hz, 1H), 4.14-4.10 (m, 1H), 3.21 (dt, J=10.9, 3.4 Hz, 1H), 3.11 (dd, J=10.9, 1.8 Hz, 1H), 2.74-2.70 (m, 1H), 2.39-2.29 (m, 1H), 2.05-2.02 (m, 1H), 1.90-1.83 (m, 1H), 1.38 (dt, J=13.4, 3.5 Hz, 1H).
Step B: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To (1S,4R,6R)—N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine from Step A (70 mg, 0.26 mmol) and intermediate A-1 (63 mg, 0.33 mmol) in DMF (2 mL) was added DIPEA (0.27 mL, 1.57 mmol) and HATU (109 mg, 0.29 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and subjected to purification via Gilson Prep Method X to give the title compound (42 mg) as an off-white powder. MS (ESI): mass calcd. for C20H19BrN6O, 438.1. m/z found, 439.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 7.94 (s, 2H), 7.83 (d, J=7.8 Hz, 1H), 7.60-7.55 (m, 1H), 7.50-7.43 (m, 1H), 7.40 (td, J=7.9, 1.5 Hz, 1H), 6.96 (s, 1H), 6.82 (s, 1H), 6.46 (s, 1H), 3.85 (s, 2H), 3.50-3.41 (m, 1H), 3.28 (dd, J=11.1, 1.6 Hz, 1H), 2.58 (s, 1H), 2.26-2.15 (m, 1H), 1.53-1.38 (m, 1H), 1.35-1.24 (m, 1H), 1.23-1.14 (m, 1H).
Example 167
((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 166 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H19BrFN5O, 467.1. m/z found, 470.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.07 (dd, J=8.0, 1.0 Hz, 1H), 7.52 (d, J=2.4 Hz, 1H), 7.46-7.32 (m, 3H), 6.70-6.62 (m, 1H), 6.47 (d, J=9.4 Hz, 1H), 3.96-3.89 (m, 1H), 3.87-3.78 (m, 1H), 3.53 (dt, J=10.9, 3.2 Hz, 1H), 2.62-2.55 (m, 1H), 2.24-2.14 (m, 1H), 1.44-1.39 (m, 1H), 1.29-1.18 (m, 1H), 1.16-1.11 (m, 1H). 1H buried under solvent peak
Example 168
((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 166 substituting intermediate A-1 with intermediate A-6. MS (ESI): mass calcd. for C22H19BrFN5O, 467.1. m/z found, 468.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 7.69 (d, J=2.5 Hz, 1H), 7.48 (t, J=5.0 Hz, 1H), 7.45 (dd, J=8.9, 2.5 Hz, 1H), 7.17-7.10 (m, 1H), 6.99-6.92 (m, 1H), 6.81 (d, J=7.5 Hz, 1H), 6.43 (d, J=8.9 Hz, 1H), 4.15 (s, 1H), 4.01-3.91 (m, 1H), 3.25-3.18 (m, 2H), 2.52 (s, 1H), 2.27-2.15 (m, 1H), 1.52 (d, J=11.7 Hz, 1H), 1.22-1.13 (m, 1H), 1.06 (d, J=10.2 Hz, 1H).
Example 169
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (3 mL) was added Pd(OAc)2 (6 mg, 0.028 mmol) and racemic BINAP (17 mg, 0.028 mmol) at room temperature and the reaction mixture was purged with N2 for 5 min. Then, 2-bromo-5-chloropyridine (90 mg, 0.47 mmol), intermediate B-10 (109 mg), and sodium tert-butoxide (63 mg, 0.66 mmol) were added and the reaction mixture heated to 90° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-10% MeOH (with 10% 2N NH3) in DCM) to give the title compound of step A. MS (ESI) mass calcd. for C16H22ClN3O2, 323.1. m/z found 324.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 7.90 (d, J=2.6 Hz, 1H), 7.39 (dd, J=8.9, 2.7 Hz, 1H), 6.54 (d, J=9.0 Hz, 1H), 4.43 (s, 1H), 4.12-4.06 (m, 1H), 3.30-3.27 (m, 1H), 3.09-3.05 (m, 1H), 2.57-2.50 (m, 1H), 2.28-2.17 (m, 1H), 1.70-1.67 (m, 2H), 1.48-1.38 (m, 2H), 1.12 (s, 9H).
Step B: (1S,4R,6R)—N-(5-chloropyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (252 mg, 0.701 mmol) in EtOAc (9 mL) was added 4M HCl in dioxane (0.9 mL). After 1 h, the reaction was concentrated to give the title compound of step B (231 mg, 90% purity), which was used without further purification. MS (ESI) mass calcd. for C11H14ClN3, 223.1. m/z found 224.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (40 mg) and intermediate A-1 (28 mg, 0.15 mmol) in DMF (1 mL) was added DIPEA (0.2 mL, 1.2 mmol) and HATU (56 mg, 0.15 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (4×). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (30 mg). MS (ESI): mass calcd. for C20H19ClN6O, 394.1. m/z found, 395.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.25 min (major rotamer) at 254 nm.
Example 170
((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 169 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H19ClFN5O, 423.1. m/z found, 424.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.84:0.16), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 7.83 (d, J=2.0 Hz, 1H), 7.33 (t, J=4.9 Hz, 1H), 7.21-7.13 (m, 2H), 7.12-7.06 (m, 1H), 6.99 (d, J=7.2 Hz, 1H), 6.14 (d, J=8.9 Hz, 1H), 4.42 (s, 1H), 4.24-4.13 (m, 1H), 3.46 (dt, J=11.1, 3.2 Hz, 1H), 3.22 (dd, J=11.2, 1.6 Hz, 1H), 2.68-2.61 (m, 1H), 2.42-2.27 (m, 1H), 1.71-1.66 (m, 1H), 1.58-1.52 (m, 1H), 1.09-0.99 (m, 1H).
Example 171
((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 169 substituting intermediate A-1 with intermediate A-23. MS (ESI): mass calcd. for C22H19ClFN5O, 423.1. m/z found, 424.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 7.88 (dd, J=10.1, 2.7 Hz, 1H), 7.58 (d, J=2.6 Hz, 1H), 7.44-7.35 (m, 2H), 6.98-6.92 (m, 1H), 6.64-6.56 (m, 1H), 6.51-6.43 (m, 1H), 3.93 (s, 1H), 3.91-3.86 (m, 1H), 3.52 (dt, J=10.9, 3.3 Hz, 1H), 3.30-3.28 (m, 1H), 2.63-2.58 (m, 1H), 2.27-2.17 (m, 1H), 1.47 (d, J=10.0 Hz, 1H), 1.33-1.26 (m, 1H), 1.24-1.17 (m, 1H).
Example 172
((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 169 substituting intermediate A-1 with intermediate A-7. MS (ESI): mass calcd. for C22H19ClFN5O, 423.1. m/z found, 424.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.83 (d, J=4.8 Hz, 2H), 8.19 (dd, J=8.8, 5.5 Hz, 1H), 7.55 (d, J=2.6 Hz, 1H), 7.39-7.32 (m, 2H), 7.08 (td, J=8.5, 2.7 Hz, 1H), 6.72-6.64 (m, 1H), 6.50-6.42 (m, 1H), 3.95 (s, 1H), 3.92-3.86 (m, 1H), 3.50 (dt, J=11.0, 3.2 Hz, 1H), 3.30-3.28 (m, 1H), 2.62-2.58 (m, 1H), 2.26-2.18 (m, 1H), 1.46 (d, J=10.1 Hz, 1H), 1.28-1.17 (m, 2H).
Example 173
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (6 mL) was added Pd(OAc)2 (25 mg, 0.038 mmol) and racemic BINAP (27 mg, 0.043 mmol) at room temperature and the reaction mixture was purged with N2 for 5 min. Then, 2-chloro-5-(difluoromethyl)pyridine (70 μL, 0.59 mmol), intermediate B-10 (137 mg), and sodium tert-butoxide (81 mg, 0.82 mmol) were added and the reaction mixture heated to 90° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound of step A (71 mg, 0.21 mmol, 36%). MS (ESI) mass calcd. for C12H23F2N3O2, 339.2. m/z found 340.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 8.12-8.07 (m, 1H), 7.56 (dd, J=8.6, 2.3 Hz, 1H), 6.80-6.49 (m, 2H), 4.49-4.44 (m, 1H), 4.23-4.14 (m, 1H), 3.09 (d, J=9.5 Hz, 1H), 2.59-2.54 (m, 1H), 2.31-2.18 (m, 1H), 1.74-1.68 (m, 2H), 1.22-1.16 (m, 1H), 1.09 (s, 9H). 1H buried under solvent peak.
Step B: (1S,4R,6R)—N-(5-(difluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (71 mg, 0.21 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.3 mL). After 1 h, the reaction was concentrated to give the title compound of step B (65 mg), which was used without further purification. MS (ESI) mass calcd. for C12H15F2N3, 239.1. m/z found 240.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (33 mg) and intermediate A-1 (24 mg, 0.13 mmol) in DMF (1.5 mL) was added DIPEA (0.11 mL, 0.63 mmol) and HATU (44 mg, 0.12 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (27 mg). MS (ESI): mass calcd. for C21H20F2N6O, 410.2. m/z found, 411.1 [M+H]+. Analytical HPLC using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). Rt=1.83 and 2.03 min (major rotamers) at 254 nm.
Example 174
((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 173 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H20F3N5O, 439.2. m/z found, 440.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H), 7.81 (s, 1H), 7.53 (dd, J=8.8, 2.4 Hz, 1H), 7.48 (t, J=4.9 Hz, 1H), 7.10-7.02 (m, 1H), 6.91-6.82 (m, 1H), 6.82-6.51 (m, 3H), 4.20-4.13 (m, 1H), 4.11-4.01 (m, 1H), 3.27-3.22 (m, 2H), 2.58-2.51 (m, 1H), 2.29-2.18 (m, 1H), 1.55 (d, J=9.6 Hz, 1H), 1.25-1.17 (m, 1H), 1.11 (d, J=9.5 Hz, 1H).
Example 175
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (4 mL) was added Pd(OAc)2 (9 mg, 0.038 mmol) and racemic BINAP (24 mg, 0.038 mmol) at room temperature and the reaction mixture was purged with N2 for 5 min. Then, 2-chloro-5-methoxypyridine (75 μL, 0.63 mmol), intermediate B-10 (148 mg, 0.695 mmol), and sodium tert-butoxide (85 mg, 0.89 mmol) were added and the reaction mixture heated to 90° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-10% MeOH (with 10% 2 N NH3) in DCM) to give the title compound of step A (158 mg, 0.49 mmol, 90% purity, 70%) MS (ESI) mass calcd. for C12H25N3O3, 319.2. m/z found 320.3 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 7.65 (d, J=3.0 Hz, 1H), 7.18 (dd, J=9.1, 3.0 Hz, 1H), 6.55 (d, J=9.1 Hz, 1H), 4.44-4.40 (m, 1H), 4.09-4.01 (m, 1H), 3.75 (s, 3H), 3.30-3.26 (m, 1H), 3.07 (d, J=9.4 Hz, 1H), 2.57-2.49 (m, 1H), 2.30-2.19 (m, 1H), 1.71-1.67 (m, 2H), 1.48-1.45 (m, 1H), 1.11 (s, 9H).
Step B: (1S,4R,6R)—N-(5-methoxypyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (176 mg, 0.49 mmol, 90% purity) in EtOAc (6 mL) was added 4M HCl in dioxane (0.6 mL). After 3 h, the reaction was concentrated to give the title compound of step B (150 mg), which was used without further purification. MS (ESI) mass calcd. for C12H12N3O, 219.1. m/z found 220.2 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (30 mg) and intermediate A-1 (21 mg, 0.11 mmol) in DMF (1 mL) was added DIPEA (0.10 mL, 0.55 mmol) and HATU (39 mg, 0.10 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (17 mg). MS (ESI): mass calcd. for C21H22N6O2, 390.2. m/z found, 391.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 7.93 (s, 2H), 7.82 (d, J=8.1 Hz, 1H), 7.39-7.33 (m, 1H), 7.29 (d, J=2.4 Hz, 1H), 7.17-7.10 (m, 1H), 7.02-6.92 (m, 1H), 6.85-6.69 (m, 1H), 6.57-6.38 (m, 1H), 3.93-3.80 (m, 2H), 3.76 (s, 3H), 3.49-3.41 (m, 1H), 3.30-3.26 (m, 1H), 2.57 (s, 1H), 2.27-2.16 (m, 1H), 1.53-1.43 (m, 1H), 1.41-1.26 (m, 1H), 1.20-1.12 (m, 1H).
Example 176
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 175 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H22FN5O2, 419.2. m/z found, 420.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H), 7.47 (t, J=4.9 Hz, 1H), 7.41 (d, J=3.0 Hz, 1H), 7.15-7.10 (m, 1H), 7.11-7.07 (m, 1H), 6.94-6.88 (m, 1H), 6.82 (d, J=7.6 Hz, 1H), 6.44 (d, J=9.1 Hz, 1H), 4.18-4.11 (m, 1H), 3.98-3.92 (m, 1H), 3.76 (s, 3H), 3.23 (t, J=3.0 Hz, 1H), 3.22-3.20 (m, 1H), 2.55-2.50 (m, 1H), 2.29-2.19 (m, 1H), 1.57 (d, J=11.2 Hz, 1H), 1.22-1.16 (m, 1H), 1.16-1.11 (m, 1H).
Example 177
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (170 mg, 0.801 mmol) in DMF (2.5 mL) was added 2,3-difluoro-5-(trifluoromethyl)pyridine (176 mg, 0.961 mmol) and Et3N (0.17 mL, 1.20 mmol), and the reaction mixture was sealed and heated to 90° C. bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and directly subjected to silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound of step A (322 mg). MS (ESI) mass calcd. for C17H21F4N3O2; 375.16. m/z found 376.0 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.15 (s, 1H), 7.33-7.28 (m, 1H), 5.37-5.23 (m, 1H), 4.42-4.34 (m, 2H), 3.44-3.39 (m, 1H), 3.11 (d, J=9.3 Hz, 1H), 2.64-2.60 (m, 1H), 2.42-2.31 (m, 1H), 1.69-1.63 (m, 1H), 1.26 (s, 9H), 1.10-1.04 (m, 1H).
Step B: (1S,4R,6R)—N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (322 mg) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL), and the reaction mixture was stirred at room temperature for 2 h. The reaction was concentrated to give the title compound of step B (327 mg), which was used without further purification. MS (ESI) mass calcd. for C12H13F4N3, 275.1. m/z found 276.0 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (40 mg) and intermediate A-1 (24 mg, 0.126 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (26 mg). MS (ESI): mass calcd. for C21H18F4N6O, 446.1. m/z found, 447.1 [M+H]+. 1H NMR (500 MHz, Methanol-4 Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 7.95 (s, 2H), 7.81 (d, J=8.2 Hz, 1H), 7.66 (s, 1H), 7.58-7.44 (m, 1H), 7.30 (t, J=7.8 Hz, 1H), 7.04-6.95 (m, 1H), 6.83-6.72 (m, 1H), 4.11-4.03 (m, 1H), 3.88-3.79 (m, 1H), 3.50-3.33 (m, 2H), 2.63-2.57 (m, 1H), 2.22-2.12 (m, 1H), 1.51-1.41 (m, 2H), 1.29-1.18 (m, 1H). Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.81 min (major rotamer) at 254 nm.
Example 178
((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 177 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C21H19F4N7O, 461.2. m/z found, 462.1 [M+H]+. 1H NMR (500 MHz, Methanol-4 Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.14 (d, J=8.4 Hz, 1H), 7.98 (s, 2H), 7.84-7.78 (m, 1H), 7.43 (dd, J=11.1, 2.0 Hz, 1H), 7.31 (d, J=8.6 Hz, 1H), 4.25-4.19 (m, 1H), 4.12-4.04 (m, 1H), 3.56 (dt, J=11.0, 3.2 Hz, 1H), 3.35 (dd, J=10.9, 1.4 Hz, 1H), 2.72-2.67 (m, 1H), 2.37 (s, 3H), 2.35-2.27 (m, 1H), 1.65-1.61 (m, 2H), 1.44-1.38 (m, 1H).
Example 179
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 177 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H18F5N5O, 475.1. m/z found, 476.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.90 (d, J=4.9 Hz, 2H), 7.80-7.73 (m, 1H), 7.52-7.46 (m, 2H), 7.08-7.01 (m, 1H), 6.95-6.87 (m, 1H), 6.80 (d, J=7.7 Hz, 1H), 4.20 (s, 1H), 4.17-4.10 (m, 1H), 3.33-3.32 (m, 1H), 3.19 (dt, J=11.1, 3.2 Hz, 1H), 2.57-2.49 (m, 1H), 2.23-2.13 (m, 1H), 1.52 (d, J=9.8 Hz, 1H), 1.45-1.36 (m, 1H), 0.93 (d, J=10.1 Hz, 1H).
Example 180
((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 177 substituting intermediate A-1 with intermediate A-34. MS (ESI): mass calcd. for C23H18F5N5O, 475.1. m/z found, 476.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.81 (d, J=0.6 Hz, 2H), 8.11 (d, J=7.3 Hz, 1H), 7.70-7.63 (m, 1H), 7.62-7.42 (m, 1H), 7.32-7.22 (m, 1H), 7.01-6.90 (m, 1H), 6.90-6.79 (m, 1H), 4.16-4.08 (m, 1H), 4.07-3.95 (m, 1H), 3.53 (dt, J=10.8, 3.2 Hz, 1H), 3.40 (dd, J=10.8, 1.6 Hz, 1H), 2.68-2.63 (m, 1H), 2.26-2.16 (m, 1H), 1.58-1.51 (m, 1H), 1.51-1.45 (m, 1H), 1.38-1.28 (m, 1H).
Example 181
((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Step A: (1S,4S)-tert-butyl 6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (183 mg, 0.862 mmol) in MeCN (2 mL) was added 2-chlorobenzoxazole (0.12 mL, 1.03 mmol) and Et3N (0.18 mL, 1.29 mmol), and the reaction mixture was sealed and heated to 100° C. bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H2O. The reaction mixture was extracted with EtOAc (3×). The combined organics were concentrated and the concentrate subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (199 mg, 0.604 mmol, 70%) MS (ESI) mass calcd. for C18H23N3O3; 329.2. m/z found 330.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 7.40-7.34 (m, 1H), 7.26-7.20 (m, 1H), 7.20-7.12 (m, 1H), 7.07-6.99 (m, 1H), 5.88-5.78 and 5.29-5.19 (two m, 1H), 4.51-4.43 (m, 1H), 4.33-4.19 (m, 1H), 3.45-3.33 (m, 1H), 3.15-3.04 (m, 1H), 2.64-2.57 (m, 1H), 2.46-2.31 (m, 1H), 1.80-0.99 (series of m, 12H).
Step B: N-((1S,4R)-2-azabicyclo[2.2.1]heptan-6-yl)benzo[d]oxazol-2-amine.xHCl. To the title compound of step A (199 mg, 0.604 mmol) in EtOAc (1.5 mL) was added 4M HCl in dioxane (4 mL). After 1 h, the reaction was concentrated to give the title compound of step B (194 mg), which was used without further purification. MS (ESI) mass calcd. for C13H15N3O, 229.1. m/z found 230.1 [M+H]+.
Step C: ((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone. To the title compound of step B (40 mg) and intermediate A-40 (30 mg, 0.15 mmol) in DMF (1 mL) was added DIPEA (0.13 mL, 0.75 mmol) and HATU (55 mg, 0.15 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (24 mg). MS (ESI): mass calcd. for C22H21N7O2, 415.2. m/z found, 416.2 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.12-8.05 (m, 1H), 7.99 (s, 2H), 7.26-7.21 (m, 1H), 7.16-7.08 (m, 3H), 7.08-7.01 (m, 1H), 4.26-4.21 (m, 1H), 3.98-3.88 (m, 1H), 3.59 (dt, J=11.0, 3.2 Hz, 1H), 3.35 (d, J=11.0 Hz, 1H), 2.76-2.68 (m, 1H), 2.40-2.28 (m, 1H), 2.09 (s, 3H), 1.68-1.60 (m, 2H), 1.40-1.33 (m, 1H).
Example 182
((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 181 substituting intermediate A-40 with intermediate A-16. MS (ESI): mass calcd. for C22H19FN6O2, 418.2. m/z found, 419.2 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.00 (s, 2H), 7.37-7.31 (m, 1H), 7.20-7.16 (m, 1H), 7.12 (d, J=7.1 Hz, 2H), 6.91 (d, J=8.2 Hz, 2H), 6.49-6.37 (m, 1H), 4.12 (s, 1H), 4.01-3.88 (m, 1H), 3.63 (s, 1H), 3.27-3.22 (m, 1H), 2.60-2.54 (m, 1H), 2.31-2.21 (m, 1H), 1.59 (d, J=10.3 Hz, 1H), 1.32-1.19 (m, 2H).
Example 183
((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 181 substituting intermediate A-40 with intermediate A-2. MS (ESI): mass calcd. for C24H20FN5O2, 429.2. m/z found, 430.2 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.91 (d, J=5.0 Hz, 2H), 7.49 (t, J=5.0 Hz, 1H), 7.30 (d, J=7.9 Hz, 1H), 7.21-7.06 (m, 3H), 6.93 (d, J=7.5 Hz, 1H), 6.86-6.79 (m, 1H), 6.62-6.49 (m, 1H), 4.27 (s, 1H), 4.05-3.97 (m, 1H), 3.29-3.28 (m, 1H), 3.27 (s, 1H), 2.67-2.56 (m, 1H), 2.37-2.25 (m, 1H), 1.63 (d, J=10.2 Hz, 1H), 1.35-1.23 (m, 2H).
Example 184
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S)-tert-butyl 6-(p-tolylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed dioxane (2 mL), intermediate B-10 (60 mg, 0.28 mmol) and 4-bromotoluene (73 mg, 0.42 mmol) was added BrettPhos Palladacycle (11 mg, 0.014 mmol), BrettPhos (8 mg, 0.014 mmol) and sodium tert-butoxide (33 mg, 0.34 mmol). The reaction mixture was heated to 90° C. bench top for 3 h. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H2O and EtOAc. The reaction mixture was extracted with EtOAc (3×) and the combined organics washed with brine, dried (Na2SO4), and filtered. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-40% EtOAc in hexanes) to give the title compound of step A (68 mg, 0.22 mmol, 80%) MS (ESI) mass calcd. for C18H26N2O2, 302.2. m/z found 303.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 6.91 (d, J=8.1 Hz, 2H), 6.55 (d, J=8.3 Hz, 2H), 4.39 (s, 1H), 3.86-3.73 (m, 1H), 3.27 (dt, J=9.4, 3.2 Hz, 1H), 3.05 (d, J=9.3 Hz, 1H), 2.52-2.48 (m, 1H), 2.28-2.21 (m, 1H), 2.18 (s, 3H), 1.74-1.40 (m, 3H), 1.08 (s, 9H).
Step B: (1S,4R)—N-(p-tolyl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (68 mg, 0.22 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.3 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (70 mg), which was used without further purification. MS (ESI) mass calcd. for C13H18N2, 202.2. m/z found 203.3 [M+H]+.
Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (61 mg) and intermediate A-2 (71 mg, 0.27 mmol, 82% purity) in DMF (2 mL) was added DIPEA (0.23 mL, 1.33 mmol) and HATU (93 mg, 0.24 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (31 mg). MS (ESI): mass calcd. for C24H23FN4O, 402.2. m/z found, 403.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.88 (d, J=5.0 Hz, 2H), 7.48 (t, J=5.0 Hz, 1H), 7.09-7.02 (m, 1H), 6.85-6.77 (m, 4H), 6.34-6.27 (m, 2H), 4.10 (s, 1H), 3.73-3.64 (m, 1H), 3.29-3.11 (m, 2H), 2.57-2.48 (m, 1H), 2.32-2.23 (m, 1H), 2.21 (s, 3H), 1.60 (d, J=10.1 Hz, 1H), 1.26-1.19 (m, 1H), 1.15-1.09 (m, 1H).
Example 185
(1H-indol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-29. MS (ESI): mass calcd. for C21H19F3N4O, 400.2. m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 7.53 (s, 1H), 7.32-7.25 (m, 1H), 7.23 (d, J=3.1 Hz, 1H), 7.17 (dt, J=8.0, 1.0 Hz, 1H), 6.70-6.60 (m, 2H), 6.37 (dd, J=3.1, 0.9 Hz, 1H), 6.33 (s, 1H), 4.59 (s, 1H), 3.98-3.89 (m, 1H), 3.63 (dt, J=11.1, 3.3 Hz, 1H), 3.51 (dd, J=11.2, 1.6 Hz, 1H), 2.76-2.66 (m, 1H), 2.33-2.20 (m, 1H), 2.05-1.95 (m, 1H), 1.81-1.74 (m, 1H), 1.36-1.25 (m, 1H).
Example 186
(1H-indazol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-44. MS (ESI): mass calcd. for C20H18F3N5O, 401.1. m/z found, 402.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 7.88 (s, 1H), 7.55 (d, J=8.1 Hz, 1H), 7.52 (s, 1H), 7.22 (d, J=7.1 Hz, 1H), 7.09 (dd, J=8.9, 2.5 Hz, 1H), 6.89-6.80 (m, 1H), 6.11 (d, J=8.9 Hz, 1H), 4.76 (s, 1H), 4.00-3.92 (m, 1H), 3.67-3.56 (m, 2H), 2.76-2.68 (m, 1H), 2.36-2.25 (m, 1H), 2.17-2.08 (m, 1H), 1.83 (d, J=10.4 Hz, 1H), 1.33-1.22 (m, 1H).
Example 187
(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-19. MS (ESI): mass calcd. for C20H19F3N8O, 444.2. m/z found, 445.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.32-8.26 (m, 1H), 8.18 (s, 1H), 8.11-8.06 (m, 1H), 7.88 (s, 3H), 7.56 (s, 1H), 4.31 (s, 1H), 4.26-4.12 (m, 1H), 3.72 (dt, J=11.0, 3.2 Hz, 1H), 3.35 (dd, J=11.0, 1.7 Hz, 1H), 2.85-2.72 (m, 1H), 2.47-2.36 (m, 4H), 1.98-1.89 (m, 1H), 1.72 (d, J=10.5 Hz, 1H), 1.21 (dt, J=13.4, 4.0 Hz, 1H).
Example 188
(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-39. MS (ESI): mass calcd. for C19H17F3N8O, 430.1. m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.36 (dd, J=4.8, 1.8 Hz, 1H), 8.07 (s, 2H), 7.98-7.83 (m, 2H), 7.61-7.48 (m, 1H), 6.89-6.75 (m, 1H), 4.01-3.89 (m, 1H), 3.85-3.70 (m, 1H), 3.51 (dt, J=11.2, 3.2 Hz, 1H), 3.35 (dd, J=11.1, 1.7 Hz, 1H), 2.64 (s, 1H), 2.30-2.19 (m, 1H), 1.57-1.47 (m, 1H), 1.43-1.32 (m, 1H), 1.32-1.21 (m, 1H).
Example 189
(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-42. MS (ESI): mass calcd. for C21H18F3N7O, 441.2. m/z found, 442.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 8.53 (dd, J=8.0, 1.6 Hz, 1H), 8.02 (d, J=4.8 Hz, 1H), 7.94-7.86 (m, 2H), 7.44 (t, J=4.9 Hz, 1H), 7.37 (dd, J=8.0, 4.8 Hz, 1H), 4.20-4.14 (m, 1H), 4.11-4.01 (m, 1H), 3.63 (dt, J=10.9, 3.2 Hz, 1H), 3.35 (d, J=10.9 Hz, 1H), 2.77-2.68 (m, 1H), 2.36-2.30 (m, 1H), 1.70-1.54 (m, 2H), 1.40-1.30 (m, 1H).
Example 190
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-47. MS (ESI): mass calcd. for C22H20F3N7O, 455.2. m/z found, 456.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.88 (d, J=4.9 Hz, 2H), 8.33 (dd, J=2.1, 0.9 Hz, 1H), 7.90 (s, 1H), 7.89-7.88 (m, 1H), 7.82 (s, 1H), 7.43 (t, J=4.9 Hz, 1H), 4.20-4.15 (m, 1H), 4.10-3.99 (m, 1H), 3.60 (dt, J=10.9, 3.2 Hz, 1H), 3.35 (dd, J=11.0, 1.5 Hz, 1H), 2.73-2.67 (m, 1H), 2.33 (s, 3H), 2.32-2.26 (m, 1H), 1.66-1.51 (m, 2H), 1.38-1.31 (m, 1H).
Example 191
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-41. MS (ESI): mass calcd. for C22H20F3N7O, 455.2. m/z found, 456.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 7.37 (d, J=4.9 Hz, 2H), 6.88 (d, J=8.1 Hz, 1H), 6.45 (s, 1H), 6.33 (d, J=1.4 Hz, 1H), 5.91 (t, J=4.9 Hz, 1H), 5.74 (d, J=8.1 Hz, 1H), 2.76-2.67 (m, 1H), 2.59-2.48 (m, 1H), 2.11 (dt, J=11.0, 3.2 Hz, 1H), 1.83 (dd, J=10.9, 1.6 Hz, 1H), 1.20-1.18 (m, 1H), 0.87-0.75 (m, 4H), 0.17-−0.00 (m, 2H), −0.13-−0.27 (m, 1H).
Example 192
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-16. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 448.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.35 min (major rotamer) at 254 nm.
Example 193
(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-12. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 448.2 [M+H]+.]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.56 min (major rotamer) at 254 nm.
Example 194
((5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-10. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 448.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.36 min (major rotamer) at 254 nm.
Example 195
(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-11. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 448.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.41 min (major rotamer) at 254 nm.
Example 196
(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-22. MS (ESI): mass calcd. for C21H20F3N7O, 443.2. m/z found, 444.2 [M+H]+.]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.61 min (major rotamer) at 254 nm.
Example 197
(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-5. MS (ESI): mass calcd. for C21H20F3N7O2, 459.2. m/z found, 460.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.30 min (major rotamer) at 254 nm.
Example 198
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-23. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.24 min (major rotamer) at 254 nm.
Example 199
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-7. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.9 [M+H]+. 1H NMR (600 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.84 (d, J=4.8 Hz, 2H), 8.19 (dd, J=8.8, 5.5 Hz, 1H), 7.95-7.87 (m, 2H), 7.38 (t, J=4.9 Hz, 1H), 7.04 (td, J=8.4, 2.7 Hz, 1H), 6.74-6.64 (m, 1H), 4.04-3.93 (m, 2H), 3.54 (dt, J=11.0, 3.2 Hz, 1H), 3.36-3.33 (m, 1H), 2.66-2.62 (m, 1H), 2.30-2.22 (m, 1H), 1.50 (d, J=10.0 Hz, 1H), 1.34-1.24 (m, 2H).
Example 200
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-6. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.2 [M+H]+.]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.16 min (major rotamer) at 254 nm.
Example 201
(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-37. MS (ESI): mass calcd. for C22H19F3N6O, 440.2. m/z found, 441.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.12 (d, J=7.6 Hz, 1H), 7.94-7.87 (m, 1H), 7.86-7.78 (m, 1H), 7.40 (t, J=4.9 Hz, 1H), 7.30 (td, J=7.7, 1.4 Hz, 1H), 7.02-6.92 (m, 1H), 6.87-6.75 (m, 1H), 4.06-3.90 (m, 2H), 3.52 (dt, J=11.0, 3.1 Hz, 1H), 3.36-3.33 (m, 1H), 2.67-2.60 (m, 1H), 2.31-2.20 (m, 1H), 1.47 (d, J=10.0 Hz, 1H), 1.32-1.26 (m, 1H), 1.25-1.15 (m, 1H).
Example 202
(5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-49. MS (ESI): mass calcd. for C21H17F4N5O2, 447.1. m/z found, 448.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.30 (s, 1H), 8.11 (dd, J=8.8, 5.3 Hz, 1H), 7.99-7.89 (m, 1H), 7.85 (d, J=1.4 Hz, 1H), 7.80 (d, J=0.9 Hz, 1H), 7.29-7.26 (m, 1H), 7.21 (ddd, J=8.9, 7.9, 2.7 Hz, 1H), 7.05 (dd, J=8.3, 2.6 Hz, 1H), 4.88 (s, 1H), 4.85-4.70 (m, 1H), 3.22 (dt, J=8.9, 2.9 Hz, 1H), 2.95 (dd, J=8.9, 1.5 Hz, 1H), 2.63-2.55 (m, 1H), 2.49-2.31 (m, 1H), 1.90-1.75 (m, 2H), 1.18-1.11 (m, 1H).
Example 203
(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-34. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.2 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.81 (s, 2H), 8.12 (d, J=7.9 Hz, 1H), 7.97-7.87 (m, 1H), 7.86-7.76 (m, 1H), 7.29 (td, J=7.7, 1.4 Hz, 1H), 6.95 (d, J=7.5 Hz, 1H), 6.85-6.70 (m, 1H), 4.08-3.90 (m, 2H), 3.55 (dt, J=10.9, 3.2 Hz, 1H), 3.38-3.32 (m, 1H), 2.66 (s, 1H), 2.31-2.18 (m, 1H), 1.51 (d, J=10.0 Hz, 1H), 1.41-1.24 (m, 2H).
Example 204
(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-35. MS (ESI): mass calcd. for C22H17F5N6O, 476.1. m/z found, 477.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.88 (d, J=0.7 Hz, 2H), 7.96-7.89 (m, 2H), 7.11-7.03 (m, 1H), 6.93-6.81 (m, 2H), 4.20 (s, 1H), 4.10-4.02 (m, 1H), 3.28-3.25 (m, 2H), 2.58 (s, 1H), 2.32-2.19 (m, 1H), 1.57 (d, J=10.1 Hz, 1H), 1.32-1.21 (m, 1H), 1.15-1.02 (m, 1H).
Example 205
(3-phenylpyrazin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-43. MS (ESI): mass calcd. for C22H19F3N6O, 440.2. m/z found, 441.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.48 (d, J=2.4 Hz, 1H), 7.93 (s, 1H), 7.84 (s, 1H), 7.78 (d, J=2.4 Hz, 1H), 7.73-7.66 (m, 2H), 7.56-7.50 (m, 3H), 3.90-3.82 (m, 1H), 3.81-3.73 (m, 1H), 3.34 (dd, J=11.3, 1.6 Hz, 1H), 3.27 (dt, J=11.3, 3.2 Hz, 1H), 2.53-2.48 (m, 1H), 2.20-2.08 (m, 1H), 1.38-1.28 (m, 1H), 1.29-1.19 (m, 1H), 0.66-0.55 (m, 1H).
Example 206
[1,1′-biphenyl]-2-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with [1,1′-biphenyl]-2-carboxylic acid. MS (ESI): mass calcd. for C24H21F3N4O, 438.2. m/z found, 439.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 7.91 (br. s, 1H), 7.76 (br. s, 1H), 7.49-7.33 (m, 6H), 7.25 (td, J=7.6, 1.4 Hz, 1H), 6.87 (dd, J=7.6, 1.3 Hz, 1H), 6.68 (td, J=7.5, 1.3 Hz, 1H), 3.93-3.72 (m, 2H), 3.25 (dd, J=11.2, 1.6 Hz, 1H), 3.09 (dt, J=11.2, 3.2 Hz, 1H), 2.43-2.33 (m, 1H), 2.16-2.05 (m, 1H), 1.26-1.11 (m, 3H).
Example 207
(3-phenylfuran-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-45. MS (ESI): mass calcd. for C22H19F3N4O2, 428.1. m/z found, 429.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.09-8.05 (m, 1H), 7.74 (d, J=1.4 Hz, 1H), 7.43-7.36 (m, 4H), 7.36-7.31 (m, 1H), 7.06 (d, J=1.8 Hz, 1H), 6.41 (d, J=1.8 Hz, 1H), 4.50-4.46 (m, 1H), 4.04-3.96 (m, 1H), 3.49-3.45 (m, 2H), 2.64-2.58 (m, 1H), 2.28-2.20 (m, 1H), 1.61-1.49 (m, 2H), 1.32-1.24 (m, 1H).
Example 208
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-2, followed by alkylation step of Example 153. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 473.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H), 8.18-8.16 (m, 1H), 8.14-8.12 (m, 1H), 7.50 (t, J=5.0 Hz, 1H), 7.10-7.01 (m, 1H), 6.91-6.83 (m, 1H), 6.78 (dd, J=7.6, 1.2 Hz, 1H), 4.56-4.47 (m, 1H), 4.15-4.09 (m, 1H), 3.37 (dd, J=11.5, 1.6 Hz, 1H), 3.22-3.16 (m, 4H), 2.63-2.59 (m, 1H), 2.08-1.98 (m, 1H), 1.97-1.88 (m, 1H), 1.55-1.48 (m, 1H), 0.84-0.77 (m, 1H).
Example 209
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 208 substituting intermediate A-2 with intermediate A-7. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 473.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.84 (d, J=4.9 Hz, 2H), 8.18 (dd, J=8.8, 5.5 Hz, 1H), 8.15 (s, 1H), 8.09-8.04 (m, 1H), 7.39 (t, J=4.9 Hz, 1H), 7.05-6.96 (m, 1H), 6.64 (dd, J=8.5, 2.7 Hz, 1H), 4.51-4.41 (m, 1H), 4.03-3.95 (m, 1H), 3.54 (dt, J=11.3, 3.1 Hz, 1H), 3.45 (dd, J=11.3, 1.6 Hz, 1H), 3.24 (s, 3H), 2.78-2.69 (m, 1H), 2.13-1.97 (m, 2H), 1.57-1.46 (m, 1H), 1.23-1.11 (m, 1H).
Example 210
((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 208 substituting intermediate A-2 with intermediate A-37. MS (ESI): mass calcd. for C23H21F3N6O, 454.2. m/z found, 455.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 8.10 (dd, J=7.9, 1.2 Hz, 1H), 8.08 (s, 2H), 7.39 (t, J=4.9 Hz, 1H), 7.26 (td, J=7.7, 1.4 Hz, 1H), 6.92 (dd, J=7.6, 1.3 Hz, 1H), 6.82 (td, J=7.5, 1.3 Hz, 1H), 4.50-4.43 (m, 1H), 3.99-3.92 (m, 1H), 3.52 (dt, J=11.3, 3.1 Hz, 1H), 3.44 (dd, J=11.3, 1.5 Hz, 1H), 3.23 (s, 3H), 2.76-2.67 (m, 1H), 2.12-1.91 (m, 2H), 1.52-1.42 (m, 1H), 1.19-1.07 (m, 1H).
Example 211
((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-2, followed by alklyation step of Example 161. MS (ESI): mass calcd. for C26H24F4N6O, 512.2. m/z found, 513.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 8.18 (br. s, 1H), 8.15 (br. s, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.04-6.98 (m, 1H), 6.89-6.81 (m, 1H), 6.78 (dd, J=7.6, 1.2 Hz, 1H), 4.48-4.40 (m, 1H), 4.18-4.14 (m, 1H), 3.84 (dd, J=16.1, 5.9 Hz, 1H), 3.39-3.33 (m, 2H), 3.14 (dt, J=11.4, 3.2 Hz, 1H), 2.63-2.58 (m, 1H), 2.19-2.08 (m, 1H), 1.91-1.84 (m, 1H), 1.53 (d, J=10.3 Hz, 1H), 1.01-0.92 (m, 1H), 0.77-0.70 (m, 1H), 0.65-0.52 (m, 2H), 0.51-0.43 (m, 1H), 0.38-0.30 (m, 1H).
Example 212
((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (300 mg, 1.41 mmol) in MeCN (3 mL) was added 2,5-dichloropyrazine (0.17 mL, 1.70 mmol) and Et3N (0.30 mL, 2.12 mmol), and the reaction mixture was sealed and heated to 90° C. bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H2O. The reaction mixture was extracted with EtOAc (3×). The combined organics were concentrated and the concentrate subjected directly to silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound of step A (153 mg, 0.471 mmol, 33%) MS (ESI) mass calcd. for C15H21ClN4O2; 324.1. m/z found 269.1 [M+2H-tBu]+. 1H NMR (500 MHz, Methanol-d4) δ 7.99 (d, J=1.4 Hz, 1H), 7.71 (d, J=1.4 Hz, 1H), 4.45-4.39 (m, 1H), 4.16-4.12 (m, 1H), 3.08 (d, J=10.1 Hz, 1H), 2.62-2.50 (m, 1H), 2.29-2.19 (m, 1H), 1.74-1.64 (m, 2H), 1.22-1.16 (m, 1H), 1.11 (s, 9H). 1H buried under solvent.
Step B: (1S,4R,6R)—N-(5-chloropyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (150 mg, 0.46 mmol) in EtOAc (5 mL) was added 4M HCl in dioxane (0.6 mL), and the reaction mixture was stirred overnight. The reaction was concentrated to give the title compound of step B (137 mg), which was used without further purification. MS (ESI) mass calcd. for C10H13ClN4, 224.1. m/z found 225.1 [M+H]+.
Step C: ((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone. To the title compound of step B (34 mg) and intermediate A-16 (28 mg, 0.14 mmol) in DMF (1 mL) was added DIPEA (0.12 mL, 0.69 mmol) and HATU (48 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (35 mg). MS (ESI): mass calcd. for C19H17ClFN7O, 413.1. m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.01 (s, 2H), 7.70-7.66 (m, 1H), 7.62 (d, J=1.4 Hz, 1H), 7.33-7.27 (m, 1H), 7.02-6.93 (m, 1H), 6.87 (d, J=7.7 Hz, 1H), 4.02 (s, 1H), 3.95-3.86 (m, 1H), 3.24-3.20 (m, 2H), 2.53 (s, 1H), 2.27-2.15 (m, 1H), 1.52 (d, J=10.3 Hz, 1H), 1.22-1.05 (m, 2H).
Example 213
1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-10. MS (ESI): mass calcd. for C19H17ClFN7O, 413.1. m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 7.95 (s, 2H), 7.84 (dd, J=9.0, 4.7 Hz, 1H), 7.69-7.62 (m, 1H), 7.60 (d, J=1.4 Hz, 1H), 7.22-7.15 (m, 1H), 6.81-6.70 (m, 1H), 3.92-3.74 (m, 1H), 3.48-3.39 (m, 1H), 3.29-3.27 (m, 1H), 2.59 (s, 1H), 2.27-2.16 (m, 1H), 1.51-1.41 (m, 1H), 1.29-1.16 (m, 2H). 1H buried under solvent peak.
Example 214
((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-2. MS (ESI): mass calcd. for C21H18ClFN6O, 424.1. m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.91 (d, J=5.0 Hz, 2H), 7.63 (dd, J=9.3, 1.5 Hz, 2H), 7.50 (t, J=5.0 Hz, 1H), 7.19-7.12 (m, 1H), 7.01-6.93 (m, 1H), 6.85 (d, J=6.9 Hz, 1H), 4.15 (s, 1H), 3.97-3.91 (m, 1H), 3.24-3.20 (m, 2H), 2.56-2.48 (m, 1H), 2.27-2.17 (m, 1H), 1.50 (d, J=10.3 Hz, 1H), 1.22-1.15 (m, 1H), 0.94 (d, J=10.2 Hz, 1H).
Example 215
((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-37. MS (ESI): mass calcd. for C21H19ClN6O, 406.1. m/z found, 407.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 8.12 (d, J=8.0 Hz, 1H), 7.68-7.61 (m, 1H), 7.54-7.50 (m, 1H), 7.43-7.34 (m, 2H), 6.97 (d, J=7.6 Hz, 1H), 6.95-6.85 (m, 1H), 3.94 (s, 1H), 3.91-3.84 (m, 1H), 3.50 (dt, J=11.0, 3.2 Hz, 1H), 3.30-3.29 (m, 1H), 2.66-2.58 (m, 1H), 2.28-2.17 (m, 1H), 1.51-1.42 (m, J=10.1 Hz, 1H), 1.27-1.14 (m, 2H).
Example 216
((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-35. MS (ESI): mass calcd. for C23H18F5N5O, 475.1. m/z found, 476.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.87 (s, 2H), 7.93 (s, 1H), 7.58 (dd, J=8.9, 2.5 Hz, 1H), 7.13-7.00 (m, 1H), 6.90-6.82 (m, 1H), 6.82-6.75 (m, 1H), 6.65-6.54 (m, 1H), 4.17 (s, 1H), 4.13-4.04 (m, 1H), 3.28-3.21 (m, 2H), 2.61-2.50 (m, 1H), 2.31-2.16 (m, 1H), 1.59 (d, J=10.2 Hz, 1H), 1.27-1.08 (m, 2H).
Example 217
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (9 mL) was added Pd(OAc)2 (24 mg, 0.035 mmol) and racemic BINAP (22 mg, 0.035 mmol) at room temperature and the reaction mixture was purged with N2 for 5 min. Then, 2-chloro-5-methylpyrazine (112 mg, 0.87 mmol), intermediate B-10 (204 mg), and sodium tert-butoxide (121 mg, 1.22 mmol) were added and the reaction mixture heated to 70° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (10-80% EtOAc in hexanes) to give the title compound of step A (139 mg, 0.457 mmol, 52%). MS (ESI) mass calcd. for C16H24N4O2, 304.2. m/z found 305.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 7.93-7.79 (m, 2H), 4.45-4.40 (m, 1H), 4.16-4.12 (m, 1H), 3.09 (dd, J=9.5, 1.2 Hz, 1H), 2.60-2.53 (m, 1H), 2.33 (s, 3H), 2.29-2.20 (m, 1H), 1.74-1.64 (m, 2H), 1.20-1.15 (m, 1H), 1.08 (s, 9H). 1H buried under solvent.
Step B: (1S,4R,6R)—N-(5-methylpyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (139 mg, 0.46 mmol) in EtOAc (5 mL) was added 4M HCl in dioxane (0.6 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (140 mg), which was used without further purification. MS (ESI) mass calcd. for C11H16N4, 204.1. m/z found 205.2 [M+H]+.
Step C: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (31 mg) and intermediate A-16 (28 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.12 mL, 0.67 mmol) and HATU (47 mg, 0.12 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (18 mg). MS (ESI): mass calcd. for C20H20FN7O, 393.2. m/z found, 394.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.00 (s, 2H), 7.80-7.75 (m, 1H), 7.55-7.49 (m, 1H), 7.29-7.22 (m, 1H), 6.93-6.78 (m, 2H), 4.10-3.97 (m, 1H), 3.97-3.89 (m, 1H), 3.25-3.20 (m, 2H), 2.53 (s, 1H), 2.33 (s, 3H), 2.27-2.17 (m, 1H), 1.54 (d, J=10.1 Hz, 1H), 1.23-1.11 (m, 2H).
Example 218
(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 217 substituting intermediate A-16 with intermediate A-10. MS (ESI): mass calcd. for C20H20FN7O, 393.2. m/z found, 394.5 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 7.95 (s, 2H), 7.82 (dd, J=9.0, 4.7 Hz, 1H), 7.78 (s, 1H), 7.50-7.45 (m, 1H), 7.19-7.11 (m, 1H), 6.69 (s, 1H), 3.91-3.77 (m, 2H), 3.48-3.38 (m, 1H), 2.58 (s, 1H), 2.32 (s, 3H), 2.27-2.18 (m, 1H), 1.50-1.38 (m, 1H), 1.29-1.14 (m, 2H). 1H buried under solvent.
Example 219
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 217 substituting intermediate A-16 with intermediate A-2. MS (ESI): mass calcd. for C22H21FN6O, 404.2. m/z found, 405.5 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H), 7.75 (d, J=1.5 Hz, 1H), 7.55-7.52 (m, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.15-7.09 (m, 1H), 6.92-6.86 (m, 1H), 6.85-6.82 (m, 1H), 4.18-4.13 (m, 1H), 4.01-3.93 (m, 1H), 3.27-3.20 (m, 2H), 2.53 (s, 1H), 2.33 (s, 3H), 2.27-2.19 (m, 1H), 1.53 (d, J=10.3 Hz, 1H), 1.21-1.14 (m, 1H), 1.06-1.00 (m, 1H).
Example 220
((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 217 substituting intermediate A-16 with intermediate A-37. MS (ESI): mass calcd. for C22H22N6O, 386.2. m/z found, 387.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 8.11 (d, J=7.9 Hz, 1H), 7.75 (s, 1H), 7.43 (s, 1H), 7.39 (t, J=4.9 Hz, 1H), 7.33 (t, J=7.7 Hz, 1H), 6.96 (d, J=7.5 Hz, 1H), 6.87-6.76 (m, 1H), 4.03-3.84 (m, 2H), 3.51 (dt, J=11.1, 3.2 Hz, 1H), 2.67-2.57 (m, 1H), 2.33 (s, 3H), 2.28-2.14 (m, 1H), 1.48 (d, J=9.8 Hz, 1H), 1.34-1.18 (m, 2H). 1H buried under solvent peak.
Example 221
methyl 5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate




Step A: (1S,4S,6R)-tert-butyl 6-((5-(methoxycarbonyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (100 mg, 0.471 mmol) in DMF (2 mL) was added methyl 5-chloropyrazine-2-carboxylate (98 mg, 0.57 mmol) and Et3N (0.1 mL, 0.72 mmol), and the reaction mixture was sealed and heated to 70° C. bench top overnight. After 14 hours, LCMS analysis of the reaction mixture showed incomplete conversion of the starting material. The temperature was raised to 100° C. and the reaction mixture heated overnight. Upon completion of the reaction, the mixture was cooled to room temperature and directly subjected to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (112 mg). MS (ESI) mass calcd. for C12H24N4O4; 348.2. m/z found 349.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 8.78-8.68 (m, 1H), 7.93-7.74 (m, 1H), 6.30-6.18 and 5.90-5.77 (two m, 1H), 4.46-4.36 (m, 1H), 4.33-4.12 (m, 1H), 3.91 (s, 3H), 3.41-3.30 (m, 1H), 3.11-2.99 (m, 1H), 2.63-2.51 (m, 1H), 2.39-2.25 (m, 1H), 1.78-1.59 (m, 2H), 1.51-1.01 (m, 10H).
Step B: methyl 5-((1S,4R,6R)-2-azabicyclo[2.2.1]heptan-6-ylamino)pyrazine-2-carboxylate.xHCl. To the title compound of step A (112 mg, 0.321 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL), and the reaction mixture was stirred at room temperature for 2 h. The reaction was concentrated to give the title compound of step B (99 mg), which was used without further purification. MS (ESI) mass calcd. for C12H16N4O2, 248.1. m/z found 249.1 [M+H]+.
Step C: methyl 5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate. To the title compound of step B (99 mg) and intermediate A-1 (70 mg, 0.37 mmol) in DMF (2 mL) was added DIPEA (0.3 mL, 1.7 mmol) and HATU (129 mg, 0.339 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound. MS (ESI): mass calcd. for C21H21N7O3, 419.2. m/z found, 420.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=4.75 min (major rotamer) at 254 nm.
Example 222
(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-39. MS (ESI): mass calcd. for C19H17F3N8O, 430.1. m/z found, 430.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=5.15 min (major rotamer) at 254 nm.
Example 223
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-16. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 448.9 [M+H]+. 1H NMR (400 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.56 (d, J=3.2 Hz, 1H), 8.20 (d, J=3.1 Hz, 1H), 8.01 (s, 2H), 7.28-7.19 (m, 1H), 7.06-6.95 (m, 1H), 6.93-6.85 (m, 1H), 4.10-3.99 (m, 2H), 3.29-3.26 (m, 1H), 3.20 (dt, J=11.2, 3.2 Hz, 1H), 2.57-2.51 (m, 1H), 2.25-2.12 (m, 1H), 1.54 (d, J=10.3 Hz, 1H), 1.39-1.28 (m, 1H), 1.23-1.08 (m, 1H).
Example 224
(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-12. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 448.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.56 (s, 1H), 8.22-8.13 (m, 1H), 7.98 (s, 2H), 7.64 (dd, J=9.6, 2.6 Hz, 1H), 7.12-6.99 (m, 1H), 6.68-6.50 (m, 1H), 4.07-3.95 (m, 1H), 3.80 (s, 1H), 3.54-3.43 (m, 1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.62 (s, 1H), 2.26-2.14 (m, 1H), 1.52-1.42 (m, 1H), 1.38-1.29 (m, 2H).
Example 225
(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-10. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 447.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported)) δ 8.52 (s, 1H), 8.17 (d, J=3.1 Hz, 1H), 7.95 (s, 2H), 7.85 (dd, J=9.0, 4.8 Hz, 1H), 7.16-7.06 (m, 1H), 6.86-6.74 (m, 1H), 4.07-3.97 (m, 1H), 3.80 (s, 1H), 3.47-3.33 (m, 2H), 2.65-2.54 (m, 1H), 2.25-2.15 (m, 1H), 1.47 (d, J=10.2 Hz, 1H), 1.38-1.31 (m, 1H), 1.31-1.21 (m, 1H).
Example 226
(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-11. MS (ESI): mass calcd. for C20H17F4N7O, 447.1. m/z found, 447.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.18 min (major rotamer) at 254 nm.
Example 227
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-23. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.88 (d, J=4.9 Hz, 2H), 8.64-8.47 (m, 1H), 8.16 (d, J=3.1 Hz, 1H), 7.89 (dd, J=10.0, 2.7 Hz, 1H), 7.42 (t, J=4.9 Hz, 1H), 7.12-6.93 (m, 1H), 6.68 (s, 1H), 4.09-3.85 (m, 2H), 3.53 (dt, J=10.9, 3.2 Hz, 1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.69-2.61 (m, 1H), 2.30-2.16 (m, 1H), 1.54-1.43 (m, 1H), 1.41-1.34 (m, 1H), 1.33-1.23 (m, 1H).
Example 228
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous Example 60 substituting intermediate A-1 with intermediate A-7. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.84 (d, J=4.8 Hz, 2H), 8.51 (s, 1H), 8.21 (dd, J=8.8, 5.5 Hz, 1H), 8.16 (d, J=3.1 Hz, 1H), 7.38 (t, J=4.9 Hz, 1H), 7.05 (td, J=8.3, 2.7 Hz, 1H), 6.80-6.71 (m, 1H), 4.10-4.00 (m, 1H), 3.94 (s, 1H), 3.52 (dt, J=10.7, 3.1 Hz, 1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.68-2.60 (m, 1H), 2.27-2.15 (m, 1H), 1.49 (d, J=10.1 Hz, 1H), 1.41-1.33 (m, 1H), 1.33-1.23 (m, 1H).
Example 229
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-6. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.87 (d, J=4.9 Hz, 2H), 8.56-8.51 (m, 1H), 8.12-8.04 (m, 2H), 7.42 (t, J=4.9 Hz, 1H), 7.36-7.30 (m, 1H), 6.73-6.67 (m, 1H), 4.03-3.97 (m, 1H), 3.97-3.90 (m, 1H), 3.56 (dt, J=10.9, 3.2 Hz, 1H), 3.36 (dd, J=10.9, 1.7 Hz, 1H), 2.65-2.60 (m, 1H), 2.25-2.14 (m, 1H), 1.49-1.39 (m, 2H), 1.20-1.14 (m, 1H).
Example 230
(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-37. MS (ESI): mass calcd. for C22H19F3N6O, 440.2. m/z found, 441.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.56-8.48 (m, 1H), 8.15 (d, J=8.0 Hz, 1H), 8.10 (s, 1H), 7.39 (t, J=4.9 Hz, 1H), 7.36-7.28 (m, 1H), 7.01 (s, 1H), 6.95 (s, 1H), 4.11-3.91 (m, 2H), 3.52 (dt, J=11.0, 3.3 Hz, 1H), 3.35 (dd, J=10.9, 1.6 Hz, 1H), 2.64 (s, 1H), 2.28-2.16 (m, 1H), 1.56-1.44 (m, 1H), 1.41-1.16 (m, 2H).
Example 231
(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-34. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.82 (s, 2H), 8.58-8.47 (m, 1H), 8.15 (d, J=7.8 Hz, 1H), 8.13-8.04 (m, 1H), 7.32 (t, J=7.6 Hz, 1H), 7.10-6.83 (m, 2H), 4.12-4.03 (m, 1H), 4.04-3.89 (m, 1H), 3.56 (dt, J=10.9, 3.3 Hz, 1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.70-2.62 (m, 1H), 2.29-2.17 (m, 1H), 1.61-1.14 (m, 3H).
Example 232
(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-50. MS (ESI): mass calcd. for C21H17F4N5O2, 447.1. m/z found, 447.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.15 min (major rotamer) at 254 nm.
Example 233
(3-ethoxy-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-8. MS (ESI): mass calcd. for C20H22F3N5O2, 421.2. m/z found, 422.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.47 (d, J=3.2 Hz, 1H), 8.11 (d, J=3.1 Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), 7.06 (d, J=8.9 Hz, 1H), 4.47-4.42 (m, 1H), 4.08-3.95 (m, 3H), 3.60 (dt, J=11.1, 3.2 Hz, 1H), 3.38 (dd, J=11.1, 1.6 Hz, 1H), 2.77-2.69 (m, 1H), 2.36-2.28 (m, 1H), 2.26 (s, 3H), 1.92-1.87 (m, 1H), 1.83-1.78 (m, 1H), 1.42-1.35 (m, 4H).
Example 234
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (305 mg, 1.44 mmol) in DMF (6 mL) was added 2,5-dichloropyrimidine (257 mg, 1.72 mmol) and DIPEA (0.99 mL, 5.75 mmol), and the reaction mixture was sealed and heated to 80° C. bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H2O. The reaction mixture was extracted with EtOAc (3×). The combined organics were washed with 5% aqueous LiCl, dried (Na2SO4), filtered, and concentrated. The concentrate was subjected directly to silica gel chromatography (10-90% EtOAc in hexanes) to give the title compound of step A (433 mg, 1.33 mmol, 93%). MS (ESI) mass calcd. for C15H21ClN4O2; 324.1. m/z found 269.1 [M+2H-tBu]+.
Step B: (1S,4R,6R)—N-(5-chloropyrimidin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (433 mg, 1.33 mmol) in EtOAc (7 mL) was added 4M HCl in dioxane (2 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (370 mg), which was used without further purification. MS (ESI) mass calcd. for C10H13ClN4, 224.1. m/z found 225.1 [M+H]+.
Step C: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-16 (25 mg, 0.12 mmol) in DMF (1 mL) was added DIPEA (0.10 mL, 0.61 mmol) and HATU (42 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (32 mg). MS (ESI): mass calcd. for C19H12ClFN2O, 413.1. m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.35-8.20 (m, 1H), 8.00 (s, 2H), 7.94-7.82 (m, 1H), 7.33-7.24 (m, 1H), 7.08-7.00 (m, 1H), 6.88 (d, J=7.7 Hz, 1H), 4.01 (s, 1H), 3.98-3.92 (m, 1H), 3.27 (dd, J=11.1, 1.6 Hz, 1H), 3.18 (dt, J=10.8, 3.0 Hz, 1H), 2.55-2.48 (m, 1H), 2.22-2.12 (m, 1H), 1.52 (d, J=10.3 Hz, 1H), 1.30-1.22 (m, 1H), 1.18-1.10 (m, 1H).
Example 235
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-10. MS (ESI): mass calcd. for C19H17ClFN7O, 413.1. m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 8.25 (s, 1H), 8.14-8.01 (m, 1H), 7.95 (s, 2H), 7.85 (dd, J=9.0, 4.8 Hz, 1H), 7.17 (ddd, J=9.0, 7.8, 2.9 Hz, 1H), 6.84-6.75 (m, 1H), 3.98-3.86 (m, 1H), 3.85-3.75 (m, 1H), 3.44-3.38 (m, 1H), 3.36-3.32 (m, 1H), 2.63-2.54 (m, 1H), 2.23-2.12 (m, 1H), 1.49-1.41 (m, 1H), 1.34-1.20 (m, 2H).
Example 236
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-2. MS (ESI): mass calcd. for C21H18ClFN6O, 424.1. m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d, J=5.0 Hz, 2H), 8.35-8.15 (m, 1H), 8.02-7.85 (m, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.20-7.12 (m, 1H), 7.10-7.01 (m, 1H), 6.88 (d, J=7.9 Hz, 1H), 4.14 (s, 1H), 4.05-3.95 (m, 1H), 3.26-3.21 (m, 1H), 2.56-2.48 (m, 1H), 2.24-2.12 (m, 1H), 1.52 (d, J=9.5 Hz, 1H), 1.31-1.18 (m, 1H), 1.03 (d, J=10.1 Hz, 1H). 1H buried under solvent.
Example 237
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-23. MS (ESI): mass calcd. for C21H18ClFN6O, 424.1. m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.87 (d, J=4.9 Hz, 2H), 8.34-8.19 (m, 1H), 8.03-7.76 (m, 2H), 7.41 (t, J=4.9 Hz, 1H), 7.10-6.98 (m, 1H), 6.80-6.67 (m, 1H), 4.01-3.85 (m, 2H), 3.51 (dt, J=11.0, 3.2 Hz, 1H), 3.37-3.31 (m, 1H), 2.62 (s, 1H), 2.25-2.14 (m, 1H), 1.47 (d, J=9.9 Hz, 1H), 1.37-1.20 (m, 2H).
Example 238
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-7. MS (ESI): mass calcd. for C21H18ClFN6O, 424.1. m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.84 (d, J=4.8 Hz, 2H), 8.29-8.19 (m, 2H), 7.86 (br. s, 1H), 7.38 (t, J=4.9 Hz, 1H), 7.11 (td, J=8.5, 2.7 Hz, 1H), 6.79-6.70 (m, 1H), 3.98-3.88 (m, 2H), 3.50 (dt, J=10.9, 3.2 Hz, 1H), 3.34 (dd, J=11.0, 1.7 Hz, 1H), 2.64-2.59 (m, 1H), 2.24-2.15 (m, 1H), 1.47 (d, J=10.0 Hz, 1H), 1.35-1.19 (m, 2H).
Example 239
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-6. MS (ESI): mass calcd. for C21H18ClFN6O, 424.1. m/z found, 425.1 [M+H]+. Analytical HPLC using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). Rt=1.85 and 2.12 min (major rotamers) at 254 nm.
Example 240
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-37. MS (ESI): mass calcd. for C21H19ClN6O, 406.1. m/z found, 407.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 8.29-8.18 (m, 1H), 8.14 (dt, J=8.0, 0.9 Hz, 1H), 7.92-7.70 (m, 1H), 7.42-7.35 (m, 2H), 7.07-6.92 (m, 2H), 4.10-3.86 (m, 2H), 3.50 (dt, J=10.8, 3.3 Hz, 1H), 3.35-3.32 (m, 1H), 2.65-2.59 (m, 1H), 2.27-2.13 (m, 1H), 1.54-1.43 (m, 1H), 1.36-1.19 (m, 2H).
Example 241
((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-34. MS (ESI): mass calcd. for C21H18ClFN6O, 424.1. m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.81 (s, 2H), 8.38-8.17 (m, 1H), 8.17-8.13 (m, 1H), 7.93-7.75 (m, 1H), 7.44-7.32 (m, 1H), 7.11-6.91 (m, 2H), 4.06-3.86 (m, 2H), 3.54 (dt, J=10.8, 3.3 Hz, 1H), 3.34 (dd, J=11.0, 1.7 Hz, 1H), 2.71-2.61 (m, 1H), 2.29-2.15 (m, 1H), 1.59-1.46 (m, 1H), 1.45-1.27 (m, 2H).
Example 242
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a vial containing intermediate B-10 (100 mg, 0.471 mmol) in MeCN (2 mL) was added 3-chloro-6-(trifluoromethyl)pyridazine (103 mg, 0.565 mmol) and Et3N (0.15 mL, 1.1 mmol), and the reaction mixture was sealed and heated to 90° C. bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (143 mg), which contained a small amount of impurity. The title compound was carried forward as is to the next step. MS (ESI) mass calcd. for C16H21F3N4O2; 358.2, m/z found 359.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 7.45-7.33 (m, 1H), 6.71-6.56 (m, 1H), 6.12 and 5.60 (2 br. s, 1H), 4.53-4.21 (m, 2H), 3.44-3.29 (m, 1H), 3.13-3.01 (m, 1H), 2.63-2.56 (m, 1H), 2.50-2.28 (m, 1H), 1.77-1.06 (m, 12H).
Step B: (1S,4R,6R)—N-(6-(trifluoromethyl)pyridazin-3-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (143 mg, 0.399 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL), and the reaction mixture was stirred at room temperature for 1.5 h. The reaction was concentrated to give the title compound of step B (130 mg), which was used without further purification. MS (ESI) mass calcd. for C11H13F3N4, 258.1. m/z found 259.2 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (33 mg) and intermediate A-1 (21 mg, 0.11 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (42 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (26 mg). MS (ESI): mass calcd. for C20H18F3N2O, 429.2. m/z found, 430.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=5.48 min (major rotamer) at 254 nm.
Example 243
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 242 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C20H19F3N8O, 444.2. m/z found, 445.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 8.18 (d, J=8.4 Hz, 1H), 7.86 (s, 2H), 7.36 (d, J=9.3 Hz, 1H), 7.33 (d, J=8.3 Hz, 1H), 6.73 (d, J=9.3 Hz, 1H), 4.34-4.29 (m, 1H), 3.72 (dt, J=11.0, 3.2 Hz, 1H), 3.32 (dd, J=11.0, 1.6 Hz, 1H), 2.84-2.76 (m, 1H), 2.62-2.44 (m, 5H), 2.01-1.92 (m, 1H), 1.78-1.69 (m, 1H), 1.26 (dt, J=13.4, 3.4 Hz, 1H).
Example 244
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 242 substituting intermediate A-1 with intermediate A-41. MS (ESI): mass calcd. for C22H20F3N7O, 455.2. m/z found, 456.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.79 (d, J=4.8 Hz, 2H), 8.48 (d, J=8.1 Hz, 1H), 8.16-7.96 (m, 1H), 7.37 (d, J=9.3 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.26-7.23 (m, 1H), 6.77 (d, J=9.2 Hz, 1H), 4.27 (s, 1H), 3.74 (dt, J=10.9, 3.2 Hz, 1H), 3.33 (dd, J=10.8, 1.6 Hz, 1H), 2.86-2.77 (m, 1H), 2.64-2.49 (m, 5H), 2.03-1.90 (m, 1H), 1.73 (d, J=10.1 Hz, 1H), 1.27 (dt, J=13.2, 3.5 Hz, 1H).
Example 245
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 242 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C22H18F4N6O, 458.1. m/z found, 459.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.90 (d, J=4.9 Hz, 2H), 7.39 (t, J=5.0 Hz, 1H), 7.32-7.22 (m, 2H), 7.22-7.16 (m, 1H), 7.11-7.06 (m, 1H), 6.47 (d, J=9.3 Hz, 1H), 4.67 (s, 1H), 3.55 (dt, J=11.1, 3.2 Hz, 1H), 3.26 (dd, J=11.0, 1.5 Hz, 1H), 2.79-2.69 (m, 1H), 2.54-2.42 (m, 1H), 1.95-1.72 (m, 2H), 1.69-1.61 (m, 1H), 1.20-1.07 (m, 1H).
Example 246
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (2 mL) was added 5-bromo-2-(trifluoromethyl)pyridine (116 mg, 0.514 mmol), intermediate B-10 (120 mg) and racemic BINAP (13 mg, 0.021 mmol) at room temperature and the reaction mixture was purged with N2 for 5 min. Then, Pd(OAc)2 (14 mg, 0.021 mmol) and sodium tert-butoxide (71 mg, 0.72 mmol) were added and the reaction mixture heated to 70° C. overnight. Upon completion of the reaction, the mixture was cooled to room temperature and the crude material subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (184 mg). MS (ESI) mass calcd. for C12H22F3N3O2, 357.2. m/z found 358.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 8.02 and 7.90 (two s, 1H), 7.46-7.35 (m, 1H), 6.88-6.81 and 6.77-6.68 (two m, 1H), 5.39-5.29 and 4.72-4.62 (two m, 1H), 4.47-4.33 (m, 1H), 3.87-3.72 (m, 1H), 3.41-3.31 (m, 1H), 3.11-2.99 (m, 1H), 2.64-2.56 (m, 1H), 2.37-2.17 (m, 1H), 1.81-1.67 (m, 1H), 1.66-1.60 (m, 1H), 1.53-1.01 (m, 11H).
Step B: (1S,4R,6R)—N-(6-(trifluoromethyl)pyridin-3-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. To the title compound of step A (77 mg, 0.22 mmol) in EtOAc (0.6 mL) was added 4M HCl in dioxane (3 mL), and the reaction mixture was stirred at room temperature for 2.5 h. The reaction was concentrated to give the title compound of step B (72 mg), which was used without further purification. MS (ESI) mass calcd. for C12H14F3N3, 257.1. m/z found 258.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (36 mg) and intermediate A-1 (25 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.2 mL, 1.2 mmol) and HATU (46 mg, 0.12 mmol), and the reaction mixture was stirred at room temperature for 1.5 h. The reaction was quenched by the addition of H2O and the aqueous layer was extracted with EtOAc (2×). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (29 mg). MS (ESI): mass calcd. for C21H19F3N6O, 428.2. m/z found, 429.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.07 min (major rotamer) at 254 nm.
Example 247
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 246 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H19F4N5O, 457.2. m/z found, 458.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d, J=5.0 Hz, 2H), 7.87 (d, J=2.7 Hz, 1H), 7.50 (t, J=5.0 Hz, 1H), 7.31 (d, J=8.7 Hz, 1H), 7.06-6.99 (m, 1H), 6.87-6.80 (m, 2H), 6.73 (dd, J=8.7, 2.8 Hz, 1H), 4.11 (s, 1H), 3.80-3.71 (m, 1H), 3.28-3.22 (m, 2H), 2.60-2.52 (m, 1H), 2.34-2.25 (m, 1H), 1.59 (d, J=10.8 Hz, 1H), 1.24-1.18 (m, 1H), 1.11 (d, J=10.3 Hz, 1H).
Example 248
(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5A (50 mg, 0.22 mmol) dissolved in DMF (2 mL) was added NaH (18 mg, 0.44 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyridine (64 mg, 0.35 mmol) was then added and the mixture stirred at room temperature for 3 h. The reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (67 mg, 0.18 mmol, 82%). MS (ESI) mass calcd. for C18H23F3N2O3, 372.2. m/z found 373.2 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, (0.68:0.32), major rotamer reported) δ 8.49-8.45 (m, 1H), 7.94 (dd, J=8.8, 2.6 Hz, 1H), 6.90 (d, J=8.7, 0.8 Hz, 1H), 5.22 (dt, J=9.7, 2.9 Hz, 1H), 4.48-4.41 (m, 1H), 3.42 (dt, J=10.9, 2.5 Hz, 1H), 3.25 (dt, J=11.0, 2.6 Hz, 1H), 2.27-2.18 (m, 1H), 2.09-2.04 (m, 1H), 1.97-1.87 (m, 1H), 1.77-1.71 (m, 1H), 1.68-1.59 (m, 3H), 1.13 (s, 9H).
Step B: (R/S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (67 mg, 0.18 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.23 mL). After 3 h, the reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C13H15F3N2O, 272.1. m/z found 273.1 [M+H]+.
Step C: (R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (46 mg) and intermediate A-2 (54 mg, 0.20 mmol, 82% purity) in DMF (1.7 mL) was added DIPEA (0.18 mL, 1.01 mmol) and HATU (71 mg, 0.19 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with H2O and EtOAc. The aqueous layer was extracted with EtOAc (3×) and the combined organics were concentrated and subjected directly to purification using Gilson Prep Method X to give the title compound (20 mg). MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 473.1 [M+H]+. Analytical HPLC using a XBridge C18 column (5 um, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). Rt=2.18 and 2.29 min (major rotamers) at 254 nm Enantiomers of Example 248 can be separated by Chiral SFC purification using a Chiralpak AZ-H column (5 μm 250×21 mm), mobile phase of 35% EtOH+(0.2% TEA): 65% CO2, and a flow rate of 40 mL/min (Temperature=40° C.).
Example 249
(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 248 substituting intermediate A-2 with intermediate A-16. MS (ESI): mass calcd. for C22H19F4N5O2, 461.2. m/z found, 461.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound present as a mixture of rotamers, major rotamer reported) δ 8.25 (s, 1H), 8.11-7.95 (m, 3H), 7.27 (t, J=9.3 Hz, 1H), 7.14-7.00 (m, 2H), 6.91 (d, J=7.8 Hz, 1H), 5.14-5.06 (m, 1H), 3.82 (s, 1H), 3.60 (d, J=12.8 Hz, 1H), 3.24 (d, J=12.7 Hz, 1H), 2.34-2.24 (m, 1H), 2.11 (s, 1H), 1.81-1.41 (series of m, 5H).
Example 250
(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 248 substituting intermediate A-2 with intermediate A-23. MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 472.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound is present as a mixture of rotamers) δ 8.96-8.78 (m, 2H), 8.22-8.14 (m, 1H), 8.04-7.97 (m, 1H), 7.92 (dd, J=10.1, 2.6 Hz, 1H), 7.49-7.42 (m, 1H), 7.10-6.88 (m, 2H), 6.76-6.58 (m, 1H), 5.05-4.98 (m, 1H), 3.85-3.73 (m, 1H), 3.69 (d, J=12.3 Hz, 1H), 3.55-3.48 (m, 1H), 2.33-2.24 (m, 1H), 2.21-2.07 (m, 1H), 1.86-1.77 (m, 1H), 1.74-1.37 (m, 3H), 1.27-1.14 (m, 1H).
Example 251
(R/S)-(2-(5-fluoropyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 248 substituting intermediate A-2 with intermediate A-34. MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 472.9 [M+H]+. 1H NMR (500 MHz, Methanol-d4, Compound is present as a mixture of rotamers) δ 8.87-8.74 (m, 2H), 8.20-8.12 (m, 2H), 8.05-7.93 (m, 1H), 7.65-7.55 (m, 1H), 7.38-7.30 (m, 1H), 7.09-6.86 (m, 2H), 5.13-5.02 (m, 1H), 3.84-3.76 (m, 1H), 3.71-3.64 (m, 1H), 3.60-3.51 (m, 1H), 2.35-2.26 (m, 1H), 2.22-2.13 (m, 1H), 1.87-1.76 (m, 1H), 1.73-1.29 (m, 4H).
Example 252
(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octane-2-carboxylate. To a microwave vial containing C-7A (308 mg, 1.36 mmol) in MeCN (5 mL) was added 2-chloro-5-(trifluoromethyl)pyrazine (0.20 mL, 1.63 mmol) and Et3N (0.28 mL, 2.04 mmol), and the reaction mixture was sealed and heated to 70° C. bench top overnight. Analysis of the reaction mixture still showed unreacted starting material. Additional equivalents of 2-chloro-5-(trifluoromethyl)pyrazine (0.20 mL, 1.63 mmol) and Et3N (0.28 mL, 2.04 mmol) were added, and the reaction mixture was heated again to 70° C. bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H2O. The reaction mixture was extracted with EtOAc (3×). The combined organics were concentrated and the concentrate subjected directly to silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound of step A (245 mg, 0.658 mmol, 48%) MS (ESI) mass calcd. for C17H23F3N4O2; 372.2. m/z found 371.1 [M+2H-tBu]+.
Step B: (R/S)—N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.2]octan-6-amine.xHCl. To the title compound of step A (245 mg, 0.658 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL), and the reaction mixture was stirred at room temperature for 3 h. The reaction was concentrated to give the title compound of step B (249 mg), which was used without further purification. MS (ESI) mass calcd. for C12H15F3N4, 272.1. m/z found 273.0 [M+H]+.
Step C: (R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (50 mg) and intermediate A-40 (36 mg, 0.18 mmol) in DMF (0.5 mL) was added DIPEA (0.15 mL, 0.87 mmol) and HATU (68 mg, 0.18 mmol), and the reaction mixture was stirred at room temperature for 3 h. The reaction was diluted with MeOH and the crude reaction mixture subjected directly to purification via Agilent Prep Method X to give the title compound (25 mg). MS (ESI): mass calcd. for C21H21F3N8O, 458.2. m/z found, 458.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.45 min (major rotamer) at 254 nm.
Example 253
(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 252, isolated from Step C during HPLC purification. MS (ESI): mass calcd. for C21H21F3N8O, 458.2. m/z found, 459.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.26 min (major rotamer) at 254 nm.
Example 254
(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-1. MS (ESI): mass calcd. for C21H20F3N7O, 443.2. m/z found, 443.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.65 min (major rotamer) at 254 nm.
Example 255
(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-16. MS (ESI): mass calcd. for C21H19F4N7O, 461.2. m/z found, 461.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.65 min (major rotamer) at 254 nm.
Example 256
(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-22. MS (ESI): mass calcd. for C22H22F3N7O, 457.2. m/z found, 458.0 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.96 min (major rotamer) at 254 nm.
Example 257
(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-2. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 472.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.49 min (major rotamer) at 254 nm.
Example 258
(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-23. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 472.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.57 min (major rotamer) at 254 nm.
Example 259
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-23. MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.28 min (major rotamer) at 254 nm.
Example 260
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-7. MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.59 min (major rotamer) at 254 nm.
Example 261
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-6. MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.41 min (major rotamer) at 254 nm.
Example 262
(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-34. MS (ESI): mass calcd. for C24H20F4N4O2, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.83 min (major rotamer) at 254 nm.
Example 263
(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-35. MS (ESI): mass calcd. for C24H19F5N4O2, 490.1. m/z found, 491.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.78 min (major rotamer) at 254 nm.
Example 264
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-47. MS (ESI): mass calcd. for C24H22F3N5O2, 469.2. m/z found, 470.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.999 min (major rotamer) at 254 nm.
Example 265
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-41. MS (ESI): mass calcd. for C24H22F3N5O2, 469.2. m/z found, 470.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.73 min (major rotamer) at 254 nm.
Example 266
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (52 mg, 0.23 mmol) dissolved in DMF (2 mL) was added NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil). After 5 minutes 2,3-difluoro-5-(trifluoromethyl)pyridine (63 mg, 0.34 mmol) was then added and the mixture stirred at room temperature for 1 h. The reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (67 mg, 0.17 mmol, 75%). MS (ESI) mass calcd. for C18H22F4N2O3, 390.2. m/z found 336.1 [M+2H-tBu]+.
Step B: (1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (67 mg, 0.17 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.22 mL), and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed mostly starting material. Additional 4 M HCl in dioxane (0.5 mL) was added and the reaction mixture stirred at room temperature for 5 h. The reaction mixture was then concentrated to give the title compound of step B (30 mg) which was used without further purification. MS (ESI) mass calcd. for C13H14F4N2O, 290.1. m/z found 291.1 [M+H]+.
Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (30 mg) and intermediate A-2 (27 mg, 0.12 mmol) in DMF (1 mL) was added DIPEA (0.11 mL, 0.62 mmol) and HATU (43 mg, 0.11 mmol). Upon completion of the reaction, purification was performed using Agilent Prep Method X to give the title compound (11 mg). MS (ESI): mass calcd. for C24H19F5N4O2, 490.2. m/z found, 491.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.35 min (major rotamer) at 254 nm.
Example 267
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) was added NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-methylpyridine (0.03 mL, 0.26 mmol) was then added and the mixture stirred at room temperature for 2 h. Analysis of the reaction mixture showed only starting material was present. The reaction mixture was heated to 70° C. overnight. Analysis of the reaction mixture showed small amount of product formation. Additional NaH was added and the reaction mixture heated to 70° C. over the weekend. The reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (8 mg, 0.03 mmol, 15%). MS (ESI) mass calcd. for C18H26N2O3, 318.2. m/z found 319.2 [M+H]+.
Step B: (1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (8 mg, 0.03 mmol) in EtOAc (0.3 mL) was added 4 M HCl in dioxane (0.03 mL) and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material still remained. Additional 4 M HCl in dioxane (0.25 mL) was added and the reaction mixture stirred at room temperature for 5 h. The reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C13H18N2O, 218.1. m/z found 219.2 [M+H]+.
Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (5 mg) and intermediate A-2 (6 mg, 0.03 mmol) in DMF (0.3 mL) was added DIPEA (0.02 mL, 0.14 mmol) and HATU (10 mg, 0.03 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with MeOH and the crude reaction mixture directly subjected to purification using Agilent Prep Method X to give the title compound (1 mg). MS (ESI): mass calcd. for C24H23FN4O2, 418.2. m/z found, 419.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.35 min (major rotamer) at 254 nm.
Example 268
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) was added NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5 minutes 5-bromo-2-fluoropyridine (0.03 mL, 0.26 mmol) was then added and the mixture stirred at room temperature for 2 h. The reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (63 mg, 0.16 mmol, 100%). MS (ESI) mass calcd. for C12H23BrN2O3, 382.1. m/z found 383.1 [M+H]+.
Step B: (1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (63 mg, 0.16 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.21 mL) and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material still remained. Additional 4 M HCl in dioxane (0.21 mL) was added and the reaction mixture stirred at room temperature for 5 h. The reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C12H15BrN2O, 282.0. m/z found 283.0 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (23 mg) and intermediate A-1 (47 mg, 0.25 mmol) in DMF (0.8 mL) was added DIPEA (0.08 mL, 0.49 mmol) and HATU (34 mg, 0.09 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with MeOH and the crude reaction mixture directly subjected to purification using Agilent Prep Method X to give the title compound (7.7 mg). MS (ESI): mass calcd. for C21H20BrN5O2, 453.1. m/z found, 454.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.51 min (major rotamer) at 254 nm.
Example 269
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 268 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H20BrFN4O2, 482.1. m/z found, 483.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.10 min (major rotamer) at 254 nm.
Example 270
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) was added NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5 minutes 5-chloro-2-fluoropyridine (0.03 mL, 0.26 mmol) was then added and the mixture stirred at room temperature for 1.5 h. The reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered and concentrated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (52 mg, 0.15 mmol, 94%). MS (ESI) mass calcd. for C12H23ClN2O3, 338.1. m/z found 339.2 [M+H]+.
Step B: (1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (52 mg, 0.15 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.19 mL) and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C12H15ClN2O, 238.1. m/z found 239.1 [M+H]+.
Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (18 mg) and intermediate A-1 (44 mg, 0.23 mmol) in DMF (0.8 mL) was added DIPEA (0.08 mL, 0.45 mmol) and HATU (44 mg, 0.23 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with MeOH and the crude reaction mixture directly subjected to purification using Agilent Prep Method X to give the title compound (16 mg). MS (ESI): mass calcd. for C21H20ClN5O2, 409.1. m/z found, 410.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.35 min (major rotamer) at 254 nm.
Example 271
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 270 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C23H20ClFN4O2, 438.1. m/z found, 439.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.94 min (major rotamer) at 254 nm.
Example 272
(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-34. MS (ESI): mass calcd. for C23H19F4N5O2, 473.1. m/z found, 474.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.16 min (major rotamer) at 254 nm.
Example 273
(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-35. MS (ESI): mass calcd. for C23H18F5N5O2, 491.1. m/z found, 492.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.29 min (major rotamer) at 254 nm.
Example 274
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-16. MS (ESI): mass calcd. for C21H19F4N7O, 461.2. m/z found, 462.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.71 min (major rotamer) at 254 nm.
Example 275
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-1. MS (ESI): mass calcd. for C21H20F3N7O, 443.2. m/z found, 444.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.67 min (major rotamer) at 254 nm.
Example 276
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-2 (step C), and substituting intermediate C-7B with its enantiomer (step A), (1R,4S,6S)-tert-butyl 6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 472.9 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.39 min (major rotamer) at 254 nm.
Example 277
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-23. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.62 min (major rotamer) at 254 nm.
Example 278
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-7. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.44 min (major rotamer) at 254 nm.
Example 279
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-6. MS (ESI): mass calcd. for C23H20F4N6O, 472.2. m/z found, 473.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.27 min (major rotamer) and 6.95 at 254 nm.
Example 280
(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-37. MS (ESI): mass calcd. for C23H21F3N6O, 454.2. m/z found, 455.4 [M+H]+. Analytical HPLC using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). Rt=2.01 and 1.98 min (major rotamer) at 254 nm.
Example 281
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (100 mg, 0.44 mmol) dissolved in DMF (4 mL) was added NaH (35 mg, 0.88 mmol, 60% dispersion in mineral oil). After 5 minutes 3-chloro-2-fluoro-5-(trifluoromethyl)pyridine (86 μL, 0.66 mmol) was then added and the mixture stirred at room temperature over the weekend. Analysis of the reaction mixture showed mostly starting material. Additional NaH was added. Analysis still showed incomplete conversion, however the reaction mixture was quenched with saturated NH4Cl solution, and diluted with EtOAc and H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, brine, dried with MgSO4, filtered, and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (38 mg, 0.093 mmol, 21%). MS (ESI) mass calcd. for C18H22ClF3N2O3, 406.1. m/z found 351.1 [M+2H-tBu]+.
Step B: (1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl. To the title compound of step A (38 mg, 0.093 mmol) in EtOAc (1.2 mL) was added 4 M HCl in dioxane (0.12 mL), and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material was still present. Additional 4 M HCl in dioxane (0.12 mL) was added and the reaction mixture stirred at room temperature overnight. The reaction mixture was then concentrated to give the title compound of step B (29 mg) which was used without further purification. MS (ESI) mass calcd. for C13H14ClF3N2O, 306.1. m/z found 307.1 [M+H]+.
Step C: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone. To the title compound of step B (27 mg) and intermediate A-2 (23 mg, 0.11 mmol) in DMF (0.9 mL) was added DIPEA (0.09 mL, 0.53 mmol) and HATU (37 mg, 0.097 mmol), and the reaction mixture was stirred overnight at room temperature. The crude reaction mixture was diluted with MeOH, syringe filtered, and subjected directly to purification using Agilent Prep Method X to give the title compound (11 mg). MS (ESI): mass calcd. for C24H19ClF4N4O2, 506.1. m/z found, 507.1 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.87 min (major rotamer) at 254 nm.
Example 282
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-47. MS (ESI): mass calcd. for C23H21F3N6O2, 470.2. m/z found, 471.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=6.77 min (major rotamer) at 254 nm.
Example 283
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 266 substituting intermediate A-2 with intermediate A-47. MS (ESI): mass calcd. for C24H21F4N5O2, 487.2. m/z found, 488.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.). Rt=7.38 min (major rotamer) at 254 nm.
Example 284
((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) and 2,5-dichloropyrimidine (225 mg, 1.51 mmol) dissolved in DMF (2 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 3 h LCMS analysis showed that the reaction was incomplete and additional NaH (40 mg, 1.0 mmol, 60% dispersion in mineral oil) was added and the reaction mixture allowed to stir for an additional 45 min and then quenched with H2O. The aqueous layer was extracted with EtOAc (3×). The combined organics were washed with H2O, 5% aqueous LiCl, dried with MgSO4, filtered, and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (211 mg, 0.65 mmol, 92%) as a colorless solid. MS (ESI) mass calcd. for C15H20ClN3O3, 325.1. m/z found 370.1 [M+2H-tBu]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers, both rotamers reported) δ 8.44 and 8.39 (two s, 2H), 5.25-5.16 (m, 1H), 4.68-4.65 and 4.56-4.52 (two m, 1H), 3.42-3.37 and 3.35-3.31 (two m, 1H), 3.24-3.16 (m, 1H), 2.61-2.51 (m, 1H), 2.24-2.13 (m, 1H), 1.77-1.40 (m, 3H), 1.35 and 1.12 (2s, 9H).
Step B: (1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl. To the title compound of step A (211 mg, 0.65 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 1.5 h. Then, the reaction was concentrated to give the title compound of step B (155 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for C10H12ClN3O, 225.1. m/z found 226.1 [M+H]+.
Step C: ((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-2 (27 mg, 0.13 mmol) in DMF (0.4 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 2 h. The reaction was diluted with MeOH, filtered, and purified using Agilent Prep Method X to give the title compound (27 mg). MS (ESI): mass calcd. for C21H17ClFN5O2, 425.1. m/z found, 426.1 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.72:0.28), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 8.29 (s, 2H), 7.29-7.26 (m, 1H), 7.12-6.97 (m, 3H), 4.95 (dt, J=10.1, 3.3 Hz, 1H), 4.32-4.20 (m, 1H), 3.39-3.31 (m, 2H), 2.63-2.47 (m, 1H), 2.26-2.15 (m, 1H), 1.50-1.39 (m, 2H), 1.07-0.97 (m, 1H).
Example 285
((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 284 substituting intermediate A-2 with intermediate A-41. MS (ESI): mass calcd. for C21H19ClN6O2, 422.1. m/z found, 423.2 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.63:0.37), major rotamer reported) δ 8.76 (d, J=4.8 Hz, 2H), 8.43-8.41 (m, 1H), 8.11 (s, 2H), 7.19 (t, J=4.9 Hz, 1H), 7.12 (d, J=7.9 Hz, 1H), 4.79 (dt, J=10.3, 3.2 Hz, 1H), 4.48-4.39 (m, 1H), 3.78 (dt, J=10.8, 3.0 Hz, 1H), 3.46 (dd, J=10.9, 1.4 Hz, 1H), 2.72-2.64 (m, 1H), 2.30 (s, 3H), 2.26-2.18 (m, 1H), 1.67 (dt, J=13.5, 3.6 Hz, 1H), 1.56-1.45 (m, 2H).
Example 286
((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 287 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C23H21N7O2, 427.2. m/z found, 428.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.86 (dd, J=4.4, 2.0 Hz, 1H), 8.06 (dd, J=7.9, 2.0 Hz, 1H), 7.92 (d, J=8.7 Hz, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.81 (s, 2H), 7.33 (dd, J=7.9, 4.4 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.4 Hz, 1H), 5.39 (dt, J=9.9, 3.1 Hz, 1H), 4.54-4.43 (m, 1H), 3.71 (dt, J=11.0, 3.2 Hz, 1H), 3.49 (d, J=11.0 Hz, 1H), 2.69-2.66 (m, 1H), 2.39-2.23 (m, 1H), 2.03 (s, 3H), 1.58-1.50 (m, 3H).
Example 287
((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) and 2-chloro-1,8-naphthyridine (225 mg, 1.37 mmol) dissolved in DMF (2 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 50 min the mixture was quenched with H2O and the aqueous layer was extracted with EtOAc (3×). The combined organics were washed with 5% aqueous LiCl, brine, dried with MgSO4, filtered, and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (200 mg) as a colorless solid. MS (ESI) mass calcd. for C19H23N3O3, 341.2. m/z found 342.2 [M+H]+.
Step B: 2-((1S,4R,6R)-2-azabicyclo[2.2.1]heptan-6-yloxy)-1,8-naphthyridine.xHCl. To the title compound of step A (200 mg, 0.59 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 2 h. Then, the reaction was concentrated to give the title compound of step B (192 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for C14H15N3O3, 241.1. m/z found 242.1 [M+H]+.
Step C: ((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-1,2,3-triazol-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-1 (20 mg, 0.11 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (40 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with MeOH, filtered, and purified using Agilent Prep Method X to give the title compound (22 mg). MS (ESI): mass calcd. for C23H20N6O2, 412.2. m/z found, 413.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.87 (dd, J=4.4, 2.0 Hz, 1H), 8.11 (dd, J=7.9, 2.0 Hz, 1H), 8.05 (d, J=8.8 Hz, 1H), 7.82-7.74 (m, 3H), 7.35 (dd, J=7.9, 4.4 Hz, 1H), 7.10 (dd, J=7.7, 1.5 Hz, 1H), 7.03 (d, J=8.7 Hz, 1H), 7.00-6.92 (m, 1H), 6.54 (t, J=7.6 Hz, 1H), 5.44 (dt, J=10.2, 3.2 Hz, 1H), 4.28-4.19 (m, 1H), 3.65 (dt, J=10.9, 3.2 Hz, 1H), 3.43 (d, J=9.5 Hz, 1H), 2.72-2.62 (m, 1H), 2.45-2.31 (m, 1H), 1.52-1.42 (m, 3H).
Example 288
((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 121 substituting intermediate A-1 with intermediate A-47. MS (ESI): mass calcd. for C23H21F2N5O2, 437.2. m/z found, 438.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.77 (d, J=4.9 Hz, 2H), 8.28-8.19 (m, 1H), 7.83-7.77 (m, 1H), 7.69 (dd, J=8.7, 2.4 Hz, 1H), 7.66-7.64 (m, 1H), 7.21 (t, J=4.9 Hz, 1H), 6.91 (d, J=8.6 Hz, 1H), 6.59 (t, J=56.1 Hz, 1H), 5.02 (dt, J=10.3, 3.4 Hz, 1H), 4.33-4.21 (m, 1H), 3.70 (dt, J=10.8, 3.2 Hz, 1H), 3.46 (dd, J=10.7, 1.4 Hz, 1H), 2.72-2.63 (m, 1H), 2.26 (s, 3H), 2.23-2.16 (m, 1H), 1.61-1.35 (m, 3H).
Example 289
(2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-13. MS (ESI): mass calcd. for C22H20F3N5O3, 459.2. m/z found, 460.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=45° C.). Rt=6.84 min (major rotamer) at 254 nm.
Example 290
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-46. MS (ESI): mass calcd. for C23H20F3N5O2, 455.2. m/z found, 456.4 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.87 (d, J=4.8 Hz, 2H), 8.47 (dd, J=2.1, 0.8 Hz, 1H), 8.18-8.10 (m, 1H), 7.80 (dd, J=8.7, 2.5 Hz, 1H), 7.31-7.28 (m, 2H), 6.83-6.78 (m, 1H), 5.02 (dt, J=10.1, 3.3 Hz, 1H), 4.18-4.09 (m, 1H), 3.65 (dt, J=10.9, 3.2 Hz, 1H), 3.43 (dd, J=10.9, 1.5 Hz, 1H), 2.70-2.60 (m, 1H), 2.28-2.18 (m, 1H), 2.04 (s, 3H), 1.47-1.38 (m, 2H), 1.32-1.24 (m, 1H).
Example 291
(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-51. MS (ESI): mass calcd. for C22H18F4N4O3, 462.1. m/z found, 463.4 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 8.10-8.01 (m, 1H), 7.80 (dd, J=8.8, 2.5 Hz, 1H), 7.72 (dd, J=8.9, 2.6 Hz, 1H), 7.02 (dd, J=8.5, 5.4 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.76-6.68 (m, 1H), 5.06 (dt, J=10.1, 3.3 Hz, 1H), 4.14-4.08 (m, 1H), 3.77 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5 Hz, 1H), 2.76-2.71 (m, 1H), 2.45 (s, 3H), 2.35-2.22 (m, 1H), 1.73-1.66 (m, 1H), 1.59-1.55 (m, 1H), 1.46 (dt, J=13.6, 3.6 Hz, 1H).
Example 292
(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-50. MS (ESI): mass calcd. for C22H17F4N3O3, 447.1. m/z found, 448.5 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=45° C.). Rt=7.18 min (major rotamer) at 254 nm.
Example 293
(5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-49. MS (ESI): mass calcd. for C22H17F4N3O3, 447.1. m/z found, 448.5 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 8.05-8.02 (m, 1H), 7.92 (dd, J=8.7, 5.3 Hz, 1H), 7.80 (dd, J=8.6, 2.5 Hz, 1H), 7.69 (d, J=0.8 Hz, 1H), 7.21 (d, J=0.8 Hz, 1H), 6.99-6.92 (m, 1H), 6.81 (d, J=8.7 Hz, 1H), 6.69 (dd, J=8.4, 2.7 Hz, 1H), 5.03 (dt, J=10.2, 3.3 Hz, 1H), 4.16-4.08 (m, 1H), 3.74 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5 Hz, 1H), 2.74-2.63 (m, 1H), 2.30-2.21 (m, 1H), 1.63-1.56 (m, 1H), 1.55-1.49 (m, 1H), 1.45 (dt, J=13.5, 3.6 Hz, 1H).
Example 294
(5-methyl-3-(1H-1,2,3-triazol-1-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with the N-1 isomer, 5-methyl-3-(1H-1,2,3-triazol-1-yl)picolinonitrile, from intermediate A-19. MS (ESI): mass calcd. for C2H19F3N6O2, 444.2. m/z found, 445.6 [M+H]+. 1H NMR (500 MHz, Chloroform-d) δ 8.12 (d, J=1.1 Hz, 1H), 8.02-7.98 (m, 1H), 7.97-7.94 (m, 1H), 7.81 (d, J=1.1 Hz, 1H), 7.78-7.76 (m, 1H), 7.72 (dd, J=8.8, 2.5 Hz, 1H), 6.74-6.69 (m, 1H), 4.99 (dt, J=10.2, 3.3 Hz, 1H), 4.43-4.34 (m, 1H), 3.48 (dt, J=11.2, 3.1 Hz, 1H), 3.41 (dd, J=11.2, 1.5 Hz, 1H), 2.66-2.60 (m, 1H), 2.34 (s, 3H), 2.25-2.17 (m, 1H), 1.60-1.53 (m, 1H), 1.40 (dt, J=13.6, 3.6 Hz, 1H), 1.34-1.27 (m, 1H).
Example 295
(4-methoxy-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-15. MS (ESI): mass calcd. for C24H21F3N4O3, 470.2. m/z found, 471.4 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.78 (d, J=4.8 Hz, 2H), 8.14-8.06 (m, 1H), 7.79 (dd, J=8.7, 2.5 Hz, 1H), 7.70 (d, J=2.6 Hz, 1H), 7.19 (t, J=4.8 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.85-6.83 (m, 1H), 6.45 (dd, J=8.4, 2.6 Hz, 1H), 5.04 (dt, J=10.1, 3.4 Hz, 1H), 4.19-4.09 (m, 1H), 3.81 (s, 3H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.8, 1.5 Hz, 1H), 2.65-2.59 (m, 1H), 2.27-2.15 (m, 1H), 1.44-1.35 (m, 2H), 1.29-1.17 (m, 1H).
Example 296
(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-42. MS (ESI): mass calcd. for C22H18F3N5O2, 441.1. m/z found, 442.4 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.78 (d, J=4.8 Hz, 2H), 8.47 (dd, J=8.0, 1.7 Hz, 1H), 7.97-7.90 (m, 1H), 7.83 (dd, J=4.7, 1.7 Hz, 1H), 7.73 (dd, J=8.8, 2.6 Hz, 1H), 7.22 (t, J=4.9 Hz, 1H), 7.15 (dd, J=8.0, 4.7 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 5.04 (dt, J=10.2, 3.4 Hz, 1H), 4.35-4.20 (m, 1H), 3.73 (dt, J=10.8, 3.2 Hz, 1H), 3.47 (d, J=10.9 Hz, 1H), 2.72-2.65 (m, 1H), 2.30-2.13 (m, 1H), 1.60-1.44 (m, 3H).
Example 297
(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-37. MS (ESI): mass calcd. for C23H19F3N4O2, 440.1. m/z found, 441.4 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.78 (d, J=4.8 Hz, 2H), 8.17 (dd, J=8.0, 1.2 Hz, 1H), 8.06-8.00 (m, 1H), 7.78 (dd, J=8.7, 2.5 Hz, 1H), 7.30 (td, J=7.7, 1.4 Hz, 1H), 7.19 (t, J=4.8 Hz, 1H), 7.00 (dd, J=7.6, 1.3 Hz, 1H), 6.88 (td, J=7.5, 1.3 Hz, 1H), 6.83 (d, J=8.7 Hz, 1H), 5.01 (dt, J=10.2, 3.4 Hz, 1H), 4.24-4.10 (m, 1H), 3.64 (dt, J=10.9, 3.2 Hz, 1H), 3.41 (dd, J=10.8, 1.5 Hz, 1H), 2.66-2.61 (m, 1H), 2.27-2.12 (m, 1H), 1.47-1.37 (m, 2H), 1.34-1.19 (m, 1H).
Example 298
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-47. MS (ESI): mass calcd. for C23H20F3N5O2, 455.2. m/z found, 456.4 [M+H]+. 1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.78 (d, J=4.8 Hz, 2H), 8.27-8.21 (m, 1H), 7.95-7.92 (m, 1H), 7.74 (dd, J=8.4, 2.7 Hz, 1H), 7.65-7.62 (m, 1H), 7.22 (t, J=4.8 Hz, 1H), 6.95-6.90 (m, 1H), 5.03 (dt, J=10.3, 3.3 Hz, 1H), 4.32-4.27 (m, 1H), 3.71 (dt, J=10.9, 3.2 Hz, 1H), 3.46 (dd, J=10.8, 1.4 Hz, 1H), 2.72-2.64 (m, 1H), 2.26 (s, 3H), 2.25-2.18 (m, 1H), 1.59-1.45 (m, 3H).
Example 299
((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 284 substituting intermediate A-2 with intermediate A-40. MS (ESI): mass calcd. for C19H18ClN7O2, 411.1. m/z found, 412.3 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=45° C.). Rt=5.23 min (major rotamer) at 254 nm.
Example 300
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 284 substituting intermediate A-2 with intermediate A-1. MS (ESI): mass calcd. for C19H17ClN6O2, 396.1. m/z found, 397.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major reported) δ 8.22 (s, 2H), 7.88-7.85 (m, 1H), 7.81 (s, 2H), 7.40-7.31 (m, 1H), 7.17 (dd, J=7.7, 1.5 Hz, 1H), 6.90 (t, J=7.5 Hz, 1H), 4.87 (dt, J=10.2, 3.3 Hz, 1H), 4.10-3.98 (m, 1H), 3.63 (dt, J=10.9, 3.2 Hz, 1H), 3.42 (dd, J=10.9, 1.4 Hz, 1H), 2.66-2.60 (m, 1H), 2.29-2.12 (m, 1H), 1.54 (dt, J=13.6, 3.5 Hz, 1H), 1.42-1.33 (m, 2H).
Example 301
((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 287 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for C25H20FN5O2, 441.2. m/z found, 442.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=45° C.). Rt=4.68 min at 254 nm.
Example 302
((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 287 substituting intermediate A-1 with intermediate A-41. MS (ESI): mass calcd. for C25H22N6O2, 438.2. m/z found, 439.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=45° C.). Rt=4.33 min (major rotamer) at 254 nm.
Example 303
(2-(pyridazin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 304
(2-(pyridazin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 305
(2-(pyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 306
(2-(pyridin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 307
(2-(pyridin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 308
(2-(pyrazin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 309
(2-(3-methylpyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 310
(2-(5-methylisoxazol-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 311
(2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 312
((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 313
((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 314
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 315
((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 316
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 317
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 318
((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 319
((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 320
(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 321
(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 322
(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 323
(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 324
(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 325
(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 326
(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 327
(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 328
(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 329
(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 330
(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 331
(4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 332
[2,3′-bipyridin]-2′-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 333
[2,2′-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 334
(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 335
(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 336
(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 337
(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 338
(3,4′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 339
(3-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 340
(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 341
(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 342
(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 343
(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 344
(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 345
(3-fluoro-4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 346
(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 347
(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 348
(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 349
(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 350
(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 351
(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 352
(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 353
(3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 354
(2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 355
(5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 356
(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 357
(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 358
(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 359
(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 360
(3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 361
(2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 362
(2-(pyridazin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 363
(2-(pyridazin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 364
(2-(pyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 365
(2-(pyridin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 366
(2-(pyridin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 367
(2-(pyrazin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 368
(2-(3-methylpyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 369
(2-(5-methylisoxazol-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 370
(2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 371
(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 372
(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 373
(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 374
(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 375
(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 376
(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 377
(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 378
(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 379
(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 380
(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 381
(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 382
(4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 383
[2,3′-bipyridin]-2′-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 384
[2,2′-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 385
(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 386
(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 387
(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 388
(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 389
(3,4′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 390
(3-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 391
(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 392
(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 393
(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 394
(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 395
(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 396
(3-fluoro-4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 397
(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 398
(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 399
(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 400
(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 401
(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 402
(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 403
(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 404
(3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 405
(2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 406
(5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 407
(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 408
(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 409
(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 410
(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 411
(3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 412
(2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 413
((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 414
((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 415
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 416
((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 417
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 418
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 419
(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 420
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-6. MS (ESI): mass calcd. for C23H19F4N5O2, 473.2. m/z found, 474.2 [M+H]+. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=45° C.). Rt=6.79 min (major rotamer) at 254 nm.
Example 421
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 422
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 423
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 424
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 425
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 426
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 427
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 428
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 429
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 430
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 431
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 432
(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 433
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 434
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Example 435
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 436
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 437
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 438
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 439
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 440
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 441
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 442
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 443
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 444
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Example 445
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 446
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Example 447
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 448
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 449
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 450
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 451
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 452
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 453
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Example 454
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 455
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 456
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 457
(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 458
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 459
(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 460
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 461
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 462
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 463
(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 464
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 465
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 466
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 467
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 468
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 469
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 470
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Example 471
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Example 472
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 473
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 474
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 475
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 476
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 477
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 478
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Example 479
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 480
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 481
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 482
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Example 483
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone




Example 484
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 485
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 486
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 487
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 488
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 489
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 490
((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Example 491
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 492
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 493
(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 494
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 495
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 496
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 497
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 498
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 499
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 500
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 501
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 502
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 503
(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 504
(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 505
(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 506
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 507
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 508
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 509
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 510
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 511
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 512
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 513
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 514
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 515
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 516
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 517
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 518
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 519
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 520
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 521
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 522
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Example 523
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 524
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 525
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 526
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 527
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 528
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 529
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 530
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 531
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 532
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 533
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Example 534
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 535
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 536
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 537
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 538
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 539
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 540
(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 541
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 542
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 543
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 544
(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 545
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 546
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 547
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Example 548
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone




Example 549
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Example 550
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 551
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 552
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 553
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 554
(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 555
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Example 556
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Example 557
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 558
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 559
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 560
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 561
((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone




Example 562
((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Example 563
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 564
(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 565
(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 566
(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 567
(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 568
(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 569
(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 570
((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone




Example 571
(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 572
((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone




Example 573
((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone




Example 574
(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 575
(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 576
(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 577
(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 578
((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone




Example 579
(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 580
(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 581
(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 582
(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 583
(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 584
(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 585
(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 586
(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 587
(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 588
(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 589
(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 590
(4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 591
[2,3′-bipyridin]-2′-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 592
[2,2′-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 593
(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 594
(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 595
(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 596
(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 597
(3,4′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 598
(3-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 599
(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 600
(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 601
(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 602
(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 603
(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 604
(3-fluoro-4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 605
(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 606
(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 607
(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 608
(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 609
(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 610
(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 611
(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 612
3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 613
(2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 614
5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 615
(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 616
(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 617
(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 618
(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 619
(3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 620
(2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 621
(2-(1-methyl-1H-imidazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 622
(2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 623
(3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 624
(5-methyl-3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 625
(6-methyl-2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 626
(6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 627
(2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 628
(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 629
(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 630
(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 631
(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 632
(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 633
(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 634
[2,2′-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 635
(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 636
(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 637
(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 638
(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 639
(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 640
(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 641
(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 642
(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 643
(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 644
(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 645
(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 646
(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 647
(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 648
(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 649
(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 650
(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 651
(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 652
(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 653
(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 654
(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 655
(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 656
(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 657
(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 658
(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 659
(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Example 660
(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Assays:

The in vitro affinity of the compounds of the invention for the rat/human orexin 1 and human orexin 2 receptors was determined by competitive radioligand binding using [3H](1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)(Langmead et al., 2004) and [3H]EMPA (n-ethyl-2[96-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl acetamide), respectively (Langmead et al., 2004, British Journal of Pharmacology 141:340-346; Malherbe et al., 2004, British Journal of Pharmacology 156:1326-41).
The in vitro functional antagonism of the compounds on the human orexin 1 and orexin 2 receptors was determined using fluorometric imaging plate reader (FLIPR) based calcium assays.
Data are analyzed using pc-Sandy macro and graphed on Graphpad Prism 5. For analysis, each concentration point is averaged from triplicate values and the averaged values are plotted on Graphpad Prism. The IC50 was determined by applying the following equation (GraphPad Prism 5.0, SanDiego) for one site competition where X=log (concentration) and Y=specific binding. Top denotes the total [3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) binding, bottom denotes the nonspecific [3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) binding. Graphpad Prism calculates Ki value from IC50 and the pre-determined Kd values for [3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) and [3H]-EMPA. The Ki for each compound is then uploaded into 3DX. Each run comprises individual compounds in triplicate. The data in Table 1 and Table 2 represent averages from between 2-20 runs
Rat and Human Orexin 1 Receptor Radioligand Binding Studies
Human Embryonic Kidney 293 cells (HEK293) stably expressing rat orexin 1 receptor (Genebank accession number NM_001525) or Chinese ovary cells (CHO) stably expressing human orexin 1 receptor (Genebank accession number NM_001526) were grown to confluency in DMEM (Hyclone, cat # SH30022), 10% FBS, 1× Pen/Strep, 1× sodium pyruvate, 10 mM HEPES, 600 μg/mL G418 and DMEM/F12 (Gibco, Cat #11039), 10% FBS, 1× Pen/Strep, 600 μg/mL G418 media, respectively on 150 cm2 tissue culture plates, washed with 5 mM EDTA in PBS (HyClone Dulbecco's Phosphate Buffered Saline 1× with Calcium and Magnesium, Cat # SH30264.01, hereafter referred to simply as PBS) and scraped into 50 ml tubes. After centrifugation (2K×G, 5 min at 4° C.), the supernatant was aspirated and the pellets frozen and stored at −80° C. Cells were resuspended in PBS in the presence of 1 tablet of protease inhibitor cocktail (Roche, Cat. #11836145001) per 50 mL. Each cell pellet from a 15 cm plate was resuspended in 10 mL, stored on ice, and homogenized for 45 sec prior to addition to the reactions. Competition binding experiments in 96 well polypropylene plates were performed using [3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) (Moraveck Corporation, specific activity=35.3 Ci/mmol), diluted to a 10 nM concentration in PBS (4 nM final). Compounds were solubilized in 100% DMSO (Acros Organics, Cat. #61042-1000) and tested over a range of 7 concentrations (from 0.1 nM to 10 μM). The final concentration of DMSO in the reactions is equal to or less than 0.1%. Total and nonspecific binding was determined in the absence and presence of 10 μM almorexant. The total volume of each reaction is 200 μL (20 μL of diluted compounds, 80 μL of [3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) diluted in PBS and 100 μL of the cell suspension). Reactions were run for 60 min at room temperature and terminated by filtration through GF/C filter plates (PerkinElmer, Cat. #6005174) presoaked in 0.3% polyethylenimine using the cell harvester (PerkinElmer Filtermate). The plates were washed 3 times by aspirating 30 ml PBS through the plates. Plates were dried in 55° C. oven for 60 min, scintillation fluid was added, and the radioactivity was counted on a Topcount (Packard).
IC50 values (i.e. concentration of unlabelled compound required to compete for 50% of specific binding to the radioligand) was calculated using the GraphPad Prism software (GraphPad Prism Software Inc., San Diego, Calif.) with a fit to a sigmoidal dose-response curve. Apparent Ki values were calculated as Ki=IC50/(1+C/Kd), where C is concentration of radioligand and Kd=4 nM for rat orexin 1 receptor and 6 nM for human orexin 1 receptor.
Human Orexin 2 Receptor Radioligand Binding Studies
HEK293 stably expressing human orexin 2 receptor (Genebank accession number NM_001526) were grown to confluency in DMEM (Hyclone, cat # SH30022), 10% FBS, 1× Pen/Strep, 1× NaPyruvate, 10 mM HEPES, 600 ug/ml G418 media on 150 cm2 tissue culture plates, washed with 5 mM EDTA in PBS (HyClone Dulbecco's Phosphate Buffered Saline 1× with Calcium and Magnesium, Cat # SH30264.01, hereafter referred to simply as PBS) and scraped into 50 ml tubes. After centrifugation (2K×G, 5 min at 4° C.), the supernatant was aspirated and the pellets frozen and stored at −80° C. Cells were resuspended in PBS in the presence of 1 tablet of protease inhibitor cocktail (Roche, Cat. #11836145001) per 50 mL. Each cell pellet from a 15 cm plate was resuspended in 10 mL, stored on ice, and homogenized for 45 sec just prior to addition to the reactions. Competition binding experiments in 96 well polypropylene plates were performed using [3H]-EMPA (Moraveck Corporation, specific activity=29.6 Ci/mmol), diluted to a 5 nM concentration in PBS (2 nM final concentration). Compounds were solubilized in 100% DMSO (Acros Organics, Cat. #61042-1000) and tested over a range of 7 concentration (from 0.1 nM to 10 μM). The final concentration of DMSO in the reactions is equal to or less than 0.1%. Total and nonspecific binding was determined in the absence and presence of 10 μM almorexant. The total volume of each reaction is 200 μL (20 μL of diluted compounds, 80 μL of [3H]-EMPA diluted in PBS and 100 μL of the cell suspension). Reactions were run for 60 min at room temperature and terminated by filtration through GF/C filter plates (PerkinElmer, Cat. #6005174) presoaked in 0.3% polyethylenimine using the cell harvester (PerkinElmer Filtermate). The plates were washed 3 times by aspirating 30 ml PBS through the plates. Plates were dried in 55° C. oven for 60 min, scintillation fluid was added, and the radioactivity was counted on a Topcount (Packard).
IC50 values (i.e. concentration of unlabelled compound required to compete for 50% of specific binding to the radioligand) was calculated using the GraphPad Prism software (GraphPad Prism Software Inc., San Diego, Calif.) with a fit to a sigmoidal dose-response curve. Apparent Ki values were calculated as Ki=IC50/(1+C/Kd), where C is concentration of radioligand and Kd=2 nM.
Human Orexin 1 Receptor Ca2+ Mobilization Assay
CHO cells stably transfected with the human orexin 1 receptor (Genebank accession number NM_001526) were grown to confluency in DMEM/F12, 10% FBS, 1× pen-strep, 400 μg/ml G418. Cells were seeded on to 384-well Packard viewplates at a density of 10,000 cells/well and incubated overnight at 37° C., 5% CO2. The cells were dye-loaded with BD Calcium Assay kit (BD, cat #640178) in HBSS (Gibco, cat#14025-092) with 2.5 mM probenecid and incubated at 37° C., 5% CO2 for 45 min. Cells were pre-incubated with compounds (diluted in DMEM/F-12) for 15-30 minutes before agonist (orexin A, 10 nM) stimulation. Ligand-induced Ca2+ release was measured using a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, Calif.). Functional responses were measured as peak fluorescence intensity minus basal. The concentration of agonist that produced a half-maximal response is represented by the EC50 value. Antagonistic potency values were converted to apparent pKB values using a modified Cheng-Prusoff correction. Apparent pKB=−log IC50/1+[conc agonist/EC50].
Human Orexin 2 Receptor Ca2+ Mobilization Assay
PFSK-1 cells endogenously expressing the human orexin 2 receptor were grown to confluency in RPMI1640 (Hyclone, cat#30027.02), 10% FBS, 1× pen-strep. Cells were seeded on to 384-well Packard viewplates at a density of 5,000 cells/well and incubated overnight at 37° C., 5% CO2. The cells were dye-loaded with BD Calcium Assay kit (BD, cat #640178) in HBSS (Gibco, cat#14025-092) with 2.5 mM probenecid and incubated at 37° C., 5% CO2 for 45 min. Cells were pre-incubated with compounds (diluted in DMEM/F-12) for 15-30 minutes before agonist (orexin B, 100 nM) stimulation. Ligand-induced Ca2+ release was measured using a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, Calif.). Functional responses were measured as peak fluorescence intensity minus basal. The concentration of agonist that produced a half-maximal response is represented by the EC50 value. Antagonistic potency values were converted to apparent pKB values using a modified Cheng-Prusoff correction. Apparent pKB=−log IC50/1+[conc agonist/EC50].
Preferred compounds of the invention are set forth in the table below. Orexin receptor activity of certain compounds of the invention is also set forth in Table 1 below.












TABLE 1







rOX1
hOX1
hOX2



Ex.

Ki
Ki
Ki



No.
Compound
(nM)
(nM)
(nM)
Compound Name







 1




  74
120
 4700
(R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 2




  200
342
 10000
(R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 3




  63
123
 8900
(R/S)-(3- ethoxyisoquinolin-4- yl)((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 4




  837

>10000
(R/S)-5-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 7




  21
 12
  800
(R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 8




  16
 15
 1450
(R/S)-(3- ethoxyisoquinolin-4- yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 9




  56
101
 2554
(R/S)-(5-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


10




  18
 27
  526
(R/S)-(7- ethoxyquinolin-8-yl)(6- ((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


11




  11
 8
 1475
(R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


12




  44
 59
>10000
(R/S)-(4-methoxy-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


13




  52
109
>10000
(R/S)-4-methoxy-2- (2H-1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


14




  16
 21
  855
(R/S)-(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


15




  17
 40
  229
(R/S)-2-methoxy-6- (2H-1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


16




   8
 7
 1000
(R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


17




   8
 3
  234
(R/S)-(3-methyl-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


18




  25
 23
 1800
(R/S)-(2-fluoro-6-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


19




  18
 9
  945
(R/S)-(5-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


20




  15
 15
 2700
(R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


21




>10000

>10000
(R/S)-(2-(4H-1,2,4- triazol-4-yl)phenyl)(6- ((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


22




  25
 23
 1000
(R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


23




>10000

>10000
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1R,4S,6S)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


24




  20
 16
  692
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


25




  17
 15
  466
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


26




  12
 15
 2100
(4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


27




   4
 4
  767
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


28




  32
 21
 1600
(5-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


29




  55
 47
>10000
(6-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


30




  19
 22
 1700
(3-(2H-1,2,3-triazol-2- yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


31




  707

>10000
(3-fluoro-2- methoxyphenyl)((1S,4R, 6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


32




   3
 4
  143
(3-methyl-2-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


33




  74
 86
 3500
(3-fluoro-2-(1H-1,2,3- triazol-1- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


34




  117
462
 1100
(6-methyl-2-(1H-1,2,3- triazol-1-yl)pyridin-3- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


35




   8
 3
  542
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


36




   5
 11
  322
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


37




  170
265
 1800
(3-ethoxy-6- methylpyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


38




   8
 8
  690
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


39




  132
 17
  108
(2-methoxy-6-(1H- pyrazol-5- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


40




  16
 9
  340
(2-methoxy-6- (pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


41




 4399

>10000
(2-(1,4-dimethyl-1H- pyrazol-5- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


42




  184
175
 5800
(1H-indol-7- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


43




  16
 8
  557
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


44




  22
 42
 2198
(4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


45




  60
 55
 1500
(2-bromo-3- fluorophenyl)((1S,4R, 6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


46




  10
 12
  650
(2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


47




   7
 11
  503
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2- yl)phenyl)methanone


 


48




   3
 6
  972
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


49




   6
 6
  507
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


50




   7
 9
  670
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


51




  294

  676
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((3- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


52




  550

 4000
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((3- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


53




   3
 3
  165
(2H-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


54




   5
 6
  132
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


55




   3
 3
  46
(3-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


56




   8
 10
  192
(7-ethoxyquinolin-8- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


57




   6
 5
  252
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


58




   4
 2
  181
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


59




   6
 9
  213
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


60







(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


61







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


62







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


63







(4-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


64







(4-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


65







(4-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


66







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


67







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


68







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


69







(2-(3-methyl-1,2,4- oxadiazol-5- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


70







(3-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


71







(4-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


72







(3-(5- fluoropyrimidin-2-yl)- 5-methylpyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


73







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


74







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


75







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


76







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


77







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


78







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


79







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


80







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


81







(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


82







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


83







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


84







(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone









Preferred compounds of the invention are set forth in the table below. Orexin receptor activity of certain compounds of the invention is also set forth in Table 2 below.












TABLE 2







rOX1
hOX1
hOX2



Ex.

Ki
Ki
Ki



No.
Compound
(nM)
(nM)
(nM)
Compound Name




















 1




74
120
4700
(R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 2




200
342
10000
(R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 3




63
123
8900
(R/S)-(3- ethoxyisoquinolin-4- yl)((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 4




837

>10000
(R/S)-5-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 5




25
18
779
(R/S)-(5-(4- fluorophenyl)-2- methylthiazol-4-yl)(6- ((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 6




>10000

>10000
(R/S)-(6- methylimidazo[2,1- b]thiazol-5-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 7




21
12
800
(R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 8




16
15
1450
(R/S)-(3- ethoxyisoquinolin-4- yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 9




56
102
2575
(R/S)-(5-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 10




18
27
526
(R/S)-(7- ethoxyquinolin-8-yl)(6- ((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 11




11
9
1475
(R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 12




44
59
>10000
(R/S)-(4-methoxy-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 13




52
109
>10000
(R/S)-4-methoxy-2- (2H-1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 14




17
23
882
(R/S)-(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 15




17
40
229
(R/S)-2-methoxy-6- (2H-1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 16




8
7
1000
(R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 17




8
3
234
(R/S)-(3-methyl-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 18




25
23
1800
(R/S)-(2-fluoro-6-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 19




18
9
945
(R/S)-(5-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 20




15
15
2700
(R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 21




>10000

>10000
(R/S)-(2-(4H-1,2,3- triazol-4-yl)phenyl)(6- ((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 22




25
23
1000
(R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 23




>10000

>10000
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1R,4S,6S)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 24




20
16
692
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1R,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 25




14
15
483
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 26




12
15
2100
(4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 27




6
5
725
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 28




32
21
1600
(5-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 29




55
47
>10000
(6-methyl-2-(2H-1,2,3- triaazol-2-yl)pyridin-3- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 30




19
22
1700
(3-(2H-1,2,3-triazol-2- yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 31




707

>10000
(3-fluoro-2- methoxyphenyl)((1S,4R, 6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 32




3
6
149
(3-methyl-2-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 33




74
86
3500
(3-fluoro-2-(1H-1,2,3- triazol-1- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 34




162
368
1050
(6-methyl-2-(1H-1,2,3- triazol-1-yl)pyridin-3- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 35




8
3
546
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 36




5
13
343
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 37




170
265
1800
(3-ethoxy-6- methylpyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 38




8
8
633
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 39




72
17
104
(2-methoxy-6-(1H- pyrazol-5- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 40




15
9
333
(2-methoxy-6- (pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 41




4400

>10000
(2-(1,4-dimethyl-1H- pyrazol-5- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 42




184
175
5800
(1H-indol-7- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 43




24
16
550
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 44




21
39
2333
(4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 45




60
55
1500
(2-bromo-3- fluorophenyl)((1S,4R, 6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 46




10
12
650
(2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 47




6
9
524
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2- yl)phenyl)methanone


 


 48




4
5
903
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


 49




6
5
443
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 50




7
10
578
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


 51




294

676
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((3- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 52




550

4000
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((3- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 53




3
4
169
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 54




6
5
126
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 55




3
3
46
(3-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 56




8
10
192
(7-ethoxyquinolin-8- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 57




5
5
225
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 58




5
3
193
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 59




6
7
192
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 60




20
12
617
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 61




15
19
248
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 62




28
19
569
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 66




2
5
181
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 67




7
7
264
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 68




7
8
612
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 73




8
11
575
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 74




16
16
1800
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 76




4
3
211
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 77




9
13
1700
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 80




9
7
456
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 83




8
5
289
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 85




6
6
910
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- (6-2H)-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 86




7
9
946
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]- (3- 2H, 2H)-heptan-2- yl)heptan- 2-yl)methanone


 


 87




156
211
>10000
(2-(2H-1,2,3-triazol-2- yl)pyridin-3- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 88




45
36
>10000
(5-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 89




18
8
1100
(2-(5-fluoropyrimidin- 2- yl)phenyl)((1`S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 90




15
19
2150
(3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 91




8
6
331
(2-(5-fluoropyrimidin- 2-yl)-3- methylphenyl)((1S,4R, 6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 92




13
19
362
(6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 93




125
76
3100
(3-phenylpyrazin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 94




35
30
848
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((6- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 95




29
37
137
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((4- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 96




320

1700
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((3- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 97




21
15
1100
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


 98




37
28
1200
((1S,4R,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


 99




11
10
725
((1S,4R,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone


 


100




13
12
1600
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


101




26
11
710
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-methylpyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


102




404

1600
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-(pyridin-2-yloxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


103




>10000

>10000
(6-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3- yl)((1S,4R,6R)-6- (pyridin-2-yloxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


104




497

5000
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-(pyridin-2-yloxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


105




119
337
>10000
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-2-(2H- 1,2,3-triazol-2- yl)pyridin-3- yl)methanone


 


106




3
4
436
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2- 1,2,3-triazol-2- yl)phenyl)methanone


 


107




16
26
1960
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


108




8
31
776
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


109




6
5
442
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


110




6
11
1200
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


111




5
5
458
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


112




8
10
459
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


113




17
14
984
((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-5- azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


114




11
23
668
((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


115




7
8
852
((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


116




11
12
939
((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(5- fluoropyrimidin-2- yl)phenyl)methanone


 


117




16
28
1600
((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)methanone


 


118




133
105
1600
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-fluoropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


119




262

3600
((1S,4R,6R)-6-((5- fluoropyridin-2-yl)oxy)- 2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


120




60
111
4100
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-fluoropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


121




10
11
50
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (difluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


122




28
30
218
((1S,4R,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


123




11
10
149
((1S,4R,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- methanone


 


124




200
109
4500
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


125




220
88
5500
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


126




27
22
4200
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


127




116
143
>10000
(4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromnethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


128




69
62
3800
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


129




53
47
4400
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


130




29
27
3500
(2-(pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


131




140
132
2200
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-methylpyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


132




425

6800
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- methylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


133




60
102
4200
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-methylpyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


134




668

>10000
(5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- methylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


135




61
100
1200
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-ethylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


136




380

4700
((1S,4R,6R)-6-((5- ethylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


137




39
65
1700
((1S,4R,6R)-6-((5- ethylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


138




300

2700
((1S,4R,6R)-6-((5- ethylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3- (pyrimidin-2-yl)pyridin- 2-yl)methanone


 


139




208
150
3700
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((6- (trifluoromethyl)pyridazin- 3-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


140




330

7700
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((6- (trifluoromethyl)pyridazin- 3-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


141




208
348
>10000
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((6- (trifluoromethyl)pyridazin- 3-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


142




376

7900
(6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((6- (trifluoromethyl)pyridazin- 3-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


143




24
34
7300
(6-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


144




3
3
133
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


145




17
7
934
(4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


146




6
3
150
(2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


147




5
6
190
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


148




3
5
189
(2-(pyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


149




14
7
4600
(5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


150




13
9
88
(6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


151




21
47
5100
(5-methyl-2-(pyrimidin- 2-yl)pyridin-3- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


152




30
16
1600
(4-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


153




3
3
342
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


154




4
6
329
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


155




5
3
303
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


156




7
5
274
((1S,4S,6R)-6- (methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


157




6
3
351
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


158




5
2
340
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


159




6
4
209
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


160




9
6
208
(2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


161




14
5
384
((1S,4S,6R)-6- ((cyclopropylmethyl)(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


162




>10000

>10000
N-((1S,4S,6R)-2-(3- fluoro-2-(pyrimidin-2- yl)benzoyl)-2- azabicyclo[2.2.1]heptan- 6-yl)-N-(5- (trifluoromethyl)pyridin- 2-yl)acetamide


 


163




19
12
962
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((2-methoxyethyl)(5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


166




2
4
236
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-bromopyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


167




2
6
239
((1S,4S,6R)-6-((5- bromopyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


168




2
4
351
((1S,4S,6R)-6-((5- bromopyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2- yl)phenyl)methanone


 


169




3
4
285
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-chloropyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


170




4
12
321
((1S,4S,6R)-6-((5- chloropyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


171




27
25
1900
((1S,4S,6R)-6-((5- chloropyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


172




8
7
400
((1S,4S,6R)-6-((5- chloropyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


173




55
33
264
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (difluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


174




18
15
230
((1S,4S,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


175




170
191
844
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-methoxypyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


176




56
52
1300
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-methoxypyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


177




3
3
200
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


178




6
8
112
((1S,4S,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


179




5
5
217
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


180




6
5
380
((1S,4S,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(5- fluoropyrimidin-2- yl)phenyl)methanone


 


181




5
8
163
((1S,4S,6R)-6- (benzo[d]oxazol-2- ylamino)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


182




3
4
218
((1S,4S,6R)-6- (benzo[d]oxazol-2- ylamino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


183




5
7
206
((1S,4S,6R)-6- (benzo[d]oxazol-2- ylamino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


184




13
15
337
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(p-tolylamino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


185




27
33
146
(1H-indol-7- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


186




123
151
2700
(1H-indazol-7- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


187




28
30
1600
(5-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


188




191
210
>10000
(2-(2H-1,2,3-triazol-2- yl)pyridin-3- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


189




14
11
678
(3-(pyrimidin-2- yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone.


 


190




12
12
>10000
(5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


191




15
13
163
(6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


192




8
7
249
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


193




40
65
2000
(4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


194




8
8
241
((5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluorometjyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


195




9
8
199
(2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


196




6
4
60
(3-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


197




93
39
9700
(4-methoxy-2-(2H- 1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


198




11
9
1375
(4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


199




6
8
221
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


200




7
6
240
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


201




6
6
213
(2-(pyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


202




13
13
302
(5-fluoro-2-(oxazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


203




9
9
545
(2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


204




9
9
960
(3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


205




51
35
846
(3-phenylpyrazin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


206




8
10
103
[1,1′-biphenyl]-2- yl((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


207




143
127
611
(3-phenylfuran-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


208




7
6
846
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


209




9
5
753
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


210




6
5
502
((1S,4S,6R)-6- (methyl(5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone


 


211




31
16
1300
((1S,4S,6R)-6- ((cyclopropylmethyl)(5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


212




14
9
607
((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


213




39
31
871
((1S,4S,6R)-6-((5- chloropyrazin-5- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


214




13
14
708
((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


215




12
13
435
((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone


 


216




9
9
500
((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)methanone


 


217




12
29
390
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-methylpyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


218




31
49
490
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-methylpyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


219




20
27
480
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-methylpyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


220




11
17
284
((1S,4S,6R)-6-((5- methylpyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone


 


221




2100

3000
Methyl 5-(((1S,4S,6R)- 2-(2-(2H-1,2,3-triazol- 2-yl)benzoyl)-2- azabicyclo[2.2.1]heptan- 6-ylamino)pyrazin-2- carboxylate


 


222




261

>10000
(2-(2H-1,2,3-triazol-2- yl)pyridin-3- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


223




11
6
619
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


224




37
33
1900
(4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


225




20
16
800
(5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


226




17
19
874
(2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


227




12
13
3100
(4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


228




11
9
544
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


229




9
11
724
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


230




4
4
470
(2-(pyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


231




9
12
1300
(2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


232




24
25
1352
(2-fluoro-6-(oxazol-2- yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


233




280

1100
(3-ethoxy-6- methylpyridin-2- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


234




17
12
827
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


235




36
41
1300
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)methanone


 


236




10
9
1020
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


237




32
13
1900
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


238




20
8
991
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)(methyl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


239




23
41
726
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2- yl)phenyl)methanone


 


240




17
12
831
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone


 


241




21
12
971
((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)(methyl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(5- fluoropyrimidin-2- yl)phenyl)methanone


 


242




89
113
2100
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((6- (trifluoromethyl)pyridazin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


243




112
131
1800
(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((6- (trifluoromethyl)pyridazin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


244




114
143
1700
(6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((6- (trifluoromethyl)pyridazin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


245




65
53
4300
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((6- (trifluoromethyl)pyridazin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


246




194
155
843
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((6- (trifluoromethyl)pyridin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


247




26
31
939
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((6- (trifluoromethyl)pyridin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone


 


248




11
14
467
(R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


249




8
15
758
(R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)(phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


250




22
24
1800
(R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


251




18
11
760
(R/S)-(2-(5- fluoropyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyridiun- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


252




13
14
312
(R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


253




>10000

>10000
(R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)((1S,4R,6S)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


254




12
10
307
(R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


255




12
11
1000
(R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


256




20
10
348
(R/S)-(3-methyl-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


257




21
24
741
(R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


258




26
17
2600
(R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


259




16
19
865
(4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


260




11
10
294
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


261




21
9
400
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


262




10
10
550
(2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


263




11
9
1100
(3-fluoro-2-(5- fluoropyrimidin-2- yl)phenbyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


264




10
16
>10000
(5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


265




14
19
306
(6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


266




11
11
654
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


267




26
19
1100
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-methylpyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


268




5
4
200
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


269




4
5
363
((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


270




4
3
200
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


271




7
8
452
((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


272




23
11
1400
(2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


273




44
16
3800
(3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


274




11
8
534
(3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


275




8
5
175
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


276




2700

>10000
(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1R,4S,6S)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


277




17
15
998
(4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


278




14
7
243
(5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


279




11
13
177
(2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


280




7
4
189
(2-(pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


281




5
19
336
((1S,4R,6R)-6-((3- chloro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


282




81
65
>10000
(5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


283




21
27
>10000
((1S,4R,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(5-methyl-3- (pyrimidin-2-yl)pyridin- 2-yl)methanone


 


284




45
47
5600
((1S,4R,6R)-6-((5- chloropyrimdin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


285




117
215
6000
((1S,4R,6R)-6-((5- chloropyrimidin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(6-methyl-3- (pyrimidin-2-yl)pyridin- 2-yl)methanone


 


286




822

3100
((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2- azabicyclo[2.2.2]octan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


287




155
226
2700
((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2- azabicyclo[2.2.2]octan- 2-yl)(2-(2H-1,2,3- triazol-2- yl)phenyl)methanone


 


288




29
39
5100
((1S,4R,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(5-methyl-3- (pyrimidin-2-yl)pyridin- 2-yl)methanone


 


289




14
24
207
(2-methoxy-6-(2H- 1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


290




97
188
>10000
(5-methyl-2-(pyrimidin- 2-yl)pyridin-3- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


291




43
82
4200
(4-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


292




19
40
673
(2-fluoro-6-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


293




16
26
535
(5-fluoro-2-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


294




166
580
1400
(5-methyl-3-(1H-1,2,3- triazol-1-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


295




19
34
5800
(4-methoxy-2- (pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


296




8
14
474
(3-(pyrimidin-2- yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


297




10
10
606
(2-(pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


298




24
29
>10000
(5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


299







(1S,4R,6R)-6-((5- chloropyrimidin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone


 


300




92
112
3700
(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-chloropyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone


 


301







((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2- azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone


 


302







((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2- azabicyclo[2.2.2]octan- 2-yl)(6-methyl-3- (pyrimidin-2-yl)pyridin- 2-yl)methanone

## Claims

1. A compound which is selected from the group consisting of







or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

2. The compound of claim 1 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

3. The compound of claim 2 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.

4. The compound of claim 1 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-(6-2H)-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

5. The compound of claim 4 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-(6-2H)-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.

6. The compound of claim 1 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]-(3-2H, 2H)-heptan-2-yl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

7. The compound of claim 6 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]-(3-2H, 2H)-heptan-2-yl)methanone.

8. The compound of claim 1 which is ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

9. The compound of claim 8 which is ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.

10. The compound of claim 1 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

11. The compound of claim 10 which is (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.

12. The compound of claim 1 which is ((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

13. The compound of claim 12 which is ((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.

14. The compound of claim 1 which is ((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

15. The compound of claim 14 which is ((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.

16. The compound of claim 1 which is ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

17. The compound of claim 16 which is ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone.

18. The compound of claim 1 which is ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

19. The compound of claim 18 which is ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone.

20. The compound of claim 1 which is ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

21. The compound of claim 20 which is ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.

22. The compound of claim 1 which is ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone or a pharmaceutically acceptable salt, solvate, isotopic variant, enantiomer, diastereomer, or tautomer thereof.

23. The compound of claim 22 which is ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.